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ABSTRACT
Anti-Germinants As A New Strategy To Prevent
Clostridium Difficile Infection
by
Amber Janece Howerton
Dr. Ernesto Abel-Santos, Examination Committee Chair
Professor of Chemistry
University of Nevada, Las Vegas
Clostridium difficile infections (CDI) have emerged as a leading cause of
hospital-associated complications. CDI is the major cause of antibiotic-related
cases of diarrhea and nearly all cases of pseudomembranous colitis. The
infective form of C. difficile is the spore, a dormant and hardy structure that forms
under stress. Germination of C. difficile spores into toxin producing bacteria in
the GI tract of susceptible patients is the first step in CDI establishment. Patient
susceptibility occurs with a disruption of the natural gut microbiota by broadspectrum antibiotics. Antibiotic treatments usually resolve CDI but refractory
cases are on the rise. Of great concern is the high incidence of recurrence due to
persistence of spores in the gut following antibiotic treatment and/or spore reingestion. Besides surface decontamination there are currently no protocols for
prevention of CDI.
C. difficile spores must germinate to cause disease. Therefore, a logical
approach to preventing CDI is to prevent spore germination. Unlike other Bacillus
and Clostridia, the genome of C. difficile does not encode for any known
germination binding site(s). Small molecules are typically required to activate
spore germination in Bacillus and Clostridia. C. difficile germinates in the
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presence of taurocholate, a natural bile salt, and glycine, an amino acid. The
natural bile salt, chenodeoxycholate, has been shown to inhibit spore
germination in vitro. We used structure activity analysis to define the
microenvironment of the putative C. difficile germination binding site(s). Amino
acids and amino acid analogs were analyzed for activation or inhibition of C.
difficile spore germination.
To determine which functional groups of bile salts are necessary and
sufficient to activate or inhibit spore germination, we prepared bile salt analogs of
taurocholate and chenodeoxycholate. This analysis elucidated specific functional
groups recognized by C. difficile spores. Furthermore, many bile salt analogs are
able to bind but are not recognized by the putative C. difficile germination binding
site(s).

During this structure analysis, we discovered that a meta-benzene

sulfonic acid derivative of taurocholate (CamSA) was a strong inhibitor of spore
germination in vitro. CamSA is stable and non-toxic based on pharmacokinetic in
vitro studies. CamSA showed no acute toxicity at the highest concentrations
tested. More importantly, a single dose of CamSA prevents CDI in mice. Ingested
C. difficile spores were quantitatively recovered from feces and intestines of
CamSA-protected mice. Using CamSA as a probe, we were able to establish
when onset of disease occurs in mice after infection with C. difficile spores. The
results presented in this dissertation project support a mechanism whereby the
anti-germination effect of CamSA is responsible for preventing CDI signs.
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CHAPTER 1
INTRODUCTION
1.1. Clostridium difficile Background and Significance
Clostridium difficile is a pathogenic bacterium from the Phylum Firmicutes
of the Kingdom Eubacteria in the Domain Bacteria (Fig. 1.1). This phylum
contains two major Classes: Bacilli and Clostridia (1, 2). The Class Clostridia
consists only of organisms that are obligate anaerobes, Gram-positive and
endospore-forming bacteria (3). Microorganisms, that like C. difficile are obligate
anaerobes, are intolerant of molecular oxygen and use other molecules such as
nitrate as a final electron acceptor for cellular respiration (4, 5). For example,
vegetative C. difficile cells die in the presence of oxygen but flourish in the
anaerobic, high nutrient environment of the mammalian colon (6, 7). Like others
in the Class Clostridia, C. difficile is Gram-positive due to a thick cell wall made
up of peptidoglycan, which absorbs the primary stain, crystal violet, and appears
purple by light microscopy (Fig. 1.2) (8). In contrast, Gram-negative bacteria
have cell walls made up mostly of lipopolysaccharides that do not retain the
primary stain but absorb the counter stain, safranin, and appear red under
microscopy (Fig. 1.2) (9). The Gram-staining technique was developed by Hans
Christian Gram to separate bacteria into two large groups based on physical
properties of cell wall constituents (9). Also like other bacteria in its Class, C.
difficile produces and releases dormant spores under stressful conditions as a
survival mechanism (10). The spores survive in aerobic conditions where the

1

mother vegetative cells cannot, thereby providing a survival strategy outside of
the host (10).
Further classification of C. difficile in the Order Clostridiales, Family
Clostridiaceae is due to the usage of glucose as a source of carbon (Fig. 1.1)
(11). The Genus Clostridium contains approximately 150 species found in
diverse anaerobic environments such as soils, aquatic sediments, and intestinal
tracts of mammals (12). C. difficile is an opportunistic pathogen of the
mammalian gastrointestinal (GI) tract. C. difficile is the etiological agent of C.
difficile infection (CDI), which is the leading cause of antibiotic-associated
diarrhea in the healthcare setting in the United States and Canada (10, 13, 14).
C. difficile was first identified in 1935 during an examination of indigenous
colonic flora of healthy newborn infants and was originally named Bacillus

Figure 1.1. Classification of Clostridium difficile.

Figure 1.2. Representation of Gram staining. Comparison of C. difficile a
Gram-positive bacterium (shown as purple) and E. coli a Gram-negative
bacterium (shown as pink/red).
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difficilis due to its difficulty to grow in culture (6). The origin of C. difficile in
neonates is due to hospital contamination and it is poorly understood how
newborns carry the bacterium asymptomatically (6, 15). Neonates are not the
only symptomless carriers of C. difficile. One study found that nearly 20% of
hospitalized patients were asymptomatic carriers of C. difficile (16). Although it
would be reasonable to expect that C. difficile carriers would have a higher risk of
developing disease after antibiotic therapy, studies have shown humans that
carry C. difficile asymptomatically are actually at decreased risk of developing
CDI (17-20). This phenomenon is not understood, but speculation exists that the
host immune system is responsible. Studies have suggested that an increase of
immunoglobulin G (IgG) antibodies or an overall antibody response to C. difficile
is responsible for symptom-less carriers remaining symptom-less (21, 22).
C. difficile colonization and infection is also a concern in domestic and
food animals. Outbreaks of CDI in piglets have been reported for more than
twenty-five years and the mortality rate during outbreak is reported to be as high
as 16% (23-25). C. difficile has been found to colonize and infect feedlot cattle,
veal calves, and farm-raised deer (26-30). Since infection of humans with C.
difficile is by the oral route, contamination of food animals and processing plants
is an important concern.
C. difficile has been isolated from the feces of domesticated cats and
dogs. Environmental cross infection of C. difficile from domestic animals to
humans has been a growing concern in the last five years. Recent reports show
that dogs used as pet therapy in hospitals can acquire and shed C. difficile
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spores after contact with contaminated patients (31, 32). C. difficile has been
isolated from cats and dogs presenting signs of diarrhea although the extent of
disease in these animals is still unclear (33, 34).
CDI primarily affects the cecum and the colon of mammalian hosts. CDI
presentation

in

patients

can

range

from

mild

to

severe

diarrhea,

pseudomembranous colitis and fulminant colitis (35). Pseudomembranous colitis,
the characteristic symptom of CDI, was first described in 1893, however; it was
not until 1978 that this symptom was associated with C. difficile (36, 37).
Purportedly early CDI symptoms are persistent mild to moderate diarrhea with or
without abdominal pain and can begin within the first 48 hours of C. difficile
infection (20, 35). The progression to severe disease typically includes profuse
diarrhea, abdominal distention and in some cases, occult colonic bleeding
occurs. In up to 4% of severe cases, fulminant colitis leads to toxic megacolon
(colonic dilation), bowel perforation, sepsis, shock and death (10, 12).
Since the late 1970s, the rate of CDI progression to severe symptoms and
death has been increasing annually (38, 39). In the past decade, a highly virulent
epidemic C. difficile strain has emerged, BI/NAP1/027 (13, 39, 40). The
BI/NAP1/027 strain has been associated with increased disease severity, more
deaths, higher incidences of recurrence and a wider range of antibiotic resistance
than other strains of C. difficile (13). Indeed, approximately 500,000 patients are
reported to have CDI annually in the United States and 20,000 succumb to this
disease (41). A recent study reported CDI responsible for 25% more nosocomial
infections than methicillin-resistant Staphylococcus aureus (MRSA) (42).
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CDI is a significant burden on the health care system with hospital costs
estimated at greater than $3.2 billion in the United States annually (35, 43, 44).
The economic burden is due in part to increased hospital stay of up to two weeks
per patient (44, 45) and the high incidence of recurrence in patients with CDI.
Recurrence of CDI has been defined as either a relapse of infection by the
original strain of C. difficile or re-infection of susceptible patients exposed to new
strains (35). Recurrences happen at an alarming frequency of up to 55% (46,
47). Furthermore, the risk of recurrence increases with each episode and is
greater than 60% with more than two CDI episodes (48-50). Extreme cases have
reported more than 10 CDI recurrences per patient (51).
1.2. Clostridium difficile Infections
CDI

is

primarily

a

nosocomial

infection

with

the

elderly

and

immunocompromised patients being at the highest risk (52). High incidences of
CDI are reported in cancer patients with severe neutropenia, transplant patients,
and AIDS patients (53-56). Susceptibility to CDI has been observed in patients
administered broad-spectrum antibiotics (57). However in the last few years,
community-acquired CDI in patients previously considered at low risk have been
reported and are a growing concern (58-61).
In the 1990s an estimated 30 cases of hospital-acquired CDI was reported
per 100,000 patients per year and less than seven cases of community-acquired
CDI per 100,000 patients per year (62). An overlapping and broadening study
that ended in 2005 found that the rates for each type of acquired CDI had
increased. This report found that there were more than 40 cases of hospital-
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acquired CDI and approximately 15 cases of community-acquired CDI per
100,000 patients per year (61). This study did not find common risk factors in
patients; such as antibiotic exposure or recent hospital admittance (61). It is
important to note that standardized surveillance and reporting of CDI cases and
risk factors has been a problem (63). The study found that C. difficile strains
endemic to the hospital were responsible for hospital-acquired CDI and that
different strains were common in community-acquired cases (61). These findings
suggest that patients with community-acquired CDI were not infected by patients
with hospital-acquired CDI spreading spores at home or in the community. The
source of community-acquired CDI remains a mystery. These findings make
identification of the community exposure to C. difficile spores an important issue.
As discussed previously, food animals and domestic animals can be affected by
C. difficile and can transmit spores (26, 29, 32). One group reported that many
strains found in animals were not the same as human strains of C. difficile (64).
However, they also found that epidemiologically important strains were becoming
more common in animals, particularly the hypervirulent strain BI/NAP1/027 (64).
Although classification of C. difficile as a zoonotic infection is still unclear, these
studies suggest the potential risks.
Since C. difficile has been isolated from food animals, another potential
reservoir for spore transmission is contaminated food products and drinking
water. C. difficile spores have been recovered from up to 20% of retailmeat in the
United States and Canada. In these cases, C. difficile was approximately 5% of
the total isolated microorganisms (64, 65). These incidences of contaminated

6

food suggest that community-acquired CDI could be a food borne illness.
Community-acquired CDI is still poorly understood but it is possible that multiple
factors may be involved. It has been suggested that genetically-determined
differences in the immune system, differences in the normal gut flora of some
individuals, and administration of medications (other than antibiotics) that affect
the colonization resistance of the natural flora are possible situations that could
allow the development of CDI in unlikely patients (59).
The mode of transmission is the highly infective C. difficile spore. The
environment, hospital personnel and patients are potential reservoirs for
transmission of spores and infection (66-69). C. difficile spores are ingested from
contaminated matter and will either germinate and cause disease or will be
retained in asymptomatic carriers. Spores and/or cells are excreted in the feces
of infected patients and transferred person to person via the fecal oral route (Fig.
1.3) (63, 70). Contamination of surfaces and transmission between patients is a
cycle that can lead to outbreaks of CDI and is of serious concern to healthcare
settings. Patients are intermittently exposed to C. difficile spores during hospital
stays and the length of stay has been correlated to increased risk of CDI (16).
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Figure 1.3. Representation of the Clostridium difficile infection cycle. Mammalian hosts ingest
spores (black circles) that survive the GI tract to germinate in the lower intestine (black ovals) and
cause disease. As a survival mechanism vegetative cells produce spores that are released in the
feces. The same or different mammal ingests excreted spores thereby continuing the cycle.

C. difficile spores are metabolically dormant structures that are highly
resistant to chemicals, temperature, desiccation and can persist in aerobic
environments (71). Spores can persist on hospital surfaces for extended periods
of time and can be reservoirs for disease transmission (35, 72). To colonize and
cause disease in susceptible patients, C. difficile spores are ingested and evade
the host’s immune system allowing spores to germinate into vegetative bacteria
and colonize the gut (Fig. 1.3) (35). In a healthy individual, indigenous intestinal
bacteria resist C. difficile colonization (73). Patients undergoing aggressive
antibiotic treatment become susceptible to C. difficile due to the disruption of the
normal microflora resulting in a loss of colonization resistance (74). Most broadspectrum antibiotics can predispose a patient for C. difficile infection (35). The
key factors that lead to outgrowth of C. difficile and onset of disease are ingestion
of C. difficile spores, susceptibility due to antibiotic use, and loss of natural
protection.
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As C. difficile spores germinate and multiply, toxins are released that
cause characteristic pathology of CDI. C. difficile cells release low levels of toxins
steadily during exponential phase (up to six hours). However, during late
exponential phase (eight hours) into stationary phase (24 – 48 hours) the amount
of toxin quadruples in production (75-77). Most C. difficile strains produce toxin A
(TcdA) and toxin B (TcdB) and some produce a third binary toxin, CDT. Nontoxigenic strains exist naturally and have not been shown to cause disease (20).
The two large Clostridial toxins, TcdA and TcdB, are widely accepted as the main
virulence factors of C. difficile. Specialized assays for detection of these toxins
are used in the diagnosis of CDI (35).
The major toxins, TcdA and TcdB, are among the largest (>270 kDa)
bacterial toxins and are related to the Clostridium sordellii lethal and hemorrhagic
toxins and to the Clostridium novyi alpha toxin (78). The toxins have 49% amino
acid similarity and are both highly expressed during stationary phase growth (79).
Genes for both toxins are located on the pathogenicity region of the C. difficile
chromosome (78). TcdA and TcdB are internalized into host epithelial cells after
binding to an unknown surface binding site(s) (78). After internalization, toxins
modify intestinal epithelial cell actin cytoskeleton using UDP glucose-dependent
glycosylation of Rho family proteins (80). TcdA and TcdB disrupt the tight
junctions between epithelial cells and recruit neutrophils to the site of infection
resulting in diarrhea and characteristic colitis (78). The roles and necessity for
both toxins during CDI has been under investigation. However, using a recently
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designed C. difficile genetic manipulation system a recent report provides
evidence for the importance of both toxins in a hamster model of CDI (81, 82).
TcdA is an enterotoxin capable of triggering host cell fluid secretion,
severe

inflammation,

and

inducing

epithelial

damage,

which

are

the

characteristics of pseudomembranous colitis (83). Until a C. difficile strain was
engineered in a recent study, there have been no reports of naturally occurring
TcdA+B- strains (82).
TcdB is a very potent cytotoxin capable of mucosal necrosis, reduction of
epithelial integrity, and triggering apoptosis (84, 85). Although most C. difficile
strains clinically isolated are TcdA+B+ or TcdA-B+ the role of TcdB is not well
characterized (86). Furthermore, strains that do not produce TcdA still cause
severe pseudomembranous colitis and death in patients (87).
The third toxin is called binary toxin CDT and it was first described in 1988
(88). Binary toxin CDT is in the same family as Clostridium botulinum C2 toxin,
Clostridium perfringens iota toxin and Clostridium spiroforme iota-like toxin (89,
90). Binary toxin CDT is capable of modifying the cellular actin cytoskeleton by
ADP-ribosyltransferase activity (91). Unlike TcdA and TcdB, the binary toxin is
composed of two different proteins, a binding component and a catalytic
component. Both components are necessary for toxicity (89, 92, 93). Not all C.
difficile strains encode for binary toxin (94) and some strains that encode for it
have mutated genes (95). The epidemic strain BI/NAP1/027 produces a fully
active binary toxin (96). The hypervirulence of this strain may be due in part to
the addition of this toxin to its virulence repertoire. Evidence of increased
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virulence of strains in humans due to binary toxin production is unclear. Some
reports have shown that binary toxin is found in less than 10% of clinical isolates
where as other reports show that binary toxin is present in 65% of isolates of C.
difficile (86, 88, 91, 97). The presence of the toxin in clinical isolates does not
define whether binary toxin itself is responsible for increased C. difficile virulence
or disease severity. Using the hamster model of CDI, a recent study, found that a
strain that produced only binary toxin was able to colonize the gut of animals but
was unable to cause diarrhea or death (98). Although the C. difficile binary toxin
is unable to cause disease when produced alone, it is possible that a synergistic
effect may occur in the presence of TcdA and/or TcdB (98). Another possibility is
that binary toxin may target a specific protein or immune response that is only
present in the human GI tract. More research is needed to fully understand the
role of binary toxin CDT in C. difficile strains.
Once CDI is diagnosed, treatment options become paramount. The first
step is to discontinue antibiotic therapy that the patient is undergoing (35).
Vancomycin and metronidazole are the most commonly used treatments for
initial episodes of CDI (35). An expensive new antibiotic was recently approved
by the FDA for treatment of CDI; Fidaxomicin (Dificid) can be administered if
vancomycin and metronidazole fail to treat CDI (99). Other antibiotics are under
investigation as potential treatment options but the cure rates are variable (100).
Currently, treatment of CDI has a failure rate of up to 38% with first line
antibiotics (46). Antibiotics are only effective against metabolically active, toxinproducing bacterium and not on dormant spores (101). Therefore, current
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treatment regimens may not completely eradicate the organism from the gut
allowing for recurrence due to persistence of spores (101). Some researchers
have proposed treatment with immunoglobulin G (IgG) antibodies due to the
observation that asymptomatic patients have increased IgG titers (21, 22). Other
studies have shown that deliberately colonizing animals with non-toxigenic C.
difficile strains can partially prevent CDI (102, 103).
There is a high incidence of recurrence of CDI due to relapse and/or reinfection (35). Typical treatment of recurrent CDI is re-administration of the first
line of antibiotics (35). However there is great concern about long-term usage of
metronidazole and vancomycin because of metronidazole-induced neuropathy
and increased drug resistance of other pathogens to vancomycin (100, 104). The
newly approved antibiotic, fidaxomicin, is ineffective against recurrent CDI (105).
Furthermore by using antibiotics to treat CDI and recurrent CDI, the normal gut
flora is not allowed to recover and a vicious circle ensues.
Alternative treatments have been described for recurrent CDI but have
variable results. In severe cases of CDI, radical procedures are sometimes
necessary to combat the disease (35, 106). Fecal transplantation has been
termed the ‘ultimate probiotic’ and has been used in patients with CDI that have
exhausted all other treatment options (107). Stool samples from donors closely
associated with the patient are obtained, diluted with saline, homogenized with a
blender and filtered before being instilled into the recipient via enema or
nasogastric tube (106-108). Colectomy is also used as a last resort to combat
CDI and/or recurrent CDI. Removing part of or the entire colon can remove the
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diseased tissue as well as massive amounts of the infection. Up to 8% of severe
CDI patients require this type of aggressive treatment (109). However, surgery as
an aggressive treatment for CDI is complicated by the compromised immune
system of the patient. Patients with CDI as a complication to other illnesses, such
as cancer, are rarely treated with surgery due to the high risk of not surviving the
colectomy (109). Furthermore, total colectomy may not completely remove C.
difficile from the GI tract. In rare instances, CDI returned to the small bowel of
patients that underwent total colectomies, presenting comparable symptoms as
seen in the colon (110-112). Small bowel CDI is not well understood however;
others and we have found that although C. difficile is prominent in the cecum and
colon, spores and cells are also found in the upper GI tract of animals (113, 114).
It is likely that C. difficile spores can persist in the small intestine and begin
outgrowth after surgery resulting in small bowel CDI.
Careful use of antibiotics, early and reliable C. difficile testing, isolation of
CDI patients, and proper decontamination of hospital surfaces are the current
preventative measures for outbreaks of C. difficile (35). A recent study from a
hospital following CDI prevention guidelines showed the persistence of C. difficile
spores in stools, on skin and in the environment of CDI patients up to six weeks
after diarrhea was resolved (115). Glove use during contact with all patients is
not enforced in health care settings and could potentially lead to the transmission
of spores (35). Spores are not affected by typical disinfectants; therefore specific
C. difficile sporicidal-labeled cleaning agents are required for cleaning
contaminated surfaces (35). Unfortunately patients may not begin to show signs
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of CDI until after discharge from the hospital by which time a new patient may
inhabit the contaminated room (63). This persistence of spores provides potential
reservoirs for transmission and recurrence in patients and hospital outbreaks
(115). As described, prevention of CDI in the healthcare setting is a serious
problem. In even the strictest settings, outbreaks can still occur. As the number
of cases increases yearly, researchers are trying to understand C. difficile and
find proper ways to eradicate it from hospitals.
1.3. Sporulation and Germination
Endospore-forming bacteria produce spores during stressful conditions
like nutrient deprivation (10). Cells respond to signals from the external and
internal environments and initiate sporulation processes. Sporulation initiator and
regulator proteins are activated and subsequently activate a cascade of
sporulation proteins and sigma (σ) factors (116). The mother bacterial cell
produces a septum that separates the cellular material from a portion of the cell
pole (Fig. 1.4). The prespore is then engulfed inside the mother cell for
application of the synthesized spore cortex and spore coat (Fig. 1.4). After spore
maturation, the mother cell is lysed resulting in the release of the free spore (Fig.
1.4) (116).

Sporulation has been well studied in Bacillus subtilis but not as

thoroughly for C. difficile. Analyses have shown that many but not all sporulation
genes are conserved between B. subtilis and C. difficile (116). An interesting
difference is that B. subtilis requires up to 3 hours to transition from initiation of
sporulation to forespore formation whereas C. difficile can take 8-20 hours for the
same transition (116). This wide and variable range of time for C. difficile
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sporulation may explain the variation seen in the amount of spores produced by
different strains in vitro (117, 118).

Figure 1.4. Representation of the sporulation cycle of Clostridium difficile. After sporulation has been
triggered, vegetative bacterial cells produce a septum at one pole of the mother cell. This section
separated by the septum is then engulfed creating the prespore. In stages, the cortex and then the
spore coat are produced on the spore. The mature spore is released after lysis of the mother cell.
When the free spore is triggered to germinate, the spore outgrows into the vegetative bacteria.
Adapted from Paredes et al 2005 (116)

The newly formed C. difficile spore is covered by a loosely associated
exosporium that may be important to surface attachment by thin proteinaceous
structures (119, 120). Adhesion to animal cells by pathogens is an important step
in colonization and infection. After the normal gut flora is disturbed by antibiotic
therapy, it is likely that C. difficile spores make contact with and adhere to
previously occupied niches in the intestinal cell lining (119). Using the
exosporium proteinaceous projections, C. difficile spores attach to cells allowing
the spore to anchor itself to the intestinal wall (119).
The exosporium covers a complex, dense polypeptide component called
the spore coat (Fig. 1.5). Unlike other Bacillus and Clostridia, the genome of C.
difficile only encodes 18 of the 70 conserved spore coat proteins (121, 122). It
has been postulated that like B. subtilis, the spore coat in C. difficile has surface
proteins rich in cysteine residues that form a rigid lattice around the inner spore
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(121). These cysteine residues form disulfide bonds under aerobic (oxidative
conditions) and this mesh is weakened in the anaerobic (reducing) environment
of the host gut (121). The identity of these proteins is currently unknown but they
have likely diverged from the common ancestor of Bacillus and Clostridia. The
spore coat likely plays a part in the passage of small molecules (germinants) to
the inner layers of the spore (123). The spore coat is also responsible for
protection of the inner spore layers against harsh chemicals and lysozyme (124).
The spore cortex is separated from the coat by an outer membrane. The
cortex is comprised of highly cross-linked peptidoglycan layers forming a cagelike structure around the spore’s inner membrane and spore core (Fig. 1.5) (125).
The spore cortex plays an important role during germination of spores. As the
spore core becomes hydrated (during germination), hydrolytic enzymes are
released to degrade the cortex. This step is essential for proper spore
germination so that the spore core can become fully hydrated without the
physical barrier of the cortex (116, 123).
The inner membrane is a very rigid lipid bilayer and is the location of
germination receptors (Ger) that are found in almost all Clostridia and Bacillus
species, except C. difficile (95). Although C. difficile lacks known germination
proteins, it is expected that receptors, unique to C. difficile, are also located on
the inner membrane of the spore (126, 127). The inner membrane’s rigidity is
suspected to be due to immobile polycrystalline structures (Fig. 1.5) (128). The
inner membrane has very low permeability to protect DNA in the core. Even
water is prevented from crossing the membrane in a dormant spore (129, 130).
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The inner spore core is the location of dehydrated RNA, DNA, and
metabolic enzymes required for degradation of the spore layers and for
outgrowth (Fig. 1.5). The spore core is anhydrous and filled with a calciumdipicolinic acid complex that confers heat resistance (131). Acid-soluble proteins
(SASP) are associated with spore DNA to resist ultraviolet light radiation and
SASPs make up 10-20% of the total protein in the spore core (131). Due to their
unique structure and durability, C. difficile spores are metabolically dormant
structures that are highly resistant to harsh chemicals, temperature, desiccation
and can persist in aerobic environments (71).

Figure 1.5. Generalized C. difficile spore structure.

Like other Bacilli and Clostridia, when C. difficile spores encounter
favorable nutrient-rich environments they undergo a series of events termed
germination that lead to metabolically active vegetative bacteria (125, 132). Small
molecules and combinations of molecules trigger the irreversible first step in the
commitment to germinate (128). In fact Bacillus and Clostridia recognize a
number of different small molecules including but not limited to: amino acids,
carbohydrates, nucleosides, salts, and bile acids (125, 133-136). In most Bacillus
and Clostridia, it is believed that these molecules traverse the outer layers of the
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spore to bind to proteinaceous germination (Ger) receptors located on the inner
membrane (126). The germinant activates the receptors and water is transported
to the spore core to partially rehydrate the molecules inside. Upon water entry,
the spore’s large store of Ca2+-dipicolinic acid (DPA) complex is released. The
small acid-soluble proteins associated with DNA are hydrolyzed and the amino
acids released are used for outgrowth (131). Lytic enzymes disintegrate the
spore coat and cortex resulting in total hydration of the spore core contents (126,
131). During the spore germination process, spore-specific characteristics such
as refractility, resistance and dormancy are lost (125). The cell escapes from the
spore coats, becomes metabolically active, resumes vegetative growth and
multiplies (126, 131). In stressful conditions or as a survival strategy, vegetative
cells can renew the sporulation process as described before.
The Ger proteins are highly conserved in all sequenced Bacillus and
Clostridia spp. when using Basic Local Alignment Search Tools (BLAST).
Surprisingly, C. difficile genes encode analogs for most spore-specific proteins
except for Ger receptors and most spore coat proteins (95). C. difficile must
germinate to cause disease, therefore the C. difficile germination binding site(s)
may be very divergent from other species or they use a different set of proteins to
detect germinants (95). The lack of known germination receptor analogs in C.
difficile has impeded the use of genetic tools to design mutants. Recently a
mariner-based transposon system has been designed for mutagenesis in C.
difficile. However, preliminary phenotypic screening of the mutant library has
yielded a single clone that is defective in sporulation and/or germination (137).
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Genetic manipulation of C. difficile is still in the infancy of general use and
research in C. difficile germination will take time. An alternative approach to study
C. difficile spore germination is kinetic methods and chemical probes (127, 134).
1.4. Clostridium difficile Spore Germination
Since early cultivation of C. difficile, researchers have found that bile salts
(bile acids) are required for optimal growth in vitro (138, 139). A recent article
revealed that C. difficile spores recognize glycine, an amino acid, and
taurocholate, a natural primary bile salt, as germinants (140). Furthermore,
chenodeoxycholate another natural primary bile salt, has been shown to inhibit
C. difficile spore germination in vitro (141). Deoxycholate, a secondary bile salt,
has been shown to inhibit the growth and multiplication of vegetative C. difficile
cells (134, 140). The dynamics between the chemistry of the GI tract and
indigenous bacteria play a crucial role in establishment of C. difficile.
Unfortunately, many details are not well understood (7, 142).
Primary bile salts are synthesized in the liver of mammals from cholesterol
and secreted into the duodenum via bile ducts (Fig. 1.6) (143). The basic bile salt
structure has three six-membered rings and one five-membered ring with
hydroxyl groups and methyl groups at specific locations. Before secretion into the
GI tract, bile salts are conjugated to glycine or taurine thereby increasing their
solubility and decreasing passive absorption (Fig. 1.7) (143, 144). High amounts
of conjugated bile salts in the intestinal lumen increases the removal of
cholesterol and other lipids and aids in the digestion of fats for absorption.
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Indigenous bacteria in the GI tract alter bile salts by deconjugation and
dehydroxylation generating secondary bile salts (Fig. 1.6) (143, 144).

Figure 1.6. Conversion of cholesterol to bile acids.

The majority of bile acids are reabsorbed and recycled to the liver from the
distal ileum however; approximately 400-800 mg of bile passes to the cecum
(145, 146). The concentration of primary bile salts in the upper GI tract is
estimated at 10 mM and 2 mM in the lower GI tract (147). In the lower intestine
the indigenous bacterial flora transform primary bile acids into secondary bile
acids. Glycocholate is also deconjugated, resulting in an increase of free glycine
(144, 148). Researchers have hypothesized that in a healthy person, ingested
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spores encounter high levels of primary bile salts in the upper GI tract but may be
inhibited from outgrowth due to the aerobic environment and the presence of
chenodeoxycholate (140, 141). In the lower intestine where normal flora
transform primary bile salts into secondary bile salts, specifically deoxycholate,
growth is inhibited and cells are excreted (140). Chenodeoxycholate has a
reabsorption rate ten times greater than taurocholate in the anaerobic colon
where C. difficile spores likely germinate (149). Although chenodeoxycholate is
more readily absorbed, taurocholate is deconjugated by normal flora thus
decreasing the concentration of taurocholate in a healthy gut (149).

Figure 1.7. Synthesis of conjugated bile acids.
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Following antibiotic treatment, the indigenous flora is disrupted. Previous
reports show that after antibiotic treatment, the amount of secondary bile salts is
reduced and primary bile salts increase in animals (7, 140). The authors
postulate that bile salt shift could allow for outgrowth and colonization by C.
difficile (7).

Because chenodeoxycholate is more readily absorbed, the

concentration of chenodeoxycholate is likely too low to prevent germination in
response to the high level of taurocholate. In fact, a recent study has shown that
C. difficile spores germinate more efficiently in GI tract extracts, high in primary
bile salts, taken from antibiotic treated animals than from GI extracts from
untreated animals which contained a mixture of primary and secondary bile salts
(7). Although the concentrations of specific bile salts are unknown in antibiotic
treated mammals, it is clear that disruption of the indigenous microflora result in
susceptibility to C. difficile.
Neither glycine nor taurocholate has been previously described to activate
spore germination in Bacillus and Clostridium species, suggesting a novel mode
of germinant recognition in C. difficile spores. C. difficile spores have adapted for
survival in a variety of conditions but will germinate in the presence of specific
molecular signals found in the appropriate environment, the intestinal tract (126,
131). Highly conserved Bacillus and Clostridium germination receptors have not
been identified in C. difficile. However, recent in vitro analyses provide evidence
of receptor-like germination binding site(s) (127). Taurocholate is used by the
mammalian body to emulsify fatty acids and therefore could activate C. difficile
spore germination by non-specific disruption of spore membranes. However, our
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lab has previously shown that C. difficile spores do not germinate in the presence
of highly concentrated surfactants such as sodium dodecyl sulfate or Triton X100 (127). Kinetic analysis of C. difficile spore germination in the presence of
taurocholate and glycine shows that spores bind taurocholate and glycine in a
complex cooperative mechanism (127). This study shows that the binding of one
germinant increases the affinity for the second. Similar cooperativity, with
different germinants, has been shown with Bacillus cereus and Clostridium
sordellii (133, 136). The presence of germination receptors is also evidenced by
the ability of germinants to saturate the binding site(s) (127). Furthermore,
chenodeoxycholate, another fat emulsifier, is a competitive inhibitor of
taurocholate and is recognized specifically by the same binding site(s) (127,
141). Competitive inhibitors of C. difficile spore germination are important for
potential CDI prophylaxis treatments, especially those with a strong affinity for
the binding site even when present at low concentrations. Anti-germinants as
drugs would bind to C. difficile spores, preventing germination, and allowing the
spore to be excreted harmlessly. These reports provide evidence that C. difficile
likely encodes unknown receptor proteins to bind germinants and that other
molecules compete for these binding sites, inhibiting spore germination (127).
1.5. Aims of This Study
The initial aim of this study was to perform a structure-activity analysis of
C. difficile spores and analogs of glycine, taurocholate, and chenodeoxycholate.
This type of analysis provides evidence of functional group requirements for
recognition by the putative germination binding site(s) in C. difficile spores. Due
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to the scarcity of genetic tools, many of the metabolic capabilities encoded by C.
difficile remain poorly understood (150). This has precluded the use of molecular
microbiology to identify putative germination binding site(s) encoded by C.
difficile. As an alternative to genetic manipulation, molecular probes can be used
to study the mechanism of Bacillus and Clostridium spore germination (127, 133,
151). This provides mechanistic information, even when the identity of the
germination binding site(s) is unknown (136).
While mapping the interactions between C. difficile spores and germinants
we discovered a bile salt analog, CamSA, capable of strongly inhibiting spore
germination in vitro (Fig. 1.8). As a secondary, we hypothesized that by
screening CamSA analogs we could determine the functional groups essential
for CamSA’s potency. Furthermore, during this second structure activity analysis
we hoped to discover compounds more potent than CamSA at inhibiting C.
difficile spore germination in vitro.
Based on in vitro structure activity analyses, CamSA was chosen as a
lead compound for further study. The third aim was to characterize CamSA in
vitro for stability, oral bioavailability and cytotoxicity. The final aim was to
challenge animals with C. difficile spores or vegetative cells and treat these
animals with CamSA. We hypothesized that CamSA could prevent signs of CDI
in mice by preventing C. difficile spore germination into toxin-producing bacteria.

Figure 1.8. Structure of CamSA.
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CHAPTER 2
MAPPING INTERACTIONS BETWEEN GERMINANTS AND CLOSTRIDIUM
DIFFICILE SPORES
2.1. Introduction
Germination of C. difficile spores is the first required step in establishing
CDI (152, 153). Taurocholate, a bile salt, and glycine, an amino acid, have been
shown to be important germinants of C. difficile spores (Fig. 2.1) (140). The
question that has remained unanswered is how glycine and taurocholate interact
with the putative binding sites. Structure-activity relationship analysis of
germinant analogs allows a better understanding of the microenvironment of the
C. difficile germination binding site(s) (127, 133, 151). This approach provides
mechanistic information, even when the identity of the germination binding site(s)
is unknown by identifying essential functional groups for recognition (136). In the
current work, 30 amino acid analogs and 22 taurocholate analogs were tested as
activators or inhibitors of C. difficile spore germination. Activators of the
germination pathway identify functional groups essential for binding and
activation of the C. difficile germination binding site(s). On the other hand,
inhibiting agents provide structural details about functional groups that allow only
binding. Inhibition assays serve as an indirect method to map physiochemical
configurations in the receptor binding site(s). Competitive inhibitors most likely
bind to the same site as the cognate germinant. Strong competitive inhibitors
complement the germinant binding site shape, size, hydrophobicity, and
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hydrogen bonding pattern. Inactive compounds yield information on functional
group changes that interfere with germinant binding (151).

Figure 2.1. The structure of taurocholate (left) and glycine (right). The four rings of
the cholate backbone are labeled A-D.

As expected, changing glycine and taurocholate functional groups affected
the germination of C. difficile spores. Structure-activity relationship analysis
allowed the determination of which taurocholate and amino acid functional
groups are necessary and sufficient to bind to and/or activate C. difficile spores.
The data suggests either the presence of multiple amino acid germination
binding site(s) or that the putative glycine binding site(s) recognizes structurally
diverse amino acids. Furthermore, the putative taurocholate germination binding
site(s) recognizes its cognate germinant through multiple molecular interactions.
In fact, one interesting molecule was discovered that is four times more active
than the natural inhibitor, chenodeoxycholate, at inhibiting C. difficile spore
germination.

2.2. Materials and Methods
2.2.1. General Comments
Taurocholate and amino analogs were purchased from Sigma Aldrich
Corporation (St. Louis, MO), Steraloids (Newport, RI) or were synthesized in the
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Abel-Santos laboratory. Reagents for synthesis were purchased from Sigma
Alrdrich Corporation (St. Louis, MO) or Alfa Aesar (Ward Hill, MA). Thin layer
chromatography silica gel 60 F254 was purchased from EMD Chemicals
(Gibbstown, NJ). Silica gel for column chromatography was purchased from
Fisher Scientific (Pittsburg, PA).
2.2.2. Synthesis of Methoxylated Taurocholate Analogs
Two

methoxylated

taurocholate

analogs,

3-methoxy-7,12-

dihydroxytaurocholate [T09] and 3,7-dimethoxy-12-hydroxytaurocholate [T10],
were prepared following published procedures (154) (Scheme 2.1). To a solution
of taurocholate (1 equivalent – 1mM) in dry 1,4-dioxane, methyl iodide (50 eq.)
and sodium hydride (4 eq.) was added under nitrogen. The reaction mixture was
heated to 40 °C for 48 h with stirring. After the initial 48 h, sodium hydride (4 eq.)
was added daily to the reaction mixture for four additional days. The reaction
mixture was then diluted with dichloromethane and washed once with 1 M HCl
and twice with water. The organic layer was dried over anhydrous sodium
sulfate, and the solvent was removed under reduced pressure. The resulting
residue was purified by silica gel column chromatography eluted with a step
gradient from 100% dichloromethane (DCM) to 60% dichloromethane/acetone.
Two different compounds were obtained. Final yield for each compound was less
than 10%.

1

H nuclear magnetic resonance (NMR) and mass spectrometry

showed that one compound had a single methoxy group and the second
compound had two methoxy groups and were greater than 95% pure. The
compounds were tentatively identified 3-methoxy-7,12-dihydroxytaurocholate
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[T09] and 3,7-dimethoxy-12-hydroxytaurocholate [T10], as expected from
published OH reactivity (155, 156).

Scheme 2.1. Synthesis of methoxylated taurocholate analogs.

2.2.3. Synthesis of T11 to T16 and T18 to T21
The taurocholate analogs were prepared following published procedures
(157, 158). Cholic acid (1 eq. - 1mM) was activated with 1.4 eq. of Nethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)

and

1.3

eq.

of

N-

methylmorpholine (NMO) in dimethylformamide (DMF) (Scheme 2.2). After the
mixture was stirred for 5 min, 1.2 eq. of the appropriate amino sulfonic acid or
amino acid was added. The reaction mixture was heated to 90 °C for 40 min and
then cooled to room temperature. The solution was poured into 100 ml of ice-cold
diethyl ether, resulting in a precipitate. The ether suspension was kept at 4 °C
overnight. The ether layer was decanted and the resinous residue was dissolved
in 25 ml 0.2 N NaOH-MeOH and poured into 100 ml cold diethyl ether. The ether
solution was kept at 4 °C for at least 2 h and the resulting precipitate was filtered
and washed with diethyl ether. If necessary, the product was recrystallized by
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dissolving in hot ethanol to saturation, followed by the addition of ethyl acetate
until a precipitate appeared. The solution was kept at -20 °C for 2 h to allow
complete precipitation and then filtered to retrieve the product. The precipitated
residue was further purified by silica gel column chromatography eluted with a
step gradient from 100% DCM to 100% ethanol (EtOH). Two compounds
CA2APA [T19] and CA2ABA [T21] were obtained as side products of the
synthesis of CAAPA [T18] and CAABA [T20], respectively. Percent yields were
typically 30 – 80%. Compound structures were verified by 1H-NMR, Fourier
transform infrared spectroscopy (FTIR), and mass spectrometry. Synthesized
compounds were determined to be >95% pure based on HPLC-MS and NMR
analysis. Representative verification data for CamSA [T15] includes 1H NMR, FTIR, and MS (Fig. 2.2 and 2.3). 1H NMR (400 MHz, methanol-d4, ppm) δ = 7.93 (s,
1H), 7.78 (d, 1H, J = 12.00 Hz ), 7.53 (d, 1H, J = 8 Hz), 7.34 (t, 1H, J = 16.00
Hz), 3.96 (s, 1H), 3.80 (s, 1H), 3.34 (m, 3H), 2.41 (m, 1H), 2.27 (m, 3H), 1.88 (m,
5H), 1.76 (m, 2H), 1.50 (m, 12H), 1.06 (m, 4H), 0.98 (m, 1H) 0.91 (s, 3H), 0.72
(s, 3H). MS m/z 562.42 [M-H]-.

Scheme 2.2. Synthesis taurocholate analogs.
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Solvent

H2 O

1

Figure 2.2. H NMR spectrum of CamSA [T15]. Water and residual solvent peaks are from CD3OD.

Figure 2.3. FT-IR spectra of CamSA [T15].
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2.2.4. Synthesis of CaHESA [T22]
Conjugation of cholate to the sulfonic acid alkyl linker by an ester was
prepared following established protocols for Fischer esterification (159-161). To a
solution of cholate (1 eq. - 1mM) and hydroxyl ethane sulfonic acid (4 eq.)
concentrated sulfuric acid was added dropwise and refluxed for 1 h (Scheme
2.3). The reaction mixture was poured into cold diethyl ether, and a precipitate
formed immediately. The diethyl ether suspension was left overnight at 4°C. The
precipitate was filtered, dissolved in 0.2 N NaOH-MeOH, precipitated a second
time in diethyl ether and kept at 4°C for at least 2 h. The crude precipitate was
filtered and purified by silica gel column chromatography eluted by step gradient
from 100% DCM to 30% DCM/EtOH. The final yield was 20%. The compound
structure was verified and determined > 95% pure by 1H-NMR, FTIR, and mass
spectrometry.

Scheme 2.3. Synthesis of taurocholate analog, compound T22.

2.2.5. Bacterial Strains and Spore Preparation
Clostridium difficile strain 630 was obtained from American Tissue Culture
Collection (ATCC) (BAA-1382). C. difficile strain 630 is an epidemic strain
clinically isolated from a patient with pseudomembranous colitis in Zurich,
Switzerland in the early 1980s and is highly virulent and transmissible (122). C.
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difficile cells were plated on BHIS (brain heart infusion salt) agar supplemented
with 1% yeast extract, 0.1% L-cysteine-HCl and 0.05% sodium taurocholate to
yield single-cell colonies. Single C. difficile colonies were grown in BHIS broth
until exponential phase (approximately four hours) and spread plated onto agar
to obtain bacterial lawns. The plates were incubated for five days at 37 °C in an
anaerobic environment (5% CO2, 10% H 2, and 80% N2). The resulting bacterial
lawns were collected by flooding the plates with ice-cold deionized water. Spores
were pelleted by centrifugation at 8,800 x g for five minutes and resuspended in
fresh deionized water. After two washing steps the spores were separated from
vegetative and partially sporulated forms by centrifugation through a 20% to 50%
HistoDenz gradient at 18,200 x g for 30 minutes with no brake. The spore pellet
was washed five times with water, resuspended in sodium thioglycolate (0.5 g/L)
and stored at 4 °C.
Immediately before in vitro germination and inhibition assays, spores were
transferred to fresh tubes, centrifuged and washed with deionized water five
times to remove storage buffer. Purified spores were heat activated at 68 °C for
30 minutes and washed another five times with water. Spores were diluted in
germination buffer (100 mM sodium phosphate buffer at pH 6.0 containing 5
mg/ml sodium bicarbonate) to an optical density at 580 nm (OD580) of 1.0. The
spore strongly refracts light at 580 nm. With the loss of the spore coat and
hydration of the spore core (during germination), there is concomitant loss of
refractility, resulting in a decrease in optical density (162, 163).
2.2.6. Endospore Staining Method
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To determine spore purity, a sample was removed and stained using the
Shaeffer-Fulton staining method (122, 164). The Schaeffer-Fulton method of
endospore staining consists of two stains; a primary stain (malachite green) and
a counter stain (safranin). Slides smeared with spore/cell sample are heat fixed.
Then slides are flooded with malachite green and heated over an open flame for
five minutes. The slide is rinsed and a generous amount of safranin is added and
kept at room temperature (RT) for 1 minute before rinsing. The slide is then
viewed by light microscopy. The malachite green stain irreversibly binds to the
spore coat resulting in visualized green spores whereas the malachite green is
washed from vegetative cell walls. Safranin, a red stain, is then used to stain the
vegetative cells resulting in a contrast of green spores and red vegetative cells
(Fig. 2.4). Spore preparations were generally >95% pure after HistoDenz
gradient.

Figure 2.4.C. difficile stained using the Schaeffer-Fulton endospore staining method.

2.2.7. Activation of C. difficile Spore Germination
To test for

taurocholate activators

of

spore

germination,

spore

suspensions at OD580 of 1.0 were individually supplemented with 6 mM of a
taurocholate analog and 12 mM glycine (127). To test for amino acid activators of
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spore germination, spore suspensions were supplemented with 12 mM of an
amino acid analog and 6 mM taurocholate. As control, spores were treated with
taurocholate at 6 mM and glycine at 12 mM. Spore germination was evaluated
based on the decrease in OD580. The OD580 was measured each minute for 90
min at 30 °C and was repeated in triplicate. A 90% decrease in optical density
was determined for spores treated with taurocholate and glycine (control). This
was considered maximum germination and was set at 100%. The time point for
maximum germination was set as a reference point to compare analogs. The
percent germination at this reference time point for all analogs was calculated
and compared to spores germinated with taurocholate and glycine. As expected,
a decrease in optical density similar to taurocholate/glycine was observed in the
presence of active germinants (Fig. 2.5A). The resulting data were fitted using
the four-parameter logistic function of SigmaPlot v.9 to obtain the half maximal
effective concentration (EC50) (165, 166). The EC50 value is a relative number
used to compare analogs.

34

C

D

%
Ge
rm
ina
tio
n

%
Ge
rm
ina
tio
n

2.2.8. Inhibition
Concentration
(mM)

of C. difficile Spore Germination
Concentration (mM)

Figure
Germination
kinetic graph
showing germinant
and inhibitor
behavior
molecules
of 1.0
To2.5.test
for inhibitors
of examples
spore germination,
spore
aliquots
ODof580
with C. difficile spores. A) Activation of germination. C. difficile spores were treated with a fixed
concentration of taurocholate (6 mM) and glycine was added at 0 mM (ο), 8 mM (), 10 mM (☐), 12 mM
were
various
concentrations
of a intervals
taurocholate
(), individually
and 14 mM () supplemented
final concentrations.with
For clarity,
the data
are shown at five minute
and for
only five glycine concentrations. B) Inhibition of germination. C. difficile spores were incubated with 0 mM
(ο), 0.0005
(), 0.001
mM
(☐), 0.075
mM (),
and 7.5 mM ()were
concentrations
of CamSA
analog
or anmM
amino
acid
analog.
Spore
suspensions
incubated
for 15[T15]
minand
at
supplemented with taurocholate (6 mM) and glycine (12 mM). For clarity, the data are shown at five
minute intervals and for only five CamSA [T15] concentrations. Although data were collected for 90
room
temperature
while
the inOD
was
monitored.
If no
germination
was
minutes,
only 75 minutes
are shown
both580
graphs
for clarity.
The error bars
indicate
standard
deviations, n = 3. C) Calculation of EC50 for compound T11. D) Calculation of IC50 for compound T15,
CamSA. For both C and D graphs the percent germination was determined as described and plotted
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taurocholate and glycine were added to 6 and 12 mM final
versus concentration. The data was fitted using a four-parameter logistic function to obtain values for
EC50 and IC50.

concentrations, respectively. Relative OD 580 values were obtained every minute
for 90 min after germinant addition. As before, a 90% decrease in OD580 was

determined for spores treated with taurocholate and glycine only and set as a
reference point for comparisons. As expected, there was less change in OD 580
over time in the presence of active germination inhibitors at increasing
concentration (Fig. 2.5B). The resulting data were fitted using the four-parameter
logistic function of SigmaPlot v.9 to obtain the half maximal inhibitory
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concentration (IC 50) values (165, 166). The IC50 value is a relative number used
to compare analogs.

2.2.9. C. difficile Spore Germination in BHIS Medium
To test for germination in complex media, spores were resuspended in
BHIS alone and with combinations of taurocholate, chenodeoxycholate,
glycocholate, glycine, L-arginine, and L-phenylalanine. Bile salts were added to a
final concentration of 6 mM and amino acids were added at a final concentration
of 12 mM. Relative OD580 values were obtained every minute for 90 min after
germinant addition.

Figure 2.6. Flow chart used to identify germinants or inhibitors of C. difficile spore germination.

2.3. Results and Discussion
2.3.1. Effects of Amino Acids and Analogs with C. difficile Spores
Glycine [A01] has a methylene bridge that separates the carboxylic and
amino groups and is the simplest of the 20 common amino acids (Fig. 2.7). To
find determinants required for glycine recognition, taurocholate-treated spores
were individually supplemented with 30 different glycine analogs. Each of the
glycine analogs differs from the parent compound by a single modification in
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either the length of the alkyl chain, substitutions to the amino group, changes in
the carboxylate group or changes in the side chain. β-Alanine [A02] and γaminobutyric acid [A03] have an ethylene and a propylene bridge between the
amino and carboxylate group, respectively (Fig. 2.7). These changes
progressively increase the distance between the amino and carboxylate groups.
β-Alanine and γ-aminobutyric acid are effective as glycine as co-germinants of C.
difficile spores (Fig. 2.13). Thus, lengthening the chain between the amino and
carboxylate functional groups does not interfere with recognition by the putative
glycine germination binding site(s).

A01

A02

A03

Figure 2.7. Amino acids and alkyl chain length. Glycine
(A01) and analogs A02 – A03.

Aminomethylphosphonic acid [A04] is a glycine analog in which the
carboxylate has been changed to a phosphonic acid (Fig. 2.8). This substitution
exchanges a carbon atom for phosphorus while retaining the negative charge.
A04

significantly

decreased

C.

difficile

spore germination

(Fig.

2.13).

Furthermore, methylation of the carboxylate in glycine methyl ester [A05] (Fig.
2.8) resulted in less than 10% germination compared to glycine-triggered
germination (Fig. 2.13). A05 was previously shown to be unable to trigger
germination in C. difficile spores and this finding supports that claim (127). Any
other modification of the carboxylate (glycine ethyl ester [A06], glycinamide
[A07], and glycine hydroxamate [A08]) (Fig. 2.8) resulted in compounds that were
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unable to activate or inhibit C. difficile spore germination. The sum of these data
suggests that there is a specific requirement for a carboxylate functional group
for recognition by the glycine germination binding site(s) to activate germination.
The distance between the amino and carboxylate of diglycine [A09] is
similar to that of γ-aminobutyric acid [A03] (Fig. 2.8). However, whereas γaminobutyric acid is a good activator of C. difficile spore germination, diglycine
has no effect. Thus, the addition of an internal amide must interfere with
compound binding. Possibly there is a requirement for a more hydrophobic linker
between the two functional-group ends. Glycine anhydride [A10] is the result of
the dehydration of diglycine, forming a cyclic diamide (Fig. 2.8). Without a free
amine or carboxylate, this compound is unable to activate or inhibit C. difficile
spore germination. The rigidity and bulkiness of the analog may prevent
interaction with the glycine binding site.

A01

A04

A05

A07

A08

A09

A06

A10
Figure 2.8. Amino acids with modifications to carboxyl group. Glycine (A01)
and analogs A04 - A10.
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Alkylation (sarcosine [A11], N,N-dimethylglycine [A12], and betaine [A13]),
acetylation (N-acetylglycine [A14]), or other modification (nitrilotriacetic acid
[A15]) to the amino group of glycine resulted in compounds that can neither
activate nor inhibit C. difficile spore germination (Fig. 2.9). This suggests that
activation of C. difficile spores by glycine has a requirement for a free primary
amino group regardless of the presence of an unmodified carboxylate group.

A01

A11

A13

A14

A12

A15
Figure 2.9. Amino acids with modifications to the
amino group. Glycine (A01) and analogs A11-A15.

To test the effect of side chain substitution in amino acid recognition by
the C. difficile germination binding site(s), we exposed taurocholate-treated C.
difficile spores to other amino acid analogs (Fig. 2.10). L-Alanine [A16] has been
shown to act as a germinant and/or co-germinant in other sporulating bacteria
(133, 167). The stereoisomer, D-alanine [A17], has been shown to inhibit
alanine-mediated germination in Bacillus (168). In C. difficile, L-alanine was as
efficient at triggering germination as glycine [A01] (Fig. 2.13). Interestingly, Dalanine was unable to inhibit the germination of spores treated with L-alanine and
taurocholate. D-Alanine was also inactive as an activator of C. difficile spore
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germination. This implies that stereochemistry is important for recognition and
binding of amino acids.

A01

A16

A17

Figure 2.10. Alanine amino acids. Glycine (A01), Lalanine (A16) and D-alanine (A17).

To determine whether amino acid analogs with longer linear alkyl side
chains were able to activate C. difficile spore germination, taurocholate-treated
spores were exposed to L-2-aminobutyric acid [A18] and L-norvaline [A19] (Fig.
2.11). Both of these amino acid analogs were able to activate germination to
levels similar to those with glycine [A01] (Fig. 2.13). L-valine [A20] is a branched
isomer of L-norvaline and has similar chemical and physical properties (Fig.
2.11). However, this slight difference in structure reduced C. difficile spore
germination by more than 90% compared to that of L-norvaline. Similarly, Lisoleucine [A21] and L-leucine [A22] are poor germinants of C. difficile spores
compared to L-norvaline (Fig. 2.13). The data suggest that branched alkyl side
chains are unable to be recognized by the putative amino acid germination
binding site(s) in C. difficile.
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A01

A18

A19

A20

A21

A22

Figure 2.11. Amino acid with linear alkyl side chains.
Glycine (A01) and analogs A18 - A22.

L-Cysteine [A23] is an amino acid with a methanethiol side chain (Fig.
2.12). L-Serine [A24], on the other hand, is an L-cysteine analog in which the
thiol group is substituted for a hydroxyl group. Interestingly, whereas L-cysteine
is a good germinant of C. difficile spores, the more polar L-serine is almost
inactive (Fig. 2.13). The germination activity of L-cysteine is not due solely to
hydrophobicity, since the more hydrophobic L-methionine [A25] is a poor
germinant compared to L-cysteine (Fig. 2.13). This suggests that C. difficile
recognize the thiol group specifically as a determinant for germination.
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A01

A23

A24

A27

A25

A28

A29

A26

A30

Figure 2.12. Amino acids with modified alkyl side chains. Glycine (A01) and amino acids
A23 - A30.

Surprisingly, L-phenylalanine [A26], with a bulky aromatic side chain, is as
effective as glycine as a germinant of C. difficile spores (Fig. 2.12 and 2.13). A
reasonable expectation is that since branched amino acids are inactive, the
bulkier side chain of L-phenylalanine would also be restricted from the binding
site. The possibility that the putative glycine binding site(s) is able to
accommodate phenyl but not branched alkyl side chains cannot be completely
ruled out. However, that possibility is unlikely due to their sizes relative to glycine.
Hence, we postulate that aromatic amino acids are recognized by a separate
binding site in C. difficile spores. Indeed, other Bacillus and Clostridium strains
are able to recognize structurally different germinants by encoding multiple
binding site(s) (125, 126, 136, 151).
L-Arginine [A27] is also a strong co-germinant for C. difficile spores.
Although L-arginine has a linear alkyl chain, it also contains a positively charged,
branched guanidinium group (Fig. 2.12). Similarly, L-lysine [A28] is linear with a
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positively charged amino aside chain, yet L-lysine is a weak germinant compared
to L-arginine (Fig. 2.13). L-Histidine [A29] contains an aromatic side chain, like Lphenylalanine [A26], but it is positively charged (at physiological pH), like the Larginine side chain (Fig. 2.12). However, unlike L-phenylalanine or L-arginine, Lhistidine could not efficiently activate C. difficile spore germination. L-Aspartic
acid [A30] has a short acidic side chain and was similarly unable to affect C.
difficile spore germination. Since L-arginine has physicochemical properties that
are very different from those of the other amino acids that are able to activate C.
difficile spore germination, it suggests there is a specific recognition site for Larginine binding.

Figure 2.13. Comparison of amino acids as activators of C. difficile spore germination. Spores were
treated with taurocholate (6 mM) and amino acid analogs at 12 mM. Germination was determined by the
decrease in the OD580 for 90 min at 30 °C. The percent germination for each analog was calculated
based on glycine/taurocholate germination set as 100%. The error bars indicate standard deviations,
n = 3. Significant difference (p < 0.01) observed between glycine and each analog showing less than
85% germination (A04, A05, A20, A21, A23, A24, A25, A28, and A29).

All glycine analogs and amino acids were further tested for the ability to
inhibit C. difficile spore germination. Spores were treated with each analog or
amino acid in the presence of taurocholate and glycine. However, no individual
amino acid analog inhibited C. difficile spore germination.
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In conclusion, multiple amino acid analogs are able to activate germination
and the data suggests that there may be separate binding sites for phenylalanine
and arginine. Furthermore, no amino acids were able to inhibit C. difficile spore
germination.
2.3.2. Effects of Amino Acid Combinations on C. difficile Spore Germination
Earlier studies (140) reported that only glycine was able to trigger C.
difficile spore germination in the presence of taurocholate. This study reportedly
used three combinations of defined media to narrow down active germination
stimulators. Although glycine was supplemented with only seven amino acids,
phenylalanine and arginine were in a mixture supplemented with 15 other amino
acids. The presence of multiple weak germinants in the defined media containing
phenylalanine and arginine could mask their ability to stimulate germination.
Furthermore, in those experiments, L-phenylalanine and L-arginine were
supplemented at concentrations (1.21 mM and 1.15 mM, respectively) lower than
those used for the current experiments (12 mM) (140).
Glycine, L-arginine, and L-phenylalanine individually or in pairs do not
trigger C. difficile spore germination in the absence of taurocholate. However, a
cocktail of L-phenylalanine, L-arginine, and glycine (all at 12 mM) was able to
effectively trigger C. difficile spore germination in the absence of taurocholate.
Chenodeoxycholate (6 mM) is not able to inhibit the germination of C. difficile
spores treated with amino acids only. Other Clostridia have been shown to use
amino acids alone as germination signals (136).
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In conclusion, the data indicate that C. difficile spores can be triggered to
germinate in the presence of glycine, phenylalanine and arginine. This amino
acid cocktail does not require taurocholate for activation nor is it inhibited by
chenodeoxycholate.
2.3.3. Effects of BHIS Medium on C. difficile Spore Germination
When C. difficile spores are resuspended in BHIS medium, germination is
very slow, even though BHIS contains a complex amino acid mixture that
includes glycine, L-arginine, and L-phenylalanine (Fig. 2.14). It is possible that
BHIS contains amino acids that are weak germinants and that compete with
glycine, L-phenylalanine, and L-arginine for binding. Binding of these alternative
substrates causes a fraction of the spore population to germinate. Similar
behavior has been observed in the Abel-Santos lab in the germination of C.
sordellii spores (136). Interestingly, supplementing BHIS with taurocholate [T01]
augmented C. difficile spore germination (Fig. 2.14). The taurocholate-enhanced
spore germination in BHIS was inhibited by chenodeoxycholate. Thus, in
conclusion, amino-acid-only C. difficile spore germination occurs in vitro only
when a limited number of amino acids are present and is disfavored with
complex amino acid mixtures.
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2.3.4. Effect of
Figure 2.14. Germination kinetic graph showing behavior of C. difficile spores and germinants in buffer and
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positions 3, 7 and 12 of the cholate backbone (Fig. 2.15). All three hydroxyl
groups are in the alpha configuration. Taurocholate also has a side chain
consisting of taurine attached to the cholate backbone by an amide bond.
Taurocholate activates C. difficile spore germination with a 50% effective
concentration (EC50) of 15.9 mM (127). Taurocholate analogs were tested for the
ability to activate germination in the presence of glycine and for the ability to
inhibit germination in the presence of taurocholate and glycine.
To understand the importance of hydroxyl groups on the cholate backbone
of taurocholate, analogs T02 to T08 were tested as activatorss of C. difficile
spore germination. These analogs differ from taurocholate [T01] in the number,
placement,

or

stereochemistry

of

the

hydroxyl

groups

(Fig.

2.15).

Taurodeoxycholate [T02] lacks only the hydroxyl group at the 7 position. This
change was sufficient to reduce germination by more than 70% (Table 2.1).
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Meanwhile, taurochenodeoxycholate [T03] is only missing the hydroxyl at
position 12 and was able to induce germination only to 10% of the level of
taurocholate.

Tauroursodeoxycholate

[T04]

is

an

isomer

of

taurochenodeoxycholate in which the 7-hydroxyl is in the beta configuration.
Alteration of the stereochemistry of this one hydroxyl group further decreased
germination

activity from

10%

for

taurochenodeoxycholate

to

3%

for

tauroursodeoxycholate (Table 2.1).
As expected, taurolithocholate [T05] and taurocholanate [T06], which lack
hydroxyls at positions 7 and 12 and 3,7 and 12, respectively are unable to
activate

germination

taurohyodeoxycholate

(Fig.
[T08]

2.15).
are

isomers

Taurohyocholate
of

taurocholate

[T07]
[T01]

and
and

taurodeoxycholate [T02], respectively, in which the 12-hydroxyl groups are
moved to the 6 position (Fig. 2.15). Neither of these compounds is able to
significantly activate germination of C. difficile spores (Table 2.1). The sum of
these data suggests that both the 7 and 12 α-hydroxyls of taurocholate are
important determinants for binding and activation of C. difficile spores.
The 3-hydroxyl position of the cholate molecule is more nucleophilic than
the other two hydroxyls. Similarly, the 7-hydroxyl is more reactive than the 12hydroxyl (155, 156). Thus, methylation of taurocholate yielded two compounds
that we putatively identified as 3-methoxy-7,12-dihydroxytaurocholate [T09] and
3,7-dimethoxy-12-hydroxytaurocholate [T10] (Fig. 2.15). Interestingly, 3-methoxy7,12-dihydroxytaurocholate neither induces nor inhibits C. difficile spore
germination (Table 2.1). As expected, 3,7-dimethoxy-12-hydroxytaurocholate
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was also inactive. This suggests that the ability to donate a 3-hydroxyl hydrogen
bond is essential for recognition of taurocholate as a germinant for C. difficile
spores.
To

determine

if

analogs

differing

in

the

number,

location,

or

stereochemistry of the hydroxyl groups can inhibit taurocholate-mediated
germination, C. difficile spores were treated with taurocholate [T01], glycine
[A01], and compounds T02 to T10 (Fig. 2.15). Only taurochenodeoxycholate
[T03], tauroursodeoxycholate [T04] and taurohyodeoxycholate [T08] showed
germination-inhibitory properties (Table 2.1). All three inhibitors have the
common feature of lacking the 12-hydroxyl group. Since the 12-hydroxyl group
was necessary for triggering spore germination, these results suggest that this
hydroxyl is necessary for activation of germination but not for binding of
taurocholate to the putative C. difficile germination binding site(s). The inhibitory
compounds also have hydroxyl groups at either the 6 or 7 position (but not both),
indicating that having one (but not two) hydroxyls in the B ring is important for
inhibition of taurocholate-mediated germination of C. difficile spores.
In conclusion, bile salt analogs with hydroxyl groups at positions 3 and 12
promoted C. difficile spore germination activation, whereas the hydroxyl group at
position 7 is optimal for binding.
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T01

T02

T03

T04

T05

T06

T07

T08

T09

T10

Figure 2.15. Taurocholate analogs with hydroxyl group modifications. Taurocholate (T01) and taurocholate
analogs T02 - T10.
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Table 2.1. Effect of taurocholate hydroxyl groups on C. difficile spore germination.

a

C. difficile spores were individually treated with 6 mM glycine and 12 mM taurocholate analogs
T01 to T10. The percent germination was calculated based on taurocholate/glycine germination
set as 100%. Standard deviations are shown in parentheses.
b
C. difficile spores were incubated with various concentrations of taurocholate analogs for 15
min prior to the addition of 6 mM taurocholate and 12 mM glycine. The IC50 was calculated by
plotting the extent of germination versus the logarithm of analog T02 to T10 concentrations.
Standard deviations are shown in parentheses.
c
NA, no change in absorbance after 90 minutes under the conditions tested thus no statistics
could be performed.

2.3.5. Effect of Taurocholate Side Chain on C. difficile Spore
Germination and Inhibition
To determine the taurine side chain functional groups responsible for
recognition by the C. difficile germination binding site(s), analogs T11 to T22
were tested for the ability to induce spore germination in the presence of glycine
(Fig. 2.16). All of these compounds differ from taurocholate in the structure of the
side chain and retain the cholate backbone with hydroxyl groups at the 3, 7, and
12 positions.
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T01

T11

T12

T13

T14

T15

Figure 2.16. Taurocholate analogs with modified side chains. Taurocholate (T01) and
analogs T11 - T15.

Compound T11 is a taurocholate analog in which the alkyl linker between
the sulfonate and the amide was shortened by one methylene (Fig. 2.16).
Compound T12, on the other hand, is a taurocholate analog in which the linker
was lengthened by one methylene. The results show that spores treated with
compound T11 germinate to levels comparable with those spores treated with
taurocholate [T01] (Table 2.2). In contrast, the longer alkyl chain, compound T12,
does not activate germination. To further analyze the necessity for the alkyl linker
in germination, three analogs containing a benzene ring in place of the ethylene
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linker of taurine were synthesized. These analogs differed in the position of the
sulfonate, para [T13], ortho [T14], or meta (CamSA) [T15], with respect to the
amino group in the benzene ring (Fig. 2.16). These three taurocholate analogs
were unable to activate C. difficile spore germination (Table 2.2). This suggests
that C. difficile spores are activated by taurocholate analogs with shorter, but not
longer or bulkier, linkers.
Hypotaurocholate [T16] differs from taurocholate by a substitution of a
sulfonate for a sulfinate (Fig. 2.17). This analog was unable to activate C. difficile
spore germination (Table 2.2). Interestingly, glycocholate [T17] is a compound
T11 analog in which a sulfonate has been substituted for a carboxylate (Fig.
2.17). In our hands, glycocholate like compound T11, is able to significantly
activate C. difficile spore germination in buffer (Table 2.2). A previous report had
determined that glycocholate is not a germinant for C. difficile spores in BHIS
medium (140). Indeed, when we tested glycocholate in BHIS medium, the C.
difficile spore percent germination dropped almost 10-fold. However, addition of
glycine to BHIS medium partially restored glycocholate-mediated germination.
Hence, compound mixtures in BHIS medium seem to intrinsically inhibit C.
difficile spore germination.
Compound T18 is a carboxylated analog of taurocholate [T01] (Fig. 2.17).
Interestingly, whereas taurocholate, compound T11, and glycocholate [T17] are
able to activate C. difficile spore germination, compound T18 is inactive.
Similarly, compound T19, compound T20, and compound T21, with longer side
chains, are also inactive (Table 2.2). These results suggest that carboxylate is
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able to partially substitute for sulfonate, but is not optimal for activation of C.
difficile germination.

T01

T16

T17

T18

T19

T20

T21
Figure 2.17. Taurocholate analogs with modified linear side
chains. Taurocholate (T01) and analogs T16 - T21.
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Compound T22 is a taurocholate analog in which an amide group is
substituted for an ester (Fig. 2.18). Compound T22 was unable to trigger
germination in C. difficile spores (Table 2.2). This suggests that the ability of the
amide group to form hydrogen bonds is necessary for C. difficile spore
germination.

T01

T22

Figure 2.18. Taurocholate analog with an ester side chain linkage. Taurocholate
(T01) and analog T22.

To determine whether taurocholate analogs with modified side chains [T11
to T22] can inhibit C. difficile spore germination, the effects of these analogs on
C. difficile spores treated with taurocholate [T01] and glycine [A01] were
analyzed. Taurocholate analogs with one less carbon [T11] or one more carbon
[T12] in the taurine side chain were unable to inhibit germination. Interestingly,
while the addition of a benzene ring in the linker with the sulfonate in the para
[T13] or the ortho [T14] position does not inhibit spore germination. CAmSA [T15]
has an IC50 of 58.3 μM is the strongest inhibitor of C. difficile spore germination
reported so far (Table 2.2). The conversion of the sulfonate functional group to a
sulfinate [T16] resulted in a compound with slight inhibitory activity at an IC50 of
640 μM (Table 2.2). Interestingly, compounds with longer alkyl linkers followed by
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a carboxylate [T20 and T21] are able to inhibit C. difficile spore germination,
whereas shorter carboxylate end groups [T17 to T19] are inactive. Compound
T20 has an IC50 of 762 μM, whereas the longer side chain, Compound T21,
containing two amide groups has an IC 50 of approximately 3,000 μM (Table 2.2).
Replacement of the amide group of taurocholate with an ester [T22] results in a
compound with slight inhibitory activity (IC50 of 1,322 μM).
In conclusion, recognition and activation of C. difficile spore germination
by compounds containing the taurine side chain is optimal however a shorter
side chain is also capable of activating germination. Longer and bulkier side
chains are not able to activate C. difficile spore germination, but several were
able to inhibit germination in vitro. Furthermore, compound T15 is a potent
inhibitor of C. difficile spore germination.
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Table 2.2. Effect of taurocholate side chain (R) on C. difficile spore germination.

a

C. difficile spores were individually treated with 6 mM glycine and 12 mM taurocholate analogs
T11 to T22. The percent germination was calculated based on taurocholate/glycine germination
set as 100%. Standard deviations are shown in parentheses.
b
C. difficile spores were incubated with various concentrations of taurocholate analogs for 15
min prior to the addition of 6 mM taurocholate and 12 mM glycine. The IC50 was calculated by
plotting the extent of germination versus the logarithm of analog T11 to T22 concentrations.
Standard deviations are shown in parentheses.
c
NA, no change in absorbance after 90 minutes under the conditions tested thus no statistics
could be performed.

2.4. Conclusions
In this study, taurocholate and glycine analogs were used to better
understand how the C. difficile germination binding site(s) recognizes its
germinants. Chemical probes can reveal the chemical, physical, and spatial
requirements of the germination binding site(s). The present study has shown
that the C. difficile germination binding site(s) recognizes a number of amino acid
side chains and that the putative glycine binding site(s) requires both a free
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carboxylate and a free amino group to recognize glycine, but the binding site is
flexible enough to accommodate longer separations between the two functional
groups. Linear alkyl amino acid side chains are recognized but their branched
isomers are not. The Abel-Santos lab has observed and reported similar
branched-chain restriction in the recognition of inosine analogs of B. cereus
spores (169). These size and polarity restrictions also suggest the existence of
separate binding sites for L-phenylalanine, L-arginine, and possibly L-cysteine.
It is reasonable to hypothesize that the binding region for L-alanine in C.
difficile is divergent enough from the L-alanine binding site in Bacillus to impede
the binding and inhibition by D-alanine. Because none of the amino acid analogs
were able to compete with glycine to inhibit C. difficile spore germination, the
functional groups in the amino acid moieties are needed for both binding and
activation of the putative amino acid germination binding site(s).
Few bile salt analogs were able to activate C. difficile spore germination.
Hydroxyl groups at positions 3 and 12 seem to be required for both binding and
activation of C. difficile spore germination. In contrast, hydroxyl groups in the B
ring appear to be important only for binding. Hence, the data imply that there is a
requirement for hydrogen bonding with hydroxyls at specific locations and
configurations in the C. difficile germination binding pocket.
Recognition of the taurine side chain seems to be even more restricted.
Even small changes in the linker length and rigidity, amide bond, or oxidation
state of the sulfonate group had a large effect on C. difficile spore germination.
Although the sulfonate group is optimal for spore germination activation, it can be
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partially substituted with a carboxylate as long as the alkyl chain is short. These
data suggest that the binding site for taurocholate recognizes the taurine side
chain for optimal germination.
In contrast to germinant specificity, the putative taurocholate binding
site(s) was more flexible in regard to inhibitor binding. The meta-sulfonic benzene
derivative CamSA [T15] is active at concentrations approximately 275-fold lower
than taurocholate and is almost 4 times more active than the natural inhibitor
chenodeoxycholate (127, 141). The benzene ring is a rigid functional group with
little free rotation. We speculate that the sulfonate in the meta position is able to
fit tightly into the sulfonate binding pocket but the overall binding site(s) does not
recognize the benzene ring to trigger germination. This is further confirmed by
the inactivity of the ortho and para isomers that would spatially place the
sulfonate in different locations. The rigidity and positioning of the m-sulfonate
probably provides an entropic advantage over alkyl sulfonates. It is possible that
longer alkyl side chains are too flexible to allow the sulfonate moiety to bind
efficiently to the putative taurocholate binding site(s). The discovery of CamSA
and its strong inhibitor effect has revealed a new path to designing compounds
for CDI prophylaxis.
The putative taurocholate and glycine binding site(s) in C. difficile
recognizes multiple functional groups in their respective germinants. Hence, even
subtle changes in the germinant structure can be detrimental to the binding ability
of the germination binding site(s) of C. difficile spores. In conclusion, a structure
activity relationship analysis of C. difficile spores and analogs of glycine and
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taurocholate can reveal necessary moieties in the germinant structure. This
analysis can also elucidate the physical and chemical spatial characteristics in
the microenvironment of the binding sites.
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CHAPTER 3
MAPPING INTERACTIONS BETWEEN INHIBITORS AND CLOSTRIDIUM
DIFFICILE SPORES
3.1. Introduction
The microenvironments of the putative taurocholate and glycine binding
sites in C. difficile spores limit the functional groups allowed to bind and/or
activate

spore

germination.

Besides

physical

requirements,

chemical

requirements are also essential for binding. For the C. difficile putative glycine
binding site(s), both the amino and carboxylate group must be unmodified for
interactions with the binding site(s). Interestingly, it seems there may be separate
binding sites for the amino acids L-phenylalanine, L-arginine, and possibly Lcysteine. Of the 30 amino acids analyzed in structure activity analyses, none
were able to inhibit C. difficile spore germination.
The C. difficile putative taurocholate germination binding site(s) can be
efficiently activated by specific functional groups. However, the germination
binding site(s) is able to bind to a broader range of compounds that are unable to
activate germination. In fact the meta-benzene sulfonic acid derivative of
taurocholate, CamSA [T15], is able to competitively inhibit taurocholate-mediated
C. difficile spore germination at low concentrations (134). We suggest that the
rigidity of the benzene ring in CamSA allows the compound to fit the sulfonic acid
directly in its binding pocket. Because the benzene ring has different
physiochemical properties than an alkyl chain, it may not be recognized to
activate germination. This prediction is supported by the fact that the C. difficile
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germination binding site(s) does not recognize the para and the ortho analogs of
CamSA (134).
Based on the structure activity relationship defined for germinants and C.
difficile spores, a new series of analogs were synthesized and assessed for
ability to inhibit germination (134). Bile salt analogs that inhibited spore
germination in the previous study were used as a basis for designing new
analogs for testing. By manipulating bile salt structures that showed activity in the
previous study, we hypothesized that a pattern would emerge that could be used
to chemically define the bile salt binding region in C. difficile spores.
Taurocholate analogs with long linear side chains containing a carboxylate
moiety [T20 – T22] were found to inhibit C. difficile spore germination (Table 2.2).
For this study, a series of linear side chains with longer alkyl groups and/or
different functional groups were produced and analyzed for activation of C.
difficile spore germination or inhibition of germination.
CamSA [T15] does not have a linear side chain but instead has a benzene
ring with a sulfonic acid group in the meta position. CamSA is a potent inhibitor of
C. difficile spore germination (134). This discovery was interesting since the side
chain structure of CamSA is quite different from taurocholate, the germinant (Fig.
3.1A). Furthermore, the para and ortho analogs of CamSA had no effect on C.
difficile spore germination. To better understand the interactions between
CamSA and C. difficile spores, a series of CamSA analogs were synthesized and
assessed for germinant and anti-germinant activity.
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The natural bile salt, chenodeoxycholate, has been reported to act as a
competitive inhibitor of taurocholate-mediated C. difficile spore germination (127,
141). Taurocholate is a conjugated natural bile salt that consists of cholate
(cholic acid) linked to a taurine side chain by an amide bond (Fig. 3.1A). The
structure

of

chenodeoxycholate is

similar

to taurocholate

except

that

chenodeoxycholate is not linked to a taurine side chain (Fig. 3.1B). Taurocholate
also has three hydroxyl groups on the cholate backbone and all are in the alpha
configuration. Chenodeoxycholate has two hydroxyl groups at position 3 and
position 7 also in the alpha configuration but not at position 12. To better
understand how chenodeoxycholate interacts with C. difficile spores, cholate and
chenodeoxycholate analogs were tested for activation and inhibition of spores in
vitro. We hypothesized that the placement and configuration of the hydroxyl
groups

are

essential

for

recognition.

Furthermore,

cholate

and

chenodeoxycholate are not linked to a side chain but each has a free carboxylic
acid. A series of analogs with modifications to the carboxylic acid were also
assessed for activity with C. difficile spores.

A.

B.

Figure 3.1. Natural bile salts. A) taurocholate, B) chenodeoxycholate

Taurochenodeoxycholate is an analog of taurocholate that is missing the
hydroxyl

group

at

position

12. As
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described

in

the previous

study,

taurochenodeoxycholate [T03] is able to inhibit C. difficile spore germination but
is not as potent as chenodeoxycholate. This data would suggest that the hydroxyl
group at position 12 may not be essential for binding but may be necessary for
activation of germination. Using chenodeoxycholate as a backbone, a variety of
bile salt analogs

with different alkyl linkers were synthesized. These

taurochenodeoxycholate

analogs

were

synthesized

based

on

whether

taurocholate analogs were found to have activity with C. difficile in vitro. For
example the meta-benzene sulfonic side chain was found to have activity when
linked to the cholate backbone, CamSA. So for this study, an analog of CamSA
was prepared using the chenodeoxycholate backbone. These analogs were
synthesized and tested to potentially discover more potent inhibitors of C. difficile
spore germination in vitro than CamSA.
Cholesterol analogs are found in many different plants and vary in
function. Some plant-derived cholesterol analogs are potent toxins that are fatal
to those who ingest them and some are use medically (176, 177, 181). Others
serve as growth hormones and are essential to plant metabolic activity making
them useful agriculturally (172, 173). Epibrassinolide is in a class of steroid plant
hormones called brassinosteroids originally isolated from Brassica napus,
rapeseed (170). Epibrassinolide stimulates various physiological plant cell
processes to bulk up foliage, is effective in fighting pathogens and prevents
fungal infections in plants (171, 172). Ursolic acid, found in high concentrations in
apple peels, has been found to inhibit muscular atrophy-associated gene
expression in humans and in mice (173, 174). In mice, ursolic acid prevents
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muscle weakening during fasting and also helps grow muscle in normal-diet mice
(174). Since epibrassinolide has shown antimicrobial effects in plants and ursolic
acid has positive effects in mammals and both are analogs of bile salts, they
were analyzed for the ability to activate and/or inhibit C. difficile spore
germination. They are not close analogs of taurocholate and chenodeoxycholate
like the other bile salt analogs analyzed in this study. However, the focus of this
project is to understand the microenvironment of the C. difficile germination
binding site(s) and to discover potent inhibitors of C. difficile spore germination.
By studying the effects of related analogs, we can determine if the compounds
screened should be broadened to include other cholesterol derivatives.
Some steroids found in plants have important impacts on biological
systems. Digoxigenin, ouabain, and digitoxin are three such steroids. Digitoxin is
found in the foxglove plant from the genus Digitalis and has been used since
1785 to treat heart arrhythmia and congestive heart failure regardless of its toxic
side effects (175, 176). Digoxigenin (DIG) is found in the Digitalis plants and is
used widely in molecular biology as a probe for non-radioactive immunoassays
(177). Ouabain is found in the seeds of plants from the genus Strophanthus and
Acokanthera (178, 179). Ouabain is a toxic cardiac glycoside and affects cell-tocell cooperation by targeting the sodium pump (180). These toxins are similar in
structure to bile salts and contain an α,β-unsaturated lactone. This type of
lactone can form an irreversible adduct by Michael addition to cysteine residues
(181-184). Since the amino acid sequence of the germination receptor for C.
difficile is unknown (95), we hypothesized that bile salt analogs containing an
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α,β-unsaturated lactone can be used as chemical probes to crosslink with the
amino acids that participate in binding. However, analogs containing the α,βunsaturated lactone must first be recognized by the C. difficile germination
binding site(s). Purification of the germination binding site(s) is out of scope of
this project but finding compounds active with C. difficile spores is the focus of
this dissertation. Therefore, the effect these three toxins have on C. difficile spore
germination was assessed in vitro.
Screening bile salt analogs for in vitro activity with C. difficile spores
provides data that can be used to elucidate the mechanistic activity of small
molecules and the putative C. difficile germination binding site(s). More
importantly, there is the potential use of anti-germinants in CDI prevention.
Thorough characterization of the germination binding site(s) in vitro will help to
design binding site(s) specific molecules to prevent C. difficile germination.
3.2. Materials and Methods
3.2.1 General Comments
Taurocholate and bile salt analogs were obtained as described in Chapter
2 as well as thin layer chromatography silica gel and silica gel for column
chromatography. Bacterial growth medium was obtained from BD (Franklin
Lakes, NJ).
3.2.2. General Synthesis of Side-Chain Modifications
Unless otherwise stated, all the taurocholate and taurochenodeoxycholate
analogs were prepared following published procedures and resulted in up to 65%
yield (157, 158). Cholic acid (1 eq. - 1mM) or chenodeoxycholic acid (1 eq. -

65

1mM)

was

activated

with

1.4

eq.

of

N-ethoxycarbonyl-2-ethoxy-1,2-

dihydroquinoline (EEDQ) and 1.3 eq. of N-methylmorpholine (NMO) in
dimethylformamide (DMF) (Scheme 3.1, as an example). After the mixture was
stirred for 5 min, 1.2 eq. of the appropriate side chain reagent was added. The
reaction mixture was heated to 90 °C for 40 min and then cooled to room
temperature.

Scheme 3.1. Coupling reaction of chenodeoxycholate and meta-aminobenzene sulfonic acid

For polar compounds, the solution was poured into 100 ml of ice-cold
diethyl ether, resulting in a precipitate. The ether suspension was kept at 4 °C
overnight. The ether layer was decanted and the resinous residue was dissolved
in 25 ml 0.2 N NaOH-MeOH and poured into 100 ml cold diethyl ether. The ether
solution was kept at 4 °C for at least 2 h and the resulting precipitate was filtered
and washed with diethyl ether. If necessary, the product was recrystallized by
dissolving to saturation in hot ethanol, followed by the addition of ethyl acetate
until a precipitate appeared. The solution was kept at -20 °C for 2 h to allow
complete precipitation and then filtered to retrieve the product. For nonpolar
compounds, the reaction mixture was diluted with ethyl acetate and washed
three times with water. The organic layer was dried over anhydrous sodium
sulfate and evaporated under reduced pressure. The resulting residues for both
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polar and nonpolar compounds were further purified by silica gel column
chromatography eluted with a step gradient from 100% ethyl acetate to 100%
methanol (MeOH). Percent yields were typically 30 – 80%. Compound structures
were verified and determined to be >95% pure by 1H-NMR, Fourier transform
infrared spectroscopy (FT-IR), and mass spectrometry.
3.2.3. Synthesis of the Phosphonic Acid Derivative of CamSA [T37]
To synthesize a phosphonic acid analog of CamSA [T37], the published
procedure for dehydrating phosphoric acid with an alcohol was first followed
(185). A solution of 3-aminophenol (1 eq. - 1mM), phosphoric acid (1 eq.), 1butylimidazole (0.1 eq.), tributyl amine (1 eq.), and DMF/nitroethane (50/50 v/v)
was refluxed under azeotropic conditions at 155 °C for six hours (Scheme 3.2,
step 1).
Step 1

Step 2

Scheme 3.2. Synthesis of a phosphonic acid analog [T37] of CamSA

Dowex 50WX2-200 cation exchange resin was directly added to the crude
mixture and stirred at room temperature for one hour. The resin was removed by
filtration and the solvent was not removed. The filtrate contained the crude
product. The production of 3-aminophenylphosphoric acid was verified by TLC
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(mobile phase 100% ethyl acetate). The 3-aminophenylphosphoric acid (filtrate in
DMF) was conjugated to cholate using the coupling procedures described above
(157, 158) (Scheme 3.1, step 2). The product was purified by silica gel column
chromatography eluted as before. The final yield was 15%. The structure was
verified and determined to be >95% pure by

1

H-NMR, FT-IR, and mass

spectrometry.
3.2.4. Preparation of Hyodeoxycholic acid [T95]
To a solution of hyodeoxycholic acid methyl ester [T96] in 15 mls 1,4dioxane, 5 mls of 0.2 M NaOH/MeOH was added and stirred at 45 °C for two
hours under nitrogen (Scheme 3.3). The de-protected hyodeoxycholic acid [T95]
was purified (85% yield) by silica gel chromatography in 90% dichloromethane/10
% MeOH. T96 was verified and found to be >95% pure by 1H-NMR, FT-IR, and
mass spectrometry.

Scheme 3.3. Preparation of hyodeoxycholic acid [T96]

3.2.5. Preparation of Tri-methoxy Cholic Acid [T89]
Tri-methoxy

cholic

acid

[T89]

was

prepared

following

published

procedures (154). A similar procedure was used to prepare methoxylated
taurocholate analogs [T09 and T10] in Chapter 2 (section 2.2.2). The previous
procedure used taurocholate as the starting reagent whereas; this procedure
68

uses methyl cholate and requires a deprotection step. To a solution of methyl
cholate (1 eq. - 1mM) in dry 1,4-dioxane, methyl iodide (50 eq.) and sodium
hydride (4 eq.) were added under nitrogen. The reaction mixture was heated to
40 °C for 48 h with stirring (Scheme 3.4). After the initial 48 h, sodium hydride (4
eq.) was added daily to the reaction mixture for four days. The reaction mixture
was diluted with dichloromethane and washed with 1 M HCl and twice with water.
The organic layer was dried over anhydrous sodium sulfate, and the solvent was
removed under reduced pressure. The crude product was dissolved in 15 mls
1,4-dioxane and 5 mls of 0.2 M NaOH/MeOH was added. The mixture was
heated to 45 °C under nitrogen for two hours. After heating the 1,4-dioxane was
removed under reduced pressure and the sample was worked up a nonpolar
compound as described before. The crude residue was purified by silica gel
column chromatography eluted with 90% chloroform and 10% MeOH. The
purified compound (10% yield) was verified and found to be >95% pure by 1H
NMR, mass spectrometry and FT-IR spectroscopy.

Scheme 3.4. Reaction scheme for the synthesis of compound T89
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3.2.6. Preparation of C. difficile Spores
Clostridium difficile strain 630 was obtained from American Tissue Culture
Collection (ATCC) (BAA-1382). C. difficile cells were plated on BHIS (brain heart
infusion salt broth) agar supplemented with 1% yeast extract, 0.1% L-cysteineHCl and 0.05% sodium taurocholate to yield single-cell colonies. Single C.
difficile

colonies

were

grown

in

BHIS

broth

until

exponential

phase

(approximately four hours) and spread plated onto agar to obtain bacterial lawns.
The plates were incubated for five days at 37 °C in an anaerobic environment
(5% CO 2, 10% H2, and 80% N2). The resulting bacterial lawns were collected by
flooding the plates with ice-cold deionized water. Spores were pelleted by
centrifugation at 8,800 x g for five minutes and resuspended in fresh deionized
water. After two washing steps the spores were separated from vegetative and
partially sporulated forms by centrifugation through a 20% to 50% HistoDenz
gradient at 18,200 x g for 30 minutes with no brake. The spore pellet was
washed five times with water, resuspended in sodium thioglycolate (0.5 g/L) and
stored at 4 °C. Immediately before in vitro germination activation or inhibition
assays, spores were transferred to fresh tubes, centrifuged, and washed with
deionized water five times to remove storage buffer.
The methods for endospore staining and the activation or inhibition of C.
difficile spore germination were described in Chapter 2 (please refer to the
Methods section 2.2.6 – 2.2.8).
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3.3. Results and Discussion
3.3.1. Taurocholate Analogs with Linear Side Chains
Based on preliminary structure activity analyses of taurocholate analogs
and their interactions with C. difficile spores, new analogs were designed and
tested for their ability to act as activators or inhibitors of C. difficile spore
germination. C. difficile strain 630 used previously (Chapter 2) was also used for
these studies.
The analysis of linear side chains discussed in chapter 2 revealed that
shorter [T11] but not longer [T12] alkyl side chains of taurocholate analogs could
activate spore germination (Table 2.2). Some longer alkyl side chains that
contain a carboxylic acid were able to inhibit C. difficile spore germination [T20
and T21] (Table 2.2 and Fig. 3.2). To further characterize the recognition of long
alkyl side chains by the C. difficile germination binding site(s), taurocholate
analogs T23-T29 were synthesized and tested in vitro. Compounds T23 and T25
differ by one carbon in the alkyl chain and both have carboxylic acids at the end
of the alkyl side chain (Fig. 3.2). T23 and T25 have longer alkyl side chains than
previously tested analogs [T17, T18, and T20] (Fig. 3.2). Neither T23 nor T25
were able to activate C. difficile spore germination. T23 did inhibit spore
germination but with an IC50 of 5.3 mM. The analog tested previously [T20],
which has one less carbon in the alkyl chain, has an IC50 of 0.76 mM, seven fold
more potent than T23 (Fig. 3.2). Interestingly, T25 with one more carbon in the
alkyl chain than T23 inhibited C. difficile spore germination with an IC 50 of 2.3
mM. These data suggest that an even number of carbons in the alkyl chain [T17
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= 2C, T20 = 4C, and T25 = 6C] is able to bind more efficiently than their odd
numbered counterparts [T18 = 3C and T23 = 5C].

T01

T20
IC50 0.76 mM (0.11)

T23

T24

IC50 5.3 mM (0.24)

T25

T26

IC50 2.3 mM (0.075)

Figure 3.2. Taurocholate analogs with linear side chains. Taurocholate [T01], taurocholate analog from
Chapter 2 [T20] and taurocholate analogs [T23 – T26]. The corresponding IC50 value is listed below each
compound with the standard deviation in parentheses. Those without a listed value had no activity under
the conditions tested.

Similar to the synthesis of compounds T18 and T20, side products [T24
and T26] were produced during the synthesis of compounds T23 and T25. These
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compounds were also analyzed for the ability to activate and/or inhibit C. difficile
spore germination. Although compound T21, the side product from T20, was
able to inhibit spore germination as described previously (Table 2.2), compounds
T24 and T26 were unable to activate nor inhibit spore germination (Fig. 3.2). The
alkyl chains in compounds T21, T24 and T26 have an total even number of
carbons connected by two amide bonds. The total chain length for T21 has 8
carbons, T24 has 10 carbons and T26 has 12 carbons. The sum of these data
suggests that shorter alkyl side chains containing a carboxylic acid with an even
number of carbons in the chain are able to bind but not activate C. difficile spore
germination.
Compound T27 is similar to taurocholate [T01] except the sulfonic acid is
replaced with a sulfate group resulting in an organosulfate (Fig. 3.3). This
rendered compound T27 unable to bind to C. difficile spores. Compound T27
neither activated nor inhibited spore germination, suggesting three but not four
oxygen atoms in the alkyl functional group are recognized by the C. difficile
germination binding site(s). Alternatively, the thioether linkage of compound T27
could by hydrolyzed. Compound T28 is a taurocholate analog containing a
thioester bond (Fig. 3.3). Compound T28 is also an analog of the ester
compound [T22] described in chapter 2. Unlike taurocholate, T28 is unable to
activate C. difficile spore germination. Compound T28 is also unable to inhibit
spore germination whereas the analog T22 inhibits spore germination. It is
possible that the reason the thioester bond is not recognized is likely due to the
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limited ability of the sulfur ester to participate in electron delocalization. This
makes the thioester bond less stable and likely to be hydrolyzed to the free thiol.
Compound T29 is a taurocholate analog with one less carbon in the alkyl
chain. It is a close analog of T11, an activator of C. difficile spore germination
(Table 2.2). Compound T29 differs from both taurocholate and T11 in the
functional group in the alkyl side chain. Instead of a sulfonic acid, T29 has a
phosphonic acid moiety (Fig. 3.3). Unlike taurocholate and T11, T29 neither
activated nor inhibited C. difficile spore germination. Phosphoric acids have a
pKa of 2 whereas sulfonic acids have a pKa of -10. Therefore, phosphoric acids
are weaker acids than sulfonic acids. The putative C. difficile taurocholate
germination binding site(s) seems to prefer the stronger acid for recognition.
In conclusion, these data indicate that the taurine side chain connected by
an amide bond is optimal for C. difficile spore germination.

T01

T27

T28

T29

Figure 3.3. Taurocholate analogs with linear side chains and modified functional groups. Taurocholate
[T01] and taurocholate analogs [T27 – T29]. No IC50 value is listed because these analogs had no activity
under the conditions tested.
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3.3.2. CamSA Analogs with Unsubstituted Aromatic Side Chains
CamSA, the potent inhibitor discovered and described in chapter 2 has an
aromatic ring in the side chain with a sulfonic acid in the meta-position. To
determine if the aromaticity of CamSA is responsible for CamSA’s strong effects,
compounds T30 and T31 were synthesized. Compound T30 is similar to CamSA,
but lacks the sulfonic acid on the benzene ring. Compound T30 inhibits C. difficile
spore germination with an IC 50 of 0.27 mM, five fold higher than CamSA (Fig.
3.4). Thus, it appears that the aromatic ring does have some effect on binding
and inhibition of spore germination. However, this suggests that the sulfonic acid
makes the inhibitor more potent.
Compound T31 has a pyridine substituent with the aromatic nitrogen at
position-3 in the aromatic ring. Compound T31 is unable to activate or inhibit C.
difficile spore germination (Fig. 3.4). The aromatic nitrogen in T31 causes the
molecule to be electron deficient as opposed to the electron rich benzene.
Although, the electron deficiency may explain the difference between T30 and
T31, the sulfonic acid moiety of CamSA creates an electron deficient aromatic
ring. CamSA and compound T31 cannot be compared directly since the sulfonic
acid is a substituent on the aromatic ring and compound T31 has aromatic
nitrogen. In conclusion, these data indicate that if no substituent is present on an
aromatic ring bound to the cholate backbone, then the C. difficile binding site(s)
is able to recognize to the aromatic ring but not a pyridine.
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T15
IC50 0.058 mM (0.035)

T30

T31

IC50 0.27 mM (0.070)
Figure 3.4. CamSA analogs with unsubstituted aromatic side chains. CamSA [T15] and CamSA
analogs [T30 – T31]. The corresponding IC50 value is listed below each compound with the standard
deviation in parentheses. Those without a listed value had no activity under the conditions tested.

3.3.3. CamSA Analogs with Mono-substituted Aromatic Side Chains
Sulfonic acids are highly polar and very strong acids. In fact, sulfonic acids
are stronger acids than their carboxylic analogs. When the sulfonic acid was
substituted for a carboxylic acid in the alkyl side chain analog of taurocholate
[T17, T18, and T20], we found that the sulfonic acid is optimal for activation of C.
difficile spore germination. The sulfonic acid can be substituted for a carboxylate
as long as the alkyl chain is short, two carbons [T17]. Longer alkyl chains with
carboxylic acids, described previously, were not able to activate C. difficile spore
germination but were able to bind and inhibit spore germination. To determine
the effect of carboxylic acid substituted aromatic rings on C. difficile spore
germination, compounds T32-T37 were synthesized and tested for the ability to
activate or inhibit C. difficile spore germination.
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Compound T32 is an analog of CamSA with a carboxylic acid in the meta
position on the aromatic ring (Fig. 3.5). Compound T32 is unable to activate
spore germination but was did inhibit C. difficile spore germination with an IC 50 of
3.1 mM (Fig. 3.5). CamSA is approximately 50 fold more potent than T32 at
inhibiting spore germination. The data suggests that the sulfonic acid is optimal
for binding and preventing C. difficile spores from germinating. This is likely due
to the stronger acidity of the sulfonic acid group and their stronger electron
withdrawing properties as substituents on aromatic rings. It should be noted that
aromatic rings have a very modest effect on acidity.
Compound T33 is the ortho analog of T32 and the carboxylic analog of
compound T14 (Chapter 2). As expected, compound T33 was not recognized by
C. difficile spores and was unable to affect spore germination (Fig. 3.5).
Compound T34 is the para analog of T32 and the carboxylic acid analog of T13.
Interestingly, compound T34 is able to bind and inactivate C. difficile spores with
an IC50 of 1.4 mM, which is 2-fold lower than the meta analog [T32] (Fig. 3.5).
This finding is surprising since the para analog of CamSA [T13] was unable to
bind to C. difficile spores. CamSA is more potent an inhibitor of C. difficile spore
germination since it is more active at concentrations 25-fold lower than T34.
Compound T35 is a non-aromatic analog of compound T32. Compound
35 has a cyclohexane group side chain with a carboxylic acid substituent on the
third carbon from the amide bond (equivalent to the meta position of an aromatic
compound). Compound T35 is seven fold more potent as an inhibitor (IC 50 0.47
mM) of C. difficile spore germination than compound T32. We expected that the
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aromaticity of the substituent was partially responsible for activity. However, it
seems that as long as there is an electronegative group on a ring structure then
the ring does not need to be aromatic. This does not fully explain why an
unsubstituted aromatic ring [T30] was able to inhibit C. difficile spore germination.
The unsubstituted aromatic ring is about 2-fold more potent than compound T35
suggesting that either the presence of an aromatic ring or the carboxylic acid is
sufficient for binding (Fig. 3.5). However, in the presence of both an aromatic ring
and carboxylic acid [T32 and T34] the activity decreases. In comparison to
CamSA, the sulfonic acid on an aromatic ring is optimal for binding and inhibition
of C. difficile spore germination.
Compound T36 is an analog of compound T32 except that the carboxylic
acid has been converted to an ester (Fig. 3.5). Carboxylic acids are weak acids
that can act as hydrogen bond acceptors and donors whereas esters are less
polar and can only act as hydrogen bond acceptors. The change from a
carboxylic acid to an ester for compound T36 resulted in complete loss of binding
to C. difficile spores (Fig. 3.5). Ester groups are unstable and undergo hydrolysis.
If the ester group in compound T36 is hydrolyzed, the resulting compound is a
carboxylic acid [T32]. It is expected that the product of the hydrolysis would
inhibit C. difficile spore germination (similar to T32). Since compound T36 did not
inhibit spore germination, it is possible the ester group was not hydrolyzed.
Therefore, compound T36 was not recognized by C. difficile spores. The data
suggests that the presence of a carbonyl, but loss of hydrogen bond donating
ability results in complete loss of C. difficile binding.
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T15

T32

IC50 0.058 mM (0.035)

IC50 3.1 mM (0.78)

T33

T34
IC50 1.4 mM (0.11)

T36

T33
IC50 0.47 mM (0.067)

Figure 3.5. CamSA analogs with mono-substituted aromatic side chains. CamSA [T15] and CamSA
analogs [T32 – T36]. The corresponding IC50 value is listed below each compound with the standard
deviation in parentheses. Those without a listed value had no activity under the conditions tested.

The sum of these data suggests that the aromatic ring of CamSA can be
partially substituted with carboxylic acid analogs and in the presence of a
carboxylic acid the ring does not have to be aromatic. The sulfonic acid
substituent on an aromatic compound remains optimal for C. difficile binding.
To determine if the C. difficile germination binding site(s) recognizes
substituents other than carboxylic or sulfonic acids, compounds T37 - T44 were
synthesized. Phosphoric acids (pKa = ~2) like carboxylic acids (pKa = 1.5 – 4.0)
are weaker acids than sulfonic acids (pKa = -10). Compound T37 contains a
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phosphoric acid in the meta position on the benzene ring (Fig. 3.6). Whereas the
carboxylic acid derivative [T32] of CamSA was able to inhibit C. difficile spore
germination, T37 is unable to bind to C. difficile spores. Based on acidity, we
would expect compound T37 to be comparable to the carboxylic acid analog
[T32]. It is possible that compound T37 inhibits at concentrations higher than the
concentration tested in these experiments. A more likely explanation is that the
binding region in C. difficile spores for bile salts is a specialized region that
simply does not recognize the phosphoric acid moiety.
Compounds T38 and T39 have hydroxyl groups in the meta or ortho
position, respectively (Fig. 3.6). Neither compound was able to bind to C. difficile
spores. Oxygen atoms in the alkyl substituents of analogs have been shown to
be optimal for C. difficile spore recognition. However, since hydroxyl groups are
unable to bind, it is possible that an sp2 hybridized oxygen group is recognized
specifically. Another explanation is the electron donating effect (through
resonance) hydroxyl groups have on aromatic rings. As described previously,
electron withdrawing groups are predicted to be optimal for spore recognition.
The finding that compounds with hydroxyl groups do not affect C. difficile spore
germination supports that hypothesis.
Taurocholate and CamSA have a sulfonic acid group in the alkyl chain. To
determine if sulfur alone is sufficient for C. difficile spore recognition, compounds
T40 and T41 were synthesized and assessed for activation or inhibition of spore
germination. Both compounds [T40 and T41] have a sulfhydryl group in either the
meta or para position, respectively. Neither T40 nor T41 was able to activate or
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inhibit spore germination (Fig. 3.6). It is likely that the acidic characteristics of the
sulfonic acid make it an optimal germinant for C. difficile.

As expected,

compound T42, containing a thiol ether, was also unable to be recognized by the
putative C. difficile bile salt germination binding site(s). The sulfhydryl and thiol
ether provide electron donating effects to the aromatic ring. These data support
the need for an electron withdrawing group on the aromatic ring and an acidic
substituent for optimal recognition by C. difficile spores.
The data suggests that electronegative compounds are favored by the C.
difficile germination binding site(s). Compound T43 has an amine group at the
meta position on the benzene ring. Unlike carboxylic and sulfonic acids, amine
groups are basic and much less electronegative. Amine group substituents of an
aromatic ring are less basic and increase the reactivity of the ring due to the
amine’s electron donating property by resonance. As expected, compound T43
did not activate C. difficile spore germination. Surprisingly, T43 inhibited spore
germination with an IC50 of 0.53 mM (Fig. 3.6). It is possible that the increased
reactivity of the aromatic ring [T30] outweighed the basic nature of the amine.
However, this is unlikely since hydroxyl groups and sulfahydryl groups were
unable to bind to C. difficile spores. Albeit a weak inhibitor, it is unclear at this
time why compound T43 is able to affect C. difficile spore germination. More in
vitro studies with amine substituted aromatic rings will need to be performed for a
better understanding of this finding.
Compound T44 contains an aromatic ring with a methyl substituent in the
meta position. The methyl substituent has an electron donating effect by
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induction. As expected, compound T44 did not affect C. difficile spore
germination (Fig. 3.6). This data supports our earlier prediction that optimal
analogs for recognition by C. difficile spores will have electron withdrawing
substituents on the aromatic ring.
In conclusion, the combined data from CamSA analogs with monosubstituted aromatic rings supports that the meta-benzene sulfonic acid analog
produces optimal inhibition of C. difficile spore germination. There are limited
instances when other functional groups are able to bind to the putative binding
site(s). None of CamSA analogs with mono-substituted aromatic rings were able
to activate C. difficile spore germination in vitro. Except for compound T43, the
data suggests that an electronegative substituent with electron withdrawing
properties is able to be bind but not activate C. difficile spore germination.
Furthermore, the aromaticity of the analog may play a role in recognition and the
presence of an sp2 hybridized oxygen in the substituent is almost always
required. More acidic substituents are also favored over weaker acid
substituents. These data provide some insight to the chemical requirements of
the putative taurocholate germination binding site(s) in C. difficile. However,
these findings also show that binding and recognition of bile salts is quite
complicated and multiple factors exist to determine if a compound is able to bind
or not.
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T37

T38

T39

T40

T41

T42

T43

T44

IC50 0.53 mM (0.022)
Figure 3.6. CamSA analogs [T37 – T44] with mono-substituted aromatic side chains. The corresponding
IC50 value is listed below the compound with the standard deviation in parentheses. Those without a
listed value had no activity under the conditions tested.

3.3.4. CamSA Analogs with Di-substituted Monocyclic Aromatic Rings
CamSA and the CamSA analogs discussed above have single
substitutions in the aromatic ring.

To determine if aromatic rings with di-

substitutions are able to activate or inhibit C. difficile spore germination,
compounds T45 to T48 were synthesized. Each of these analogs has an
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aromatic ring with a meta-sulfonic acid or meta-carboxylic acid substituent and a
second substituent. Compounds T45 and T46 have a sulfonic acid in the meta
position. Compound T45 is di-substituted with a methyl group in the ortho
position (from the amide bond) (Fig. 3.7). Unlike CamSA, compound T45 was
unable to unable to activate and unable to inhibit C. difficile spore germination.
Compound T46 is di-substituted with a methoxy group at the ortho position.
Interestingly, compound T46 activates spore germination with an EC 50 of 4.6 mM
and does not inhibit germination (Fig. 3.7). This finding was not expected since
the methoxy group in T46 would affect the aromatic ring as an electron donating
group due to resonance. In previous experiments, almost all compounds that are
active with C. difficile spores have electron withdrawing groups. Compound T46
does have the sulfonic acid moiety at the meta position which is electron
withdrawing. The recognition is not strong as reflected by the high EC50 but there
does seem to be some interaction that will need further defining in future
experiments.
Compounds T47 and T48 have a carboxylic acid in the meta position on
the aromatic ring. Compound T47 is the analog of T45 and has a methyl group in
the ortho position. Compound T47 is a very weak activator of C. difficile spore
germination with an EC50 of 16 mM (Fig. 3.7). Compound T45 was not tested at
concentrations higher than 12 mM so it is possible that it has very weak activity
like T47. Compound T48 has a methyl group in the para position. Compound T48
inhibited spore germination with an IC50 11 mM (Fig. 3.7). Both compounds [T47
and T48] are recognized by C. difficile but their activity is extremely weak.
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T15
IC50 0.058 mM (0.035)

T45

T46
EC50 4.6 mM (0.34)

T47
EC50 16 mM (0.90)

T48
IC50 11 mM (0.025)
Figure 3.7. CamSA analogs with di-substituted monocyclic aromatic rings. CamSA [T15] and CamSA
analogs [T45 – T48]. The corresponding EC50 or IC50 value is below each compound with the standard
deviation in parentheses. Those without a listed value had no activity under the conditions tested.

3.3.5. CamSA Analogs with Tri-substituted Monocyclic Aromatic Rings
CamSA analogs with di-substituted aromatic rings provided evidence that
the C. difficile germination binding site(s) could recognize more than one
aromatic substitution. To determine if tri-substituted aromatic rings could affect
spore germination compounds T49-T50 were synthesized. Both tri-substitute
analogs have a sulfonic acid in the meta position from the nitrogen in the amide
bond. Compound T49 has two methyl group substitutions, ortho and para to the
amino group, whereas compound T50 has two methyl groups, meta and para
(Fig. 3.8). Both compounds were able to bind to the putative C. difficile
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germination binding site(s) and inhibit spore germination. Compound T49
inhibited C. difficile spore germination with an IC50 of 5.6 mM and compound T50
inhibited spore germination with an IC50 of 1.1 mM (Fig. 3.8). Neither compounds
activated spore germination in vitro. In conclusion these data show that two [T49
and T50] but not one methyl group [T45] is recognized by the C. difficile spore
germination binding site(s). Methyl groups are electron donating groups to the
aromatic ring. Two methyl group substituents will increase the electron donating
effect therefore adding stability to the ring. Although the data suggests some
interaction does occur, the recognition by C. difficile spores is weak.

T15
IC50 0.058 mM (0.035)

T50
IC50 1.1 mM (0.098)

T49
IC50 5.6 mM (0.042)

Figure 3.8. CamSA analogs with tri-substituted monocyclic aromatic rings. CamSA [T15] and CamSA
analogs [T49 – T50]. The corresponding IC50 value is listed below each compound with the standard
deviation in parentheses.
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3.3.6. CamSA Analog with Methylated Amidate Group
Conjugated bile salts have the cholate backbone attached to taurine or
glycine by an amide bond. Bile salt hydrolases produced by enteric bacteria
hydrolyze the amide bond in bile salts thereby releasing free taurine or glycine
(186-188). This deconjugation aids in the enterohepatic circulation of bile salts in
the gut. In a previous report, the alkylation of the nitrogen in the amido group of a
conjugated bile salt produced an analog resistant to deconjugation (188). In
CamSA [T15], the cholate backbone is attached to a meta-benzene sulfonic acid
by an amide bond. Since CamSA is a potent inhibitor of C. difficile spore
germination in vitro, CamSA is a good candidate for in vivo studies. To have
optimal efficiency in the mammalian gut, CamSA will have to remain a
conjugated bile salt to be effective in preventing C. difficile spore germination.
However, modifying the structure of CamSA may reduce its inhibitory activity. A
CamSA analog with an alkylation of the nitrogen in the amide group [T51] was
synthesized for in vitro testing. After modification to the amine group in CamSA,
compound T51 was no longer able to inhibit C. difficile spore germination.
Unexpectedly, compound T51 activated spore germination with an EC50 of 5.8
mM (Fig. 3.9). Compound T51 is not a strong germinant but is able trigger
germination. In conclusion, the data indicates that compounds with a free amine
are adequate for binding but not necessary for activation. Although the
mechanism used by compound T51 to activate C. difficile spore germination is
unclear, compound T51 cannot be used as a preventative of CDI even if it can
resist bile salt hydrolase.
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Since deconjugation of bile salts by bile salt hydrolases results in the
release of the deconjugated alkyl group, compounds T52 and T53 were tested
for effect on C. difficile spore germination (Fig. 3.9). Neither T52 nor T53 was
able to bind to the putative germination binding site(s). This data suggests the
cholate backbone is essential to the activity of CamSA and compound T51 in
recognition by C. difficile spores.

T15

T51
EC50 5.4 mM (0.098)

IC50 0.058 mM (0.035)

T52

T53

Figure 3.9. CamSA analog with methylated amidate group. CamSA [T15], CamSA analog [T51] and
starting reagents [T52 and T53]. The corresponding EC50 value is below each compound with standard
deviation in parentheses. Those without a listed value had no activity under the conditions tested.

3.3.7. Bile Salt Analogs with Polycyclic Aromatic Hydrocarbons
To determine if polycyclic aromatic hydrocarbons in the alkyl chain with
and without substituents are able to bind to C. difficile spores, compounds T54T65 were synthesized and tested in vitro. Naphthalene is the simplest polycyclic
aromatic hydrocarbon made up of two fused benzene rings. Two analogs were
synthesized using 1-aminonaphthalene and 2-aminonaphthalene coupled with
cholic acid by an amide bond [T54 and T55] (Fig. 3.10). Neither compound T54
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nor T55 was recognized by the C. difficile germination binding site(s). Compound
T56 is cholic acid conjugated to 2-aminoanthracene. Like compounds T54 and
T55, compound T56 was unable to bind to C. difficile spores (Fig. 3.10). Pyrene
is a fluorescent polycyclic aromatic hydrocarbon. Compound T57 is a cholate
backbone conjugated by an amide bond to 1-aminopyrene. Unfortunately,
compound T57 was neither able to activate nor inhibit C. difficile spore
germination (Fig. 3.10). Polycyclic aromatic hydrocarbons are very rigid and flat
structures. The fact that they are unable to bind to C. difficile spores is not
surprising since the spatial requirements for bile salts is likely limited in size and
shape. Therefore, rigid, bulky polycyclic aromatic hydrocarbons without
substituents are unable to bind to the C. difficile bile salt germination binding
site(s).

T54

T55

T56

T57

Figure 3.10. Bile salt analogs with unsubstituted polycyclic aromatic hydrocarbons. Bile salt analogs
[T54 – T57]. Those without a listed value had no activity under the conditions tested.
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Compounds T58-T61 contain naphthalene with one substituent on the
rings. Compound T58 has a hydroxyl bonded to the carbon at position 2 from the
amino group (Fig. 3.11). Compound T58 was unable to activate or inhibit C.
difficile spore germination. This was expected since neither T54 nor T55 was
able to bind to C. difficile spores. Furthermore, aromatic rings with hydroxyl
groups in previous experiments [T38 and T39] did not affect C. difficile spore
germination. Likely, compound T58 is unable to bind due to the rigidity of the
naphthalene ring and the presence of a hydroxyl substituent. Compound T59
contains a sulfonic acid at position 1 from the amino group. Compound T59 was
not recognized by the germination binding site(s) (Fig. 3.11). Although compound
T59 has a sulfonic acid that has been shown to be optimal for C. difficile
germination binding, the functional group is on the carbon next to the amide bond
(equivalent to the ortho position in a monocyclic aromatic ring). Steric hindrance
and rigidity of the side chain are likely why compound T59 is not recognized.
Compounds T60 and T61 both have a carboxylic acid substituent on the
naphthalene side chain. In compound T60, the carboxylic acid is on the first
carbon from the amino group and is an analog to T59. Compound T60 neither
activated nor inhibited C. difficile spore germination similar to compound T59
(Fig. 3.11). Steric hindrance resulting from the carboxylic acid so near the amide
bond and the rigidity of the polycyclic aromatic hydrocarbon are likely responsible
for this inactivity. In compound T61, the naphthalene side group has a carboxylic
acid on the fourth carbon from the amino group. Interestingly, compound T61
was able to bind to C. difficile spores and trigger germination with an EC50 of 1.3
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mM (Fig. 3.11). Compound T61 is unable to prevent spore germination. It is
unclear how this rigid structure is able to activate C. difficile spore germination.
We predict that the polycyclic aromatic hydrocarbon is not directly responsible for
the effect but may act to position the carboxylic acid in a binding region capable
of recognizing it and activating germination. Glycocholate [T17] is also an analog
of taurocholate that has a carboxylic acid substituent in the side chain and is able
to effectively activate spore germination. Furthermore, compound T47 has a disubstituted aromatic side chain with a carboxylic acid and weakly activates C.
difficile spore germination. Although the sulfonic acid is optimal for binding,
carboxylic acids have been shown to also bind to the putative taurocholate
binding site(s). Compound T61 probably interacts with the germination binding
site(s) in a similar way to these compounds.

T58

T59

T60

T61
EC50 1.3 mM (0.19)

Figure 3.11. Bile salt analogs with monosubstituted polycyclic aromatic hydrocarbons. Bile salt analogs
[T58 – T61]. The corresponding EC50 value is listed below each compound with the standard deviation
in parentheses. Those without a listed value had no activity under the conditions tested.
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Compounds T62-T64 each contain naphthalene and two functional group
substituents. Compound T62 has a hydroxyl on the carbon at position 2 from the
amino group and a sulfonic acid at position 4. Compound T62 was neither able to
active nor inhibit C. difficile spore germination (Fig. 3.12). Hydroxyl groups in the
side chains seem to interfere with binding since none of the analogs discussed
that have hydroxyl moieties are able to affect C. difficile spore germination.
Compound T63 has two sulfonic acids, one at the first position and one at
position 5 from the amino in the amide bond. Compound T63 was not recognized
by C. difficile germination binding site(s) (Fig. 3.12). Since compound T59 and
T60 discussed above were unable to affect C. difficile spore germination, it is not
surprising that T63 was also ineffective. The steric effects caused by the
functional group so near the amide bond in the alkyl chain is most likely
responsible for the inability to bind to spores.
Compound T64 also has two sulfonic acids on the naphthalene side group
but at position 2 and 5 from the amino. Compound T64 was unable to inhibit
taurocholate-mediated spore germination. Interestingly, compound T64 triggered
germination with an EC50 of 5.7 mM (Fig. 3.12). Similar to compound T61,
compound T64 has an electronegative group at the position-5 on the second
aromatic ring. Both of these compounds were able to activate spore germination
in vitro. It is likely that the bulkiness and rigidity of these fused rings with the
electronegative group at position-5 is able to come into contact with a specific
region of the binding pocket that triggers germination. This effect is very
interesting and will require future experiments to explain the interaction between
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these polycyclic aromatic hydrocarbons and C. difficile spores. To rule out nonspecific effects caused by the polycyclic aromatic hydrocarbon, compound T65
was also tested for germinant and inhibitor activity with C. difficile spores. The
unconjugated di-substituted naphthalene ring was unable to bind to C. difficile
spores. Compounds not bound to cholate [T52, 53, and T65] were unable to
affect binding. Therefore, the cholate backbone is necessary for recognition by
the putative taurocholate binding site(s) in C. difficile spores.
In conclusion, polycyclic aromatic hydrocarbons without substituents are
unable to bind to the putative taurocholate binding site(s) in C. difficile spores.
Substituted naphthalene produced variable results and the interactions of these
compounds with potential binding sites are not clearly understood.

T62

T63

T64

T65

EC50 5.7 mM
Figure 3.12. Bile salt analogs with di-substituted polycyclic aromatic hydrocarbons. Bile salt analogs [T62
– T64] with di-substituted naphthalene side chains and unconjugated starting compound [T65]. The
corresponding EC50 value is listed below each compound with the standard deviation in parentheses.
Those without a listed value had no activity under the conditions tested.
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3.3.8. Taurochenodeoxycholic Acid Derivatives
Chenodeoxycholate has been shown to inhibit C. difficile spore
germination in vitro (127, 141). Chenodeoxycholate is a natural bile salt that
resembles cholic acid except that chenodeoxycholate does not have a hydroxyl
group at position-12 on the cholate backbone. Taurochenodeoxycholate [T03] is
the conjugated derivative of chenodeoxycholate and inhibits C. difficile spore
germination with an IC 50 of 0.51 mM (Fig. 3.13). Using the chenodeoxycholate
backbone, a series of analogs were synthesized. These compounds are also
analogs of taurocholate and CamSA derivatives discussed previously. In fact,
analogs using the chenodeoxycholate backbone were not synthesized unless
taurocholate and CamSA analogs were active with C. difficile spores.
In the previous study, a taurocholate analog that had one less carbon in
the alkyl chain [T11] was able to activate C. difficile spore germination as
effectively as taurocholate. The effect of this same alkyl chain coupled to
chenodeoxycholate [T66] was assessed for activation or inhibition of C. difficile
spore germination. Compound T66 activated C. difficile spore germination with
an EC50 of 0.31 mM (Fig. 3.13). Compound T66 is approximately 50 fold more
active than taurocholate. Although this compound is an analog of the inhibitor,
taurochenodeoxycholate [T03], compound T66 is an germinant like its cholate
analog compound T11. In fact, compound T66 is active at concentrations more
than two-fold lower than T11 (Fig. 3.13). No hydroxyl group at position-12 of the
cholate backbone does not prevent the molecule from activating germination as
long as the side chain is short. As the alkyl chain is lengthened as in
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taurochenodeoxycholate, the hydroxyl is required to activate spore germination.
However, the longer alkyl side chains are recognized and able to bind but their
activation properties are lost.
Compound T67 is the taurochenodeoxycholate derivative of compound
T16. Compound T67 has a sulfinic acid instead of a sulfonic acid as a substituent
of the alkyl chain. Similar to compound T16, compound T67 did not activate
spore germination but inhibited with an IC50 of 5.3 mM (Fig. 3.13). Compound
T67 is a weak inhibitor compared to T16, which is active at concentrations eightfold lower.
Compound

T68

has

two

carbons

in

the

alkyl

chain

like

taurochenodeoxycholate but instead of a sulfonic acid, T68 has a carboxylic acid
group. Like taurochenodeoxycholate, T68 inhibited C. difficile spore germination
but was more than seven-fold less effective, with an IC 50 of 3.9 mM (Fig. 3.13).
Furthermore, the taurocholate derivative [T17] activated spore germination albeit
less effective than taurocholate. This data suggests that the carboxylic acid is not
optimal for binding. Furthermore, this data suggests that if the alkyl chain is
longer and contains a carboxylic acid [T17] then a hydroxyl at position-12 is
necessary for activation of C. difficile spore germination. Based on the data to
this point, it seems that there is a direct correlation between acidic functional
group, linear chain length and the hydroxyl at position-12 on the cholate
backbone. Very simple modifications to the structure result in an analog capable
of binding and activating C. difficile spore germination and a compound simply
able to bind.
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T03

T66

IC50 0.51 mM (0.060)

EC50 0.31 mM (0.023)

T67

T68

IC50 5.3 mM (0.20)

IC50 3.9 mM (0.80)

Figure 3.13. Taurochenodeoxycholic acid derivatives. Taurochenodeoxycholate [T03] and analogs [T66 –
T68]. The corresponding EC50 and IC50 value is listed below each compound with the standard deviation in
parentheses. Those without a listed value had no activity under the conditions tested.

Taurocholate analogs with longer alkyl side chains and a carboxylic acid
functional group [T20, T21, and T23] inhibited C. difficile spore germination. To
determine if the hydroxyl group at position-12 on the cholate backbone is
essential for this inhibition, compounds T69 – T72 were synthesized. Compound
T69 inhibited C. difficile spore germination with an IC 50 of 0.64 mM comparable to
its analog compound T20, which has an IC 50 of 0.76 mM (Fig. 3.14). Compound
T70 is the side product formed during synthesis of T69 and is an analog of
compound T21. Like compound T21, compound T69 (IC 50 1.9 mM) is a weak
inhibitor of spore germination (Fig. 3.14). Compounds T71 and T72 are analogs
of compounds T23 and T24. Compound T71 inhibited spore germination with an
IC50 of 1.1 mM and compound T72 inhibited with an IC 50 of 8.6 mM (Fig. 3.14).
Compound T71 is a more effective inhibitor of C. difficile spore germination than
its analog T23. Compound T24 had no activity with spores but compound T72 is
96

a weak inhibitor of C. difficile spore germination. Taurochenodeoxycholate
analogs with linear side chains [T69 – T72] were unable to activate spore
germination. Like discussed previously, even number of carbons in the alkyl
chain result in more effective binding. This finding was supported by the
taurochenodeoxycholate analogs discussed here. The data also supports the
earlier observation that no hydroxyl group at position 12 results in no interference
with the binding of the bile salt to the putative germination binding site(s).
Furthermore, the earlier hypothesis is supported that longer alkyl side chains
containing a carboxylic acid are unable to activate C. difficile spore germination.

T69

T70

IC50 0.64 mM (0.19)

IC50 1.9 mM (0.78)

T71

T72

IC50 1.1 mM (0.23

IC50 8.6 mM (0.38)

Figure 3.14. Taurochenodeoxycholic acid derivatives with long side chains. Taurochenodeoxycholate
analogs [T69 – T72]. The corresponding IC50 value is listed below each compound with the standard
deviation in parentheses
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CamSA consists of a cholate backbone linked to meta-benzene sulfonic
acid by amide bond. Since chenodeoxycholate and taurochenodeoxycholate
inhibit C. difficile spore germination, we predicted that a CamSA analog with the
chenodeoxycholate backbone would provide a more active inhibitor. Based on
the activity of CamSA analogs described previously, CamSA analogs using
chenodeoxycholate backbone were prepared and tested for activity with C.
difficile spores in vitro.
Compound T73 is a CamSA analog that does not have the hydroxyl group
at position-12 on the cholate backbone. Like CamSA, compound T73 did not
activate spore germination. Unlike CamSA, compound T73 is a weak inhibitor of
C. difficile spore germination with an IC50 of 6.5 mM (Fig. 3.15). CamSA is 100
fold more active than compound T73. No hydroxyl group at position-12 resulted
in a significant decrease of potency in this CamSA analog. These data suggest
that the hydroxyl group at position-12 is optimal (compared to other analogs
tested) for binding when the side chain contains an aromatic ring and sulfonic
acid.

T15

T73

IC50 0.058 mM (0.035)

IC50 6.5 mM (0.20)

Figure 3.15. CamSA [T15] and CamSA analog T73. The corresponding IC50 value is listed below
each compound with the standard deviation in parentheses.
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Compound T74 is an analog of compound T30 and contains an
unsubstituted aromatic ring. As previously discussed compound T30 was able to
inhibit C. difficile spore germination. Compound T74 was not recognized by C.
difficile spores therefore was neither able to activate nor inhibit spore germination
(Fig. 3.16). This data suggests that the hydroxyl is necessary for binding when an
unsubstituted aromatic ring is part of the analog.
Compound T75 is the analog of compound T32 and has a carboxylic acid
at the meta position on the aromatic ring. Compound T32 was a weak inhibitor of
C. difficile spore germination (Fig. 3.16). Compound T75 is a more potent
inhibitor of C. difficile spore germination than T32 and is active at concentrations
three fold lower (IC 50 0.93 mM). Interestingly, the analog missing the hydroxyl is
more potent than with the hydroxyl in this instance. In previous analogs the
hydroxyl group seemed to be helpful for binding and analogs missing the
hydroxyl group were less active. Compound T76 is the analog of compound T34
with the carboxylic acid in the para position on the benzene ring. Compound T76
was not recognized by C. difficile spores (Fig. 3.16). This data suggests that an
analog without a hydroxyl at position-12 that has an aromatic ring substituted
with a carboxylic acid at the meta position only is able to be recognized by the C.
difficile germination binding site(s). Analogs that do not have a carboxylic acid at
the meta position require the hydroxyl group at position-12 for optimal binding.
During analysis of CamSA analogs in previous studies, it was observed
that the analog of compound T32 with a non-aromatic cyclic substituent [T35]
inhibited spore germination. To determine if the loss of the hydroxyl group on the
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cholate backbone would interfere with this binding, compound T77 was
synthesized. Compound T77 did not inhibit C. difficile spore germination however
it did activate spore germination with an EC50 of 7.4 mM (Fig. 3.16). This is a
weak germinant and is active at concentrations 16 fold lower than T32 and 8 fold
lower than its aromatic analog T75. This data contradicts earlier observations
that the hydroxyl at position-12 seemed to be necessary for activation of C.
difficile germination. Therefore although a hydroxyl at position-12 is optimal, it is
not essential for weak germination activation. On the other hand, there may be
other factors that affect the activity of compound T77 that are unclear at this time.
Compound T43 was found to inhibit C. difficile spore germination although
it does not have an electron withdrawing group on the aromatic ring. To
determine if the hydroxyl group at position-12 interferes with the ability of the
compound to bind, compound T78 was prepared. Compound T78 is an analog of
compound T43 that has an aromatic ring with an amine substituent at the meta
position. Unlike compound T43, compound T78 neither activated nor inhibited
spore germination (Fig. 3.16). As discussed earlier, the ability of T43 to bind is
currently unclear. This data suggests that the hydroxyl group at position-12 is
necessary for the analog to be recognized. As postulated earlier, the mechanism
by which compound T43 binds to C. difficile spores may be different than other
analogs. More studies with similar compounds are necessary to understand this
mechanism better.
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T74

T75
IC50 0.93 mM (0.12)

T76

T77
EC50 7.4 mM (0.65)

T78
Figure 3.16. Bile salt analogs [T74-T78]. The corresponding EC50 and IC50 value is listed below each
compound with the standard deviation in parentheses. Those without a listed value had no activity under
the conditions tested.

Bile salt analogs with multiple substituents on the aromatic ring and
polycyclic

aromatic hydrocarbons

with specific substituents were found

previously to either activate or inhibit C. difficile spore germination. Analogs of
these active compounds were synthesized using the chenodeoxycholate
backbone and tested for activity in vitro with C. difficile spores. Compound T79 is
an analog of compound T48 and has a carboxylic acid group at the meta-position
and a methyl group at the para-position of the aromatic ring. Compound T79
does not activate C. difficile spore germination (Fig. 3.17). Like the compound
T48, compound T79 prevents C. difficile spore germination. Interestingly,
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compound T79 is a potent inhibitor with an IC50 of 0.092 mM (Fig. 3.17).
Compound T79 is active at concentrations 120 fold lower than its analog
compound T48, which differs only by the hydroxyl at position-12. Furthermore,
T79 is the only inhibitor discovered thus far that can compare to CamSA activity
in vitro. We would expect that potent inhibitors would require the stronger sulfonic
acid. However, these data suggest that as long as there is not a hydroxyl at
position-12, the side aromatic group can have a carboxylic acid at the meta
position and a methyl at the para position and be active with C. difficile spores.
Compounds T80 and T81 are analogs of compounds T49 and T50 that
consist of tri-substituted aromatic side chains with sulfonic acids in the meta
position. Compound T80 has two methyl groups at the ortho and para position on
the aromatic ring. This analog inhibited spore germination with an IC50 of 0.92
mM, six fold more potent than its analog T49 (Fig. 3.17). In contrast to the
significant difference between the potency of compound T80 and T49, compound
T81 and compound T50 have very similar IC 50s, 0.75 mM and 1.1 mM
respectively (Fig. 3.17). Neither T80 nor T81 was able to activate spore
germination. In some cases the hydroxyl group seems to be nonessential for
binding to the C. difficile germination binding site(s) but in some cases as just
described analogs without the hydroxyl group are bind more efficiently. The
chemical properties of the side alkyl group seem to play a part in whether the
hydroxyl group is necessary or not. However, with the limited number of
compounds used for these studies, a direct correlation cannot be drawn at this
time.
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The CamSA analog containing naphthalene [T64], was shown to activate
C. difficile spore germination. Although this compound is not a potent activator,
the fact that it is able to activate spore germination is an interesting discovery. To
determine the effect the hydroxyl group has on activation, compound T82 was
synthesized and analyzed in C. difficile spore germination assays. Unlike
compound T64, compound T82 was unable to activate spore germination. In
contrast, T82 inhibited spore germination with an IC50 of 12 mM (Fig. 3.17).
Similar to compound T64, T84 is weakly recognized. As previously observed, the
hydroxyl at position-12 seems to be optimal for activation of germination.
Furthermore, the surprising finding that compound T64 was recognized
regardless of its bulkiness is supported by the recognition of compound T82 by
the C. difficile spore germination binding site(s). In conclusion, none of the
CamSA analogs were superior to CamSA as an inhibitor of C. difficile spore
germination

T79
IC50 0.092 mM (0.014)

T80
IC50 0.92 mM (0.16)

T81
IC50 0.75 mM (0.077)

T82
IC50 12 mM (0.48)

Figure 3.17. Bile salt analogs [T79-T82]. The corresponding IC50 value is listed below each compound
with the standard deviation in parentheses
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3.3.9. Cholic Acid Derivatives
To further characterize the differences between germination and inhibition
of simple bile salts, we tested a series of cholic acid derivatives. These analogs
differ in the cholic acid alkyl chain length, position of the hydroxyl groups,
configuration of hydroxyl groups, methylation of the hydroxyl groups and
alterations to the carboxylic acid functional group. The analogs differ from cholic
acid or chenodeoxycholate (Fig. 3.18) in up to three functional group changes.

Figure 3.18. Cholic acid (left) and chenodeoxycholate (right)

Cholic acid has an alkyl side chain bonded to a carbon at position-17 of
the D ring. This alkyl chain is branched and has a carboxylic acid at position-24
(Fig. 3.18). To determine if a shorter alkyl chain affects C. difficile spore
germination, compound T83 was tested for activation and inhibition of C. difficile
spores (Fig. 3.19). Interestingly, unlike cholic acid compound T83 did not induce
C. difficile spore germination however, it did inhibit spore germination with an IC50
of 6.3 mM (Fig. 3.19). This suggests that the longer alkyl chain length is
necessary for activation of germination but the shorter chain does not prevent
binding by C. difficile spores.
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T83
IC50 6.3 mM (0.0070)

Cholic acid

Figure 3.19. Cholic acid analog T83. The corresponding IC50 value is listed below each compound with
the standard deviation in parentheses.

The alkyl side chain in cholic acid has a carboxylic acid group. To
determine if the carboxylic acid is required for binding to C. difficile spores, two
analogs were tested for activation and inhibition of C. difficile spore germination.
In compound T84, the carboxylic acid has been reduced to an alcohol. In
compound T85, the carboxylic acid has been esterified to form the ester
derivative. Neither compound T84 nor T85 was able to induce C. difficile spore
germination but both inhibited germination (Fig. 3.20). Compound T84 was able
to inhibit germination with an IC 50 of 0.33 mM and compound T85 had an IC50 of
0.059 mM (Fig. 3.20). Compound T85 is a potent inhibitor of spore germination
and is active at almost the same concentration as CamSA. This data suggests
that the carbonyl group is necessary for activation of C. difficile spore
germination. Either the carbonyl group or the hydroxyl group is sufficient for
binding and inhibiting C. difficile spore germination. A free carboxylic acid seems
to be necessary for activation. Carboxylic acids are able to participate in
hydrogen bonding and form salt bridges, which may be essential for activation.
Since compound T85 is a very strong inhibitor, analogs of compound T85
with shorter alkyl chain lengths were assessed for inhibition or activation of C.
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difficile spore. Compound T86 has one less carbon in the alkyl chain and T87
has two fewer carbons in the alkyl chain. Neither compound T86 nor T87
activated C. difficile spore germination. However, both bile salts inhibited spore
germination. Compound T86 inhibited C. difficile spore germination with an IC50
of 0.154 mM and compound T87 has an IC50 of 0.660 mM (Fig. 3.20). Compound
T85 discussed above is more potent than compounds T86 and T87 however; the
ester functional group in these compounds is recognized for binding. These data
support the earlier observation that the carbonyl group may be the functional
group recognized by C. difficile spores and that the loss of hydrogen bonding
prevents activation of germination.

Furthermore the data suggests optimal

binding to C. difficile spores requires a longer not shorter alkyl side chain.
To determine if a longer alkyl ether linkage interferes with binding,
Compound T88 was tested. Compound T88 has an ester with an ethoxy group.
Surprisingly, compound T88 is a very strong inhibitor of C. difficile spore
germination. The IC50 for compound T88 is 0.0082 mM (Fig. 3.20). In fact, T88 is
seven-fold more potent than CamSA. Compound T88 is the most potent inhibitor
of C. difficile spore germination discovered in this dissertation project. Evidently
the C. difficile germination binding site(s) recognizes the ester functional group
but without the ability to hydrogen bond, the bile salt does not activate spore
germination.
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Cholic acid

T86
IC50 0.15 mM (0.063)

T84
IC50 0.33 mM (0.0072)

T85
IC50 0.0.59 mM (0.0079)

T87
IC50 0.66 mM (0.10)

T88
IC50 0.0082 mM (0.0005)

Figure 3.20. Cholic acid analogs [T84 – T88]. The corresponding IC50 value is listed below each
compound with the standard deviation in parentheses. Those without a listed value had no activity
under the conditions tested.

Cholic acid has three hydroxyl groups at positions 3, 7 and 12. To assess
whether the specific recognition of these hydroxyl is important for C. difficile
spore germination, compound T89 was prepared. In compound T89, all three
hydroxyls have been converted to methoxy groups. Compound T89 was neither
able to activate nor inhibit spore germination (Fig. 3.21). Since compound T89
was unable to bind to C. difficile spores, the data suggests that hydrogen
bonding ability of hydroxyl groups is essential for recognition. This is supported
by previous data showing that the loss of hydrogen bonding ability in
taurocholate analogs [T09 and T10] resulted in loss of recognition.

Cholic acid

T89

Figure 3.21. Cholic acid analog [T89].
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To determine the effects of modification to multiple functional groups have
on C. difficile recognition, a series of bile salt analogs were obtained and
analyzed in vitro for activity. Compounds T90 – T94 have hydroxyl groups at
position 3 and 12 but not at position 7. Furthermore, these compounds differ in
stereochemistry of the hydroxyl groups and two compounds have methyl esters
instead of carboxylic acids. Compound T90 differs from cholic acid only in the
loss of a hydroxyl group at position-7. Compound T90 inhibited C. difficile spore
germination with an IC50 of 0.19 mM (Fig. 3.22). The hydroxyl group at position12 in compound T91 is in the beta configuration. Compound T91 neither
activated nor inhibited C. difficile spore germination. The hydroxyl group at
position-3 in compound T92 is in the beta configuration. Compound T92 inhibited
spore germination with an IC50 of 0.095 mM (Fig. 3.22). Compound T92 is a
potent inhibitor of C. difficile spore germination and CamSA is active at
concentrations only 1.5-fold lower. Compounds T90 – T92 were unable to trigger
spore germination. These data suggest that no hydroxyl group at position-7
results in loss of ability to activate C. difficile spore germination but not the ability
to bind. The configuration of the hydroxyl at position-12 is important for
recognition but the configuration of the hydroxyl at position-3 is not important for
recognition. However, the optimal configuration for the hydroxyl at position-3 is
the alpha configuration. These statements represent the data when there is no
hydroxyl at position-7 in cholic acid.
Compound T93 is an analog of compound T90 that contains a methyl
ester instead of a carboxylic acid. Similar to compound T90, compound T93 was
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unable to activate germination but inhibited C. difficile spore germination with an
IC50 of 0.097 mM (Fig. 3.22). Compound T93 is a potent inhibitor of C. difficile
spore germination and is two fold more active than compound T90. This finding
supports earlier data showing that ester derivatives are more potent inhibitors of
C. difficile spore germination. Furthermore, the data supports that the hydroxyl
group at position 7 is not important for recognition but is important for activation.
Compound T94 is an analog of compound T91 but with a methyl ester and
the hydroxyl at position-12 is in the beta configuration. Compound T91 was
unable to activate C. difficile spore germination. However, compound T94
inhibited germination with an IC 50 of 0.095 mM (Fig. 3.22). Like compound T93,
compound T94 is a potent inhibitor of C. difficile spore germination. These
findings are interesting since the analog of compound T94 with a free carboxylic
acid and a hydroxyl at position-12 in the beta configuration [T91] was unable to
bind to C. difficile spores. Based on results discussed above, the alpha
configuration of the hydroxyl at position-12 seemed to be essential for binding.
These results show that as long as there is an ester group the configuration of
the hydroxyl is not important for binding. Furthermore, the activity of methyl
esters is supported by these findings. The strong interaction between the ester
and the binding region in C. difficile spores overcomes suboptimal configuration
of the hydroxyl group.
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Cholic acid

T92
IC50 0.78 mM (0.073)

T90
IC50 0.19 mM (0.025)

T93
IC50 0.097 mM (0.068)

T91

T94
IC50 0.095 mM (0.0012)

Figure 3.22. Cholic acid analogs [T90 – T94]. The corresponding IC50 value is listed below each
compound with the standard deviation in parentheses. Those without a listed value had no activity
under the conditions tested.

Compounds T95 and T96 both lack a hydroxyl group at position 12 and
position 7. However, they both have two hydroxyls in the alpha configuration at
position-3 and position-6. Compound T95 inhibited C. difficile spore germination
with an IC 50 of 1.2 mM (Fig. 3.23). Compound T96 is the methyl ester analog of
compound T95. Compound T96 inhibited spore germination with an IC50 0.037
mM, more than 33 times lower concentration than T95 (Fig. 3.23). Furthermore,
T96 is approximately 1.5-fold more potent than CamSA. Neither compound T95
nor T96 was able to activate spore germination. This data suggests that the
hydroxyl at position 12 is not necessary for binding. The hydroxyl at position-7 is
also not essential as long as there is a hydroxyl at position-6. Furthermore, a
hydroxyl at position-6 does not interfere with binding to the C. difficile germination
binding site(s). Ester functional groups increase the activity of a compound
significantly as observed in this data set.
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Cholic acid

T95

T96

IC50 1.2 mM (0.11)

IC50 0.037 mM (0.021)

Figure 3.23. Cholic acid analogs [T95 and T96]. The corresponding IC50 value is listed below each
compound with the standard deviation in parentheses.

Compounds T97 – T99 have only one hydroxyl group and no carboxylic
acid. Compound T97 has an alpha hydroxyl group at position-3 and the
carboxylic acid is reduced to an alcohol. Compound T97 was neither able to
activate nor inhibit C. difficile spore germination (Fig. 3.24). Since compound T84
was able to bind to C. difficile spores with an alcohol alkyl chain, it is unlikely that
the alcohol is solely responsible for the loss of binding. Optimal binding in C.
difficile spores is a multi-faceted approach. Only one hydroxyl group paired with
an alcohol functional group in the alkyl chain is probably does not have enough
optimal functional groups for binding. Compound T98 has a hydroxyl group in
the alpha configuration at position-12 and a methyl ester. Compound T98 was
unable to activate spore germination however inhibited with an IC 50 of 0.37 mM
(Fig. 3.24). As discussed previously, the methyl ester compound is strongly
recognized by the C. difficile germination binding site(s) therefore, the presence
of this functional group outweighs the less optimal conditions of few hydroxyls on
the cholic acid backbone. Hydroxyl groups at positions-3 and -7 are not
necessary for binding as long as there is a methyl ester present on the
compound. Compound T99 has a hydroxyl at position-3 but it is in the beta
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configuration. Compound T99 also has a methyl ester functional group in the
alkyl chain. As expected, compound T99 did not trigger germination but was able
to inhibit C. difficile spore germination with an IC50 of 1.3 mM (Fig. 3.24). This
data suggests that a hydroxyl at position 3 also requires an ester group for
efficient binding. Hydroxyls at positions-7 and -12 are not necessary as long as
there is a methyl ester functional group. Furthermore, the IC 50 for compound T99
is higher than other methyl esters. It is probable that the methyl ester activity is
able to overcome the suboptimal binding ability resulting from less hydroxyl
groups on the cholate backbone. However, since the hydroxyl at position-3 is in
the beta configuration and not in the optimal alpha configuration, the recognition
is not as sensitive as other analogs. In conclusion, the data shows that as long
as there is an ester in the side chain of the compound, the requirements for
hydroxyl groups at specific positions and configurations are not essential.

Cholic acid

T97

T98

T99

IC50 0.37 mM (0.051)

IC50 1.3 mM (0.54)

Figure 3.24. Cholic acid analogs [T97 – T99]. The corresponding IC50 value is listed below each
compound with the standard deviation in parentheses. Those without a listed value had no activity
under the conditions tested.
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Table 3.1. Effect of bile salt analogs on C. difficile spore germination.

Compound
No.
T23
T24
T25
T26
T27
T28
T29
T30

Modifications to taurocholate side
chain
NH(CH2)4COOH
NH(CH2)4CONH(CH2)4COOH
NH(CH2)5COOH
NH(CH2)5CONH(CH2)5COOH
NH(CH2)2OSO 3H
S(CH2)2SO3H
NHCH2PO3H
NHC6H5

T31
T32
T33
T34
T35

NHC5H4N
NH(m-(C 6H4))COOH
NH(o-(C6H 4))COOH
NH(p-(C6H 4))COOH
NH(m-(C 6H8))COOH

T36
T37
T38
T39
T40
T41
T42
T43

NH(m-(C 6H4))COOCH 3
NH(m-(C 6H4))OPO 3H2
NH(m-(C 6H4))OH
NH(o-(C6H 4))OH
NH(m-(C 6H4))SH
NH(p-(C6H 4))SH
NH(m-(C 6H4))SCH3
NH(m-(C 6H4))NH 2

T44
T45
T46
T47
T48
T49
T50
T51
T52
T53
T54
T55
T56
T57
T58
T59
T60

NH(m-(C 6H4))CH 3
NH(o-CH3-m-(C 6H4)SO3H
NH(o-OCH3-m-(C 6H4)SO3H
NH(o-CH3-m-(C 6H4)COOH
NH(p-CH3-m-(C 6H4)COOH
NH(o,p-(CH3) 2-m-(C6H 4)SO3H
NH(p,m-(CH3)2-m-(C6H 4)SO3H
NCH3(m-(C6H4)SO3H
NH2(m-(C6H4)SO3H
NHCH3(m-(C6H 4)SO3H
NH(1-C10H8)
NH(2-C10H8)
NH(C14H10)
NH(C16H10)
NH(C10H8)-3-OH
NH(C10H8)-1-SO3H
NH(C10H8)-1-CO 2H
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EC50a
IC50b
(stdev) mM (stdev) mM
NA
5.3 (0.24)
NA
NA
NA
2.3 (0.075)
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.27
(0.070)
NA
NA
NA
3.1 (0.78)
NA
NA
NA
1.4 (0.11)
NA
0.47
(0.069)
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.53
(0.022)
NA
NA
NA
NA
4.6 (0.34)
NA
16 (0.90)
NA
NA
11 (0.025)
NA
5.6 (0.042)
NA
1.1 (0.098)
5.4 (0.10)
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

T61
T62
T63
T64
T65

NH(C10H8)-5-CO 2H
NH(C10H8)-3-OH-5-SO 3H
NH(C10H8)-1,6-SO 3H
NH(C10H8)-2,6-SO 3H
NH2(C10H 8)-1,5-SO3H

Compound
Modifications to
No.
taurochenodeoxycholate side chain
T66
NHCH2SO3H
T67
T68
T69
T70
T71
T72
T73
T74
T75
T76
T77
T78
T79

NH(CH2)2SO 2H
NH(CH2)2COOH
NH(CH2)4COOH
NH(CH2)4CONH(CH2)4COOH
NH(CH2)5COOH
NH(CH2)5CONH(CH2)5COOH
NH(m-(C 6H4))SO 3H
NHC6H5
NH(m-(C 6H4))COOH
NH(p-(C6H 4))COOH
NH(m-(C 6H8))COOH
NH(m-(C 6H4))NH 2
NH(p-CH3-m-(C 6H4)COOH

T80
T81

NH(o,p-(CH3) 2-m-(C6H 4)SO3H
NH(p,m-(CH3)2-m-(C6H 4)SO3H

T82

NH(C10H8)-2,6-SO 3H

Compound
Modifications to cholic acid
No.
T83
Shorter alkyl chain
T84

Alcohol side chain

T85

Methyl ester side chain

T86

T88

Methyl ester side chain - shorter alkyl
chain by 1 carbon
Methyl ester side chain - shorter alkyl
chain by 2 carbon
Ethyl ester side chain

T89
T90

Methoxylated hydroxyl groups
Hydroxyls at 3 (α) and 12 (α)

T87

114

1.3 (0.19)
NA
NA
5.7 (0.26)
NA

NA
NA
NA
NA
NA

EC50
IC50
(stdev) mM (stdev) mM
0.31
NA
(0.023)
NA
5.3 (0.20)
NA
3.9 (0.80)
NA
0.64 (0.19)
NA
1.9 (0.78)
NA
1.1 (0.23)
NA
8.6 (0.38)
NA
6.5 (0.20)
NA
NA
NA
0.93 (0.12)
NA
NA
7.4 (0.65)
NA
NA
NA
NA
0.092
(0.014)
NA
0.92 (0.16)
NA
0.75
(0.077)
NA
12 (0.48)
EC50
IC50
(stdev) mM (stdev) mM
NA
6.3
(0.0070)
NA
0.33
(0.0072)
NA
0.059
(0.0079)
NA
0.15
(0.063)
NA
0.66 (0.10)
NA
NA
NA

0.0082
(0.00050)
NA
0.19

T91
T92

Hydroxyls at 3 (α) and 12 (β)
Hydroxyls at 3 (β) and 12 (α)

NA
NA

T93

NA

T97
T98

Methyl ester with hydroxyls at 3 (α) and
12(α)
Methyl ester with hydroxyls at 3 (α)
and 12 (β)
Hydroxyls at 3 (α) and 6 (α)
Methyl ester with hydroxyls at 3 (α) and
6 (α)
Alcohol with hydroxyl at 3 (α)
Methyl ester with hydroxyl at 12 (α)

NA
NA

T99

Methyl ester with hydroxyl at 3 (β)

NA

T94
T95
T96

NA
NA
NA

(0.025)
NA
0.78
(0.073)
0.097
(0.068)
0.095
(0.0012)
1.24 (0.11)
0.037
(0.021)
NA
0.37
(0.051)
1.3 (0.54)

a

C. difficile spores were individually treated with 6 mM glycine and bile salt analogs. Standard
deviations are shown in parentheses.
b
C. difficile spores were incubated with bile salt analogs for 15 min prior to the addition of 6 mM
taurocholate and 12 mM glycine. Standard deviations are shown in parentheses.
c
NA, no change in absorbance after 90 minutes under the conditions tested thus no statistics
could be performed.

3.3.10. Plant-Derived Cholesterol Analogs
Bile salts found in mammals are essentially cholesterol analogs that are
synthesized from cholesterol in the liver (143). Cholesterol analogs are also
found in plants and vary in function. Some plant-derived cholesterol analogs are
potent toxins and fatal when ingested and some are used medically. Others
serve as growth hormones and are essential to plant metabolic activity making
them useful agriculturally. During bile salt analog screening for C. difficile spore
binding, several cholesterol analogs derived from plants were available for
purchase. Although they differ from bile salts structurally, there are similarities in
ring orientation or alkyl side chains. The focus of this project is to map the
interactions between bile salt analogs and C. difficile spores therefore, all data is
helpful to better understand the putative germination binding site(s).
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Epibrassinolide is

in

a class

of steroid plant hormones

called

brassinosteroids that stimulate various physiological plant cell processes and
prevent infection (171, 172). When tested for activation or inhibition of C. difficile
spore germination, epibrassinolide was unable to trigger germination. However,
epibrassinolide inhibited C. difficile spore germination with an IC 50 of 0.076 mM
(Fig. 3.25). Epibrassinolide is a slightly less potent inhibitor of C. difficile
germination than CamSA. It is unclear at this time how epibrassinolide is able to
bind to the putative germination site(s). Although previous studies have shown
that the C. difficile germination binding site(s) is very sensitive to methyl and ethyl
esters, no cyclic esters were studied. It is possible that this sensitivity toward
esters allows the germination binding site(s) to overcome the other differences in
the structure of epibrasssinolide.
Ursolic acid, found in high concentrations in apple peels, has been found
to inhibit muscular atrophy-associated gene expression in humans and in mice
(173, 174). Ursolic acid was unable to bind C. difficile spores (Fig. 3.25). It is
likely that the lack of hydroxyls and the bulkiness of the uppermost rings prevent
proper C. difficile binding.
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IC50 0.076 mM (0.0015)
Figure 3.25. Plant-derived cholesterol analogs. Epibrassinolide (left) and ursolic acid (right). The
corresponding IC50 value is listed below each compound with the standard deviation in parentheses.
Those without a listed value had no activity under the conditions tested.

Some steroids found in plants have important impacts on biological
systems. Digoxigenin, ouabain, and digitoxin are three such steroids (175-180).
These toxins contain the four cholesterol rings and an α,β–unsaturated lactone.
An α-methylene-γ-lactone is an electrophilic functional group capable of
participating in Michael additions with biological nucleophiles such as sulfhydryl
groups of cysteine residues forming an irreversible adduct (181-184). These
compounds may be used as molecular probes to irreversibly bind the binding
site(s) for characterization. Unfortunately, neither digoxigenin nor digitoxin was
able to bind to C. difficile spores. Although ouabain did not trigger C. difficile
spore germination, it did inhibit with an IC 50 of 7.3 mM (Fig. 3.26). Ouabain has
multiple functional groups on the cholate backbone and a side chain of Lrhamnose sugar. Besides the cholate backbone the structure of ouabain is quite
different than taurocholate and other bile salt analogs tested. The mechanism by
which ouabain binds to C. difficile spores is unclear. However, ouabain could
potentially be used as a probe to determine the binding site(s) residues in C.
difficile.
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IC50 7.3 mM (0.050)
Figure 3.26. Plant-derived steroids. Digoxigenin (left), digitoxin (middle) and ouabain (right). The
corresponding IC50 value is listed below each compound with the standard deviation in parentheses. Those
without a listed value had no activity under the conditions tested.

3.3.11. Fluorinated Cholic Acid Derivative
The cholic acid derivative containing 17 fluorines was synthesized for a
different project. However, since the C. difficile germination binding site(s) are
unknown, all data generated from in vitro kinetic studies will help characterize the
binding region for bile salts. The fluorinated compound was unable to activate C.
difficile spore germination and was also unable to inhibit germination (Fig. 3.27).
The large concentration of fluorine in the alkyl chain will increase the overall
negativity of the compound. This strong negative charge and the bulky side
group likely affected this compound from being able to bind to C. difficile spores.

Figure 3.27. Fluorinated cholic acid derivative. This compound
had no activity under the conditions tested.
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3.4. Conclusions
The putative taurocholate binding site(s) in C. difficile spores is a very
complicated structure. The microenvironment is quite complex with respect to
functional groups that are recognized for binding and activating germination and
binding but inhibiting germination. Unfortunately, the data and results generated
from this project were not able to completely describe the requirements for C.
difficile bile salt recognition by the putative bile salt binding site(s). Although we
hoped to find obvious patterns in functional groups and spatial arrangements
necessary for binding, only a few final conclusions can be drawn. Many
compounds will require further screening to understand how they interact with the
germination binding site(s). On the other hand, until this project very little was
known about the microenvironment of the C. difficile taurocholate germination
binding site(s). The fact that some correlations between binding and recognition
were observed during this study is a stepping-stone in C. difficile spore
germination research.
Taurocholate, the natural bile salt activator of C. difficile spore
germination, has a linear (taurine) side chain bound to cholate by an amide bond.
The number of carbons in the taurine side chains is two carbons. Our results
suggest that inhibitors with an even number of carbons in the alkyl side chain are
more active than their odd numbered counterparts. Furthermore, the activity
diminishes with increased chain length. Although some odd numbered alkyl chain
analogs were able to interact with C. difficile spores, their activity required much
higher concentrations.
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In chapter 2, the meta-benzene sulfonic acid analog (CamSA, [T15]) was
found to be a potent inhibitor of taurocholate-mediated germination. In this study,
CamSA analogs were produced and assessed for activity with C. difficile spores
in attempt to understand why CamSA is an effective inhibitor. The aromatic ring
in CamSA is partially responsible for activity since an analog with no sulfonic acid
substituent was able to inhibit spore germination. However, the sulfonic acid
moiety is optimal for binding. Phenolic groups negatively affected the ability of
the analog to bind to the C. difficile germination binding site(s). In general, the
putative germination binding site(s) requires electronegative functional groups
that cause an electron withdrawing effect on aromatic rings. Strong acid
functional groups, specifically sulfonic acids, are preferred over weak acid
functional groups. Oxygen atoms in the functional group (except hydroxyl) on
aromatic rings are necessary for recognition. In contrast, sulfur is not essential
since carboxylic acids are recognized by the C. difficile germination binding
site(s).
Since CamSA could be used as a preventative for CDI in animal studies, it
will come into contact with bile salt hydrolases in the gut of animals. To make
CamSA more stable, the amide linkage was methylated (188). However, this
modified analog was no longer able to inhibit spore germination but activated
germination. Although it is unclear how compound T51 activates germination, the
fact that it no longer inhibits spore germination renders it impractical for animal
studies or bile salt hydrolase studies.
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Polycyclic aromatic hydrocarbons (PAH) consist of two or more fused
benzene rings that are flat and very rigid molecules. When cholate was coupled
with PAHs with two to four fused aromatic rings, the analog was weakly
recognized or not at all by C. difficile spores. Interestingly, two bile salt analogs
containing naphthalene and a carboxylic acid or a sulfonic acid at position 4 and
5 were recognized and activated C. difficile spore germination, albeit weakly.
Acid moieties at other positions (of naphthalene) had no effect on C. difficile
spore germination. Clearly, there is an interaction that can be made with the C.
difficile binding pocket when the molecule has the acid in this specific placement
on naphthalene. It is unclear at this time how this interaction occurs. We expect
that the C. difficile binding region for bile salts is dynamic in structure allowing
functional groups to bind that have certain size, shape, and chemical properties.
Taurochenodeoxycholate is a natural bile salt that inhibits C. difficile spore
germination in vitro and differs from taurocholate in the lack of a hydroxyl group
at position-12 in the cholate backbone. Taurochenodeoxycholate analogs with
linear side chains have similar activity on C. difficile spore germination. The
hydroxyl at position-12 is not necessary for binding and activating germination as
long as the chain is short. Longer alkyl side chains with carboxylic acid functional
groups are unable to activate spore germination but are able to bind to the C.
difficile germination binding site(s). Similar to the linear chain taurocholate
analogs, taurochenodeoxycholate linear analogs were more effective when the
carbons in the alkyl chain were an even number.
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Most compounds that were able to bind as the cholate (backbone)
analogs were also able to bind as the chenodeoxycholate analogs. In some
cases, no hydroxyl group at position-12 resulted in increased activity. A
compound was discovered in this study that is only about 1.5-fold less potent
than CamSA. More studies will be needed to determine if this compound is a
candidate for pharmacokinetics and animal studies.
The hydroxyl group at position-12 is necessary for activation of
germination. Except one analog, all other analogs that activated spore
germination as the cholate analog were unable to activate germination without
the hydroxyl group. Correlations between hydroxyl groups and side chains are
difficult to make conclusively with the data provided. More analogs will need to be
tested for activity in C. difficile spore germination to define patterns and explain
inconsistencies.
Cholic acid is an unconjugated bile salt with a carboxylic acid moiety. The
side chain length is important for activation of C. difficile spore germination. The
carboxylic acid moiety and the length of the alkyl chain are optimal for activation
of germination by cholic acid. Modifications to the side chain did not prevent
recognition by C. difficile spores. As long as an oxygen atom was present, the
bile salt was able to bind and inhibit spore germination. In fact, an ester
functional group in place of the carboxylic acid resulted in potent inhibition of C.
difficile spore germination. An ester with an ethoxy group inhibited spore
germination at concentrations eight fold lower than CamSA. This is the most
potent inhibitor discovered to in this project. The sum of these data suggest that
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carboxylic acids on unconjugated bile salts are optimal for activation of C. difficile
spore germination, longer not shorter alkyl chains are optimal for recognition and
ester groups with ethoxy groups are potent inhibitors of C. difficile spore
germination.
The results from these studies suggest that the hydroxyl group at position12 is not essential for C. difficile spore recognition. The hydroxyl group at
position-7 is essential for activation of C. difficile spore germination when there
are hydroxyls at position-3 and -12 or at position-3 and -6 as well as a free
carboxylic acid moiety on the alkyl chain. However, the hydroxyl group at
position-7 is not essential for binding unless the hydroxyl at position-12 is in the
beta configuration. The alpha configuration of the hydroxyl at position-12 is
optimal for binding when there is a carboxylic acid and no hydroxyl at position-7.
This requirement is void however if the carboxylic acid functional group is
replaced with an ester group. The strong recognition of the ester overcomes the
unrecognized configuration of the hydroxyl at position-12. The hydroxyl at
position-3 can be in either configuration for recognition by C. difficile spores but
the alpha configuration is preferred. As long as there is an ester in the alkyl chain
there can be one hydroxyl at either position-3 or position-12 and the bile salt can
be recognized. The results from these studies provide strong evidence that the
C. difficile germination binding site(s) is quite sensitive to ester functional groups.
Although many of the cholic acid analogs were able to bind to C. difficile
spores, none were able to activate spore germination. The requirements for
activation by cholic acid are very specific. There must be three hydroxyl groups
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all in the alpha configuration and located on position-3, -7, and -12. A carboxylic
acid functional group must be present on the alkyl chain. Any changes to these
requirements result in loss of activation but not binding, suggesting a combined
role for these germinant functional groups. In conclusion, the functional groups
and arrangements of functional groups are not flexible for activation of C. difficile
spore germination. Ester containing compounds are highly active at binding to C.
difficile spores, suggesting a specific binding region that this functional group is
able to occupy.
This project analyzed many bile salt analogs in attempt to map the
interactions between bile salts and C. difficile spores. Some correlations between
functional groups and activity were discovered however many interactions are
still uncharacterized. Another focus of this study was to identify compounds that
can inhibit C. difficile spore germination in vitro. Many inhibitors were discovered
however only a few are as good as or better than CamSA. Unfortunately, the bile
salts and analogs that were superior to CamSA are also very expensive
commercially and difficult to produce. Based on cost and activity, CamSA is the
best current candidate for pharmacokinetic characterization and animal studies of
CDI.
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CHAPTER 4
IN VITRO CHARACTERIZATION OF CAMSA
4.1. Introduction
The meta-benzene sulfonic acid derivative of taurocholate, CamSA, is a
potent inhibitor of C. difficile spore germination in vitro. In fact, CamSA is active
at concentrations 250-fold lower than taurocholate, the natural germinant.
Furthermore, CamSA is 4-fold lower than chenodeoxycholate, the natural
inhibitor. CamSA was also chosen as the lead compound for in vitro
characterization due to the high yields obtained and the relative ease of
purification. The procedure of coupling cholic acid to meta-aminobenzene
sulfonic acid yields >80% of pure CamSA. The sodium salt of CamSA has high
solubility in water and DMSO compared to other analogs. The ethyl and methyl
esters of cholate derivatives [T85, T88, and T96] have very low IC50s in vitro.
However, these compounds are highly insoluble in water and are expensive
comparatively to produce. Based on these criteria CamSA is the most practical
choice for characterization in vitro for potential CDI chemotherapeutic use.
Pharmacokinetic analysis of anti-germinants is a necessary step in
determining potential novel therapeutic agents for CDI. The fate of a drug
depends upon its absorption, distribution, metabolism, and excretion (ADME). In
vitro characterization can predict the ADME parameters prior to in vivo testing
(189). Furthermore, guidelines describe that potential drugs must be safe,
delivered to the target site, manufactured at minimal cost, and stable (190, 191).
The bioavailability of any drug must be determined to ensure proper distribution
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and dosage to target tissues/organs and limited distribution outside of the target
areas (189, 192). Oral medications must also be stable to the changing
environments of the gastro-intestinal tract (193). Because, C. difficile spores
germinate in the GI tract and the resulting infection is localized to the intestine,
proper treatment should target the intestinal tract and have low absorption into
the blood and other tissues (35).
Mammalian cell culture has been used extensively to predict the
cytotoxicity of potential drugs on different tissues (194-196). Comparison of basal
cell parameters to varying drug concentration allows researchers to predict
whether organ-specific toxin events may occur. Assessing the cytotoxicity of
drugs for CDI on epithelial cells and immune cells provides information about
toxicity to cells in direct contact with the bacterium and the drug.
C. difficile toxins cause severe damage to the epithelial cells in the
intestinal tract resulting in characteristic symptoms of CDI (78). Due to the drastic
difference in in vitro growth conditions between cultured mammalian cells and C.
difficile, toxins secreted during bacterial growth are often used to assess the
effects on cultured cells (197, 198). This is an indirect way to measure whether
C. difficile spores have germinated into toxin-producing cells and whether toxin
production is sufficient to affect the viability of cultured mammalian cells.
Based on the criteria described above, CamSA was assessed for several
pharmacokinetic parameters in vitro prior to animal studies. The effect of CamSA
on bacterial proliferation was observed using common enteric bacteria. CamSA
stability in simulated gut microenvironments was determined. The apparent
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permeability of CamSA through mammalian intestinal lining was predicted.
Finally using cell culture, CamSA was assessed for cytotoxicity and for the ability
to prevent toxin-induced cell death. The purpose of this project was to determine
if CamSA is a good candidate for animal studies.
4.2. Materials and Methods
4.2.1. General comments
Bile salts and amino analogs were purchased from Sigma Aldrich
Corporation (St. Louis, MO). CamSA was synthesized in the Abel-Santos
laboratory as described previously. Thin layer chromatography silica gel 60 F254
was purchased from EMD Chemicals (Gibbstown, NJ). Bacterial cultures, tissue
cultures, and media were purchased from the ATCC (Manassas, VA). CellTiterGlo luminescent cell viability assay was purchased from Promega (Madison, WI).
4.2.2. Effect of CamSA on Bacterial Growth
Laboratory strains of Bacillus cereus, E. coli, Bifidobacterium longum,
Lactobacillus gasseri, Clostridium difficile strains 630, and C. difficile strain VPI
10463 were inoculated from freezer stock onto appropriate agar medium as
directed by ATCC. Plates were incubated overnight at 37 °C either aerobically (L.
gasseri, B. cereus, and E. coli) or anaerobically (C. difficile and B. longum).
Single cell clones were carefully selected and used to inoculate 5 mL of liquid
medium. Inoculated broth was shaken at 37 °C for approximately four hours until
optical density at 580 nm reached 0.8 representing exponential phase of growth
(199). Bacteria were sub-cultured (1:100) into fresh media supplemented with 0
or 10 mM CamSA, taurocholate, or chenodeoxycholate. Optical density was
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recorded at time 0 and then at 1, 2, 3, 4, 6, 8, and 24 hours post inoculation.
Growth to stationary phase was determined when optical density reached OD 580
>1.5. Bacterial growth was monitored on a ThermoElectron Biomate 5
spectrophotometer at 580 nM. Cultures supplemented with bile salts were
compared to the control cultures grown under normal conditions.
4.2.3. Stability of CamSA in Artificial Gastric and Intestinal Juice
CamSA was analyzed for stability in simulated gastric and intestinal juices
as published (193). Artificial gastric juice (no pepsin) is a 0.05 M sodium chloride
solution adjusted to pH 1.5 with HCl. Artificial intestinal juice (no pancreatin) is a
0.05 M sodium dihydrogen phosphate buffer at pH 6.8 (193). CamSA (100 mg)
was added to 1 ml of either artificial intestinal or artificial gastric juice and
incubated at 37 °C for 24 hours. Aliquots were taken at 4, 8, 12, and 24 hours.
Samples (1 μl) were spotted on silica thin layer chromatography (TLC) plates and
allowed to dry. Plates were developed with 75% ethyl acetate/methanol. TLC
plates were visualized by spraying with 10% wt/vol phosphomolybdic acid
(PMA)/ethanol solution followed by heating at 100 °C for 2 minutes.
Quantification of CamSA was determined using a GE Healthcare Typhoon 9410
Variable Mode Imager and analyzed using ImageQuant TL 5.2 software.
4.2.4.Stability of CamSA with Bile Salt Hydrolase-Producing Bacteria
Bifidobacterium longum, Lactobacillus gasseri, and Escherichia coli DH5-α
were obtained from ATCC. B. longum was streaked for single colonies on tryptic
soy agar (TSA) supplemented with 5% defibrinated sheep blood and incubated
overnight anaerobically at 37 °C. L. gasseri was streaked for single colonies on
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Difco Lactobacillus MRS (de Man, Rogosa, Sharpe) agar. E. coli was streaked
for single colonies on Luria-Bertani (LB) agar. Both L. gasseri and E. coli were
incubated overnight aerobically at 37 °C. Individual colonies were chosen to
inoculate appropriate media and adjusted to an OD 580 of 1.0 with fresh media
supplemented with 6 mM CamSA. As control, bacterial cultures were separately
incubated

with

taurocholate,

cholic

acid,

taurodeoxycholate,

and

chenodeoxycholate. Bacterial cultures/bile salt mixtures were incubated at 37 °C
for 24 hours. Samples were taken at 4, 8, 12, and 24 hours for analysis. Bile salt
stability was monitored by TLC and quantified as above. Percent conjugated bile
salts were derived by comparing the intensity of cholic acid TLC spots obtained
following incubation to the intensity of the TLC spot for cholic acid obtained at the
beginning of incubation. A known concentration of cholic acid spotted on TLC
was set at 100%.
4.2.5. In vitro Caco-2 Permeability Assays
Caco-2 permeability assays of CamSA were performed by Apredica, LLC
(Watertown, MA). Briefly, CamSA was dissolved in DMSO and added to Caco-2
cell cultures to 10 μM final concentration. CamSA was analyzed for both apical to
basolateral permeability and basolateral to apical permeability across a Caco-2
cell monolayer. After a 2 hour incubation, CamSA concentrations in the apical
and basolateral sides of the Caco-2 monolayers was determined by HPLC-MS.
4.2.6. Cytotoxicity of CamSA
Vero, Caco-2, and J774A.1 cell lines stored in growth medium
supplemented with 5% (v/v) DMSO were thawed rapidly from liquid nitrogen
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storage. Cell lines were grown in minimum essential medium (MEM)
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin
(complete medium) at 37 °C in a humid incubator containing air at 95% and CO2
at 5% (200). To remove cells from tissue culture flasks, 1X trypsin-EDTA (1mM
EDTA) was added and incubated with cells for 5 minutes. Complete medium was
added and using a cell scraper, monolayers were gently removed. Cells were
recovered by 800 x g for 5 minutes at room temperature and the cell pellet was
resuspended in fresh media. A sample of cell suspension was treated with trypan
blue to determine basal cell viability (201). Trypan blue is a dye exclusion method
that selectively stains dead or dying cells that do not have an intact (viable) cell
membrane (201). Trypan blue treated cells were inserted into a hemocytometer
and viewed by light microscopy for enumeration of live cells (usually >90% live
cells). Culture cells were plated in 12-well or 96-well tissue culture treated plates
at a density of 105 cells/ml and allowed to attach overnight. Spent media was
removed and fresh media supplemented with CamSA in DMSO at a final
concentration of 50 or 200 μM was added to the wells. As negative control, cells
were supplemented with media containing DMSO. As positive control cells were
treated with 10% EtOH. Plates were incubated overnight as described above.
The 12-well plates containing cell cultures were used as a qualitative
method to visualize cytotoxicity by cell rounding and trypan blue. Following
overnight treatment with 0, 50 or 200 μM CamSA or 10% EtOH, media was
removed from wells and PBS containing 0.4% trypan blue was added. After 5
minutes, cells were visualized using a light microscope and observed for blue

130

stained cells. The number of blue cells in CamSA-treated wells was compared to
the number of blue cells in the negative and positive control wells. Morphological
change (rounding) was also determined by comparing CamSA-treated to positive
and negative control cells.
The 96-well plates cultured with mammalian cells were used as a
quantitative method using the CellTiter Glo Luminescent cell viability assay. This
assay quantitates the concentration of ATP, which indicates metabolically active
cells (202). After overnight treatment, the 96-well plates were equilibrated to
room temperature for 30 minutes before addition of the CellTiter-Glo reagent.
Luminescence was read with an integration time of 1 second per well using a
Tecan Infinite 200 plate reader and iControl software. All experiments were done
in triplicate.
4.2.7. C. difficile Toxin-Induced Cell Death
C. difficile spores were washed five times with nanopure water, heat
activated at 68 °C for 30 minutes and washed five more times with water. Spore
pellets were resuspended in 0.1 M sodium phosphate buffer at pH 6.0
supplemented with 0.5% sodium bicarbonate (germination buffer) to an OD580 of
1.0. Spores were diluted five-fold in BHI broth containing 6 mM taurocholate/12
mM glycine (germinants), germinants supplemented with CamSA at 50 μM
(CamSA 50) or 200 μM (CamSA 200), or germinants supplemented with
chenodeoxycholate at 200 μM (CDCA 200). The resulting mixtures were
incubated at 37 °C anaerobically overnight. The following day, the cells/spores
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were removed by centrifugation and the supernatants were filtered through 0.2
μm sterile filter (Fig. 4.1).
In parallel, cell lines were cultured in 96-well plates as described above.
Fresh media containing no bacterial supernatant or bacterial supernatant at
varying concentrations (percent v/v) were added to the cultured vero and Caco-2
cells (Fig. 4.1). Cells were also treated with BHI as an added control. After
overnight incubation, the plates were treated as before for the CellTiter Glo
viability assay and luminescence was obtained using a plate reader and software
as described.

Figure 4.1. Representation of the method for treating culture cells with supernatants derived from C.
difficile spores. C. difficile spores in BHI were supplemented with taurocholate and glycine (test tube A
above), taurocholate, glycine and CamSA (test tube B above), and taurocholate, glycine, and
chenodeoxycholate (test tube C above). After overnight incubation of C. difficile spores with supplements,
the supernatants were recovered by centrifugation and sterile filtered. Supernatants were titrated into wells
containing mammalian cells in growth medium.

4.2.8. Statistical Analysis
Standard deviations represent at least three independent measures, unless
otherwise stated. Analysis of data by 1-Way ANOVA for nonparametric analysis
had a statistical significance set at a p value of < 0.05. Student’s paired t-test was
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used to determine the significance of difference of means and the p value was
set at < 0.05.
4.3. Results and Discussion
4.3.1. Effect of CamSA on Bacterial Growth
Three of the bacterial strains (B. longum, L. gasseri and E. coli) chosen for
this study are indigenous human intestinal bacteria and two strains cause
disease in humans (B. cereus and C. difficile). Indigenous bacteria resist
colonization of C. difficile and these same bacteria are compromised during
antibiotic treatment (74, 142, 203). Since the natural flora is imperative to the
resistance of infection by C. difficile, therapies to counteract or prevent CDI
should not damage this natural barrier (142, 204). B. longum and L. gasseri are
both Gram-positive bacterium that harmlessly populate the human intestinal tract
and aid in bile salt degradation (205, 206). E. coli is a Gram-negative bacterium
common to the human intestine (207). Most E. coli strains are non-pathogenic
(like the strain used in this study) although some strains are associated with
infection and disease (208). E. coli, B. longum, and L. gasseri are exposed to bile
salts regularly (144, 209). In fact, B. longum, and L. gasseri with other indigenous
bacteria aid in important bile salt modifications in the gut. Modifications include
epimerization, deconjugation by bile salt hydrolases, oxidation, reduction,
hydroxylation and dehydroxylation (144, 210). Modified bile salts aid in digestion
and the removal of cholesterol from enterohepatic circulation (144, 210).
Associations between E. coli and bile are not well understood but E. coli is bile
salt resistant (144). E. coli, B. longum, and L. gasseri were each assessed for
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growth in the presence of taurocholate, chenodeoxycholate or CamSA. As
expected, these three normal gut bacteria were unaffected by bile salts
supplemented in the growth medium (Table 4.1). These results indicate that
although CamSA is a bile salt analog, it retains essential bile salt characteristics
that allow it to be tolerated by enteric bacteria tested in this study. Furthermore,
CamSA was tolerated by both Gram-positive and Gram-negative bacteria.
The Gram-positive bacterium, B. cereus, is an important bacterium that
produces toxins associated with food spoilage and subsequent food-borne illness
(211, 212). It is postulated that B. cereus is a transitory species in the natural gut
flora (213). Bacillus cereus is widely distributed in the environment and toxins
ingested from spoiled food cause severe vomiting and diarrhea (211, 212, 214).
Since B. cereus has been found in the feces of humans, cells and/or spores likely
encounter bile salts during transit through the GI tract (211, 213, 215). Previous
reports have shown that B. cereus is unable to grow in the presence of bile salts
(216, 217). B. cereus vegetative cells added to control media resulted in normal
growth with OD 580 saturation at 24 hours. However, B. cereus did not grow in
media supplemented with taurocholate, chenodeoxycholate or CamSA (Table
4.1).

This

suggests

that

CamSA

is

similar

to

taurocholate

and

chenodeoxycholate in preventing the growth of B. cereus (216, 217).
In vitro kinetic data suggests that CamSA prevents C. difficile spore
germination but other bile salts have been shown to inhibit vegetative growth
(140, 141). Recovery of C. difficile in growth medium is enhanced by the addition
of the bile salt, taurocholate (138, 218, 219). Other bile salts such as
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chenodeoxycholate prevent the vegetative growth of C. difficile in culture (140,
220). CamSA prevents C. difficile spore germination in vitro however the effect
on vegetative growth was not studied. Since C. difficile is the focus of this project,
effect of CamSA on vegetative growth was determined. Two strains of C. difficile
were observed for growth in the presence of taurocholate, chenodeoxycholate or
CamSA. C. difficile strain 630 and VPI 10463 grew to saturation in the presence
of taurocholate. However, neither grew in the presence of chenodeoxycholate as
expected (140, 220). CamSA supplemented in C. difficile growth medium did not
affect either C. difficile strain tested and each grew normally (Table 4.1). These
data support previous reports of taurocholate and chenodeoxycholate effects on
C. difficile growth. Although CamSA inhibits spore germination in vitro, CamSA
does not affect the vegetative growth of C. difficile. In conclusion, this data
supports the proposed mechanism that CamSA inhibits spore germination and
has no affect as an antibacterial agent.

Table 4.1. Effect of Bile Salts on Bacterial
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4.3.2. Stability of CamSA in Simulated Gut Microenvironments
CamSA is a taurocholate analog with an amide bond linking cholic acid to
meta-benzene sulfonic acid. To be effective CamSA must survive the changing
environments of the GI tract. If CamSA is going to be administered orally, it must
be stable to the extremely low pH of gastric juices located in the stomach.
CamSA was incubated with simulated gastric juice at pH 1.5. Degradation of
CamSA was not observed after 24 hours in gastric juice. CDI is localized to the
intestinal tract (12), therefore effective treatment must be stable in intestinal
juices. CamSA was incubated with simulated intestinal juice and no degradation
of CamSA was evident even after 24 hours. Hence, CamSA is stable in
simulated gastric and intestinal juices at the pH likely encountered during the oral
route of drug delivery to the intestinal tract.

A.

B.

C.

D.

Figure 4.2. Bile salts used for bile salt hydrolase deconjugation studies. A) taurocholate, B)
CamSA, C) taurochenodeoxycholate, and D) chenodeoxycholate
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Bacterial bile salt hydrolases (BSHs) can hydrolyze conjugated bile salts
(144, 187). Bifidobacterium longum and Lactobacillus gasseri are two intestinal
bacteria commonly used as test strains for BSH production (187, 205, 221).
CamSA is a conjugated bile salt similar to the natural bile salt that activates C.
difficile spore germination, taurocholate (Fig. 4.2). Taurochenodeoxycholate is
the conjugated derivative of chenodeoxycholate (Fig. 4.2). After four hours
incubation with a culture of B. longum, approximately 25% of CamSA is
hydrolyzed to cholic acid (Scheme 4.1 and Fig. 4.3A). Taurocholate is degraded
quickly in the first four hours resulting in almost 60% degradation (Fig. 4.3A, []
p < 0.005). Taurochenodeoxycholate is hydrolyzed faster than CamSA but slower
than taurocholate; within four hours 36% was hydrolyzed (Fig. 4.3A, [*] p <
0.005). After 24 hours incubation with B. longum, 79% of CamSA and 83% of
taurocholate are hydrolyzed to cholic acid. There was no significant difference
determined between CamSA and taurocholate degradation after 24 hours (Fig.
4.3A [**]). Taurchenodeoxycholate is hydrolyzed at a slower rate than either
CamSA or taurocholate by B. longum as only 55% had been hydrolyzed after 24
hours (Fig 4.3A [★] p < 0.01). In the first four hours following incubation with L.
gasseri, 1% of CamSA, 7% of taurocholate, and 14% of taurochenodeoxycholate
was hydrolyzed to cholic acid (Fig. 4.3B). This degradation by L. gasseri in the
first four hours for CamSA and taurocholate was significantly different than the
degradation by B. longum in the first four hours (Fig. 4.3A and B [] p < 0.05)
CamSA and taurocholate are less sensitive to degradation in the presence of L.
gasseri than to B. longum after 24 hours (Fig. 4.3A and B [+] p < 0.03). Less than
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30% of CamSA was hydrolyzed to cholic acid after 24 hours by L. gasseri (Fig.
4.3B [i] p < 0.05).

In contrast, 64% of taurochenodeoxycholate had been

hydrolyzed after 24 hours (Fig. 4.3B [iii] p < 0.05). Taurocheneodeoxycholate is
more sensitive to degradation by L. gasseri than it is to B. longum (p <0.05).
Chenodeoxycholate is not a conjugated bile salt and showed no degradation
when incubated with either B. longum or L. gasseri. E. coli does not produce
BSH and bile salts were stable after 24 hour incubation with E. coli cultures.

Scheme 4.1. Schematic representation of the hydrolysis of CamSA by bile salt hydrolase.
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Bile salt hydrolases produced by enteric bacteria will degrade CamSA

Figure 4.3 Incubation of CamSA with bile salt hydrolase-producing bacteria. A) Incubation of bile salts with
B. longum. B) Incubation of bile salts with L. gasseri. Data indicates percent of conjugated bile salt
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intestinal lumen, CamSA will be hydrolyzed and excreted. Further metabolic in
vivo data will be needed to support this hypothesis.
4.3.3. CamSA Predicted Oral Bioavailability
To prevent C. difficile spores from germinating, CamSA needs to be
retained in the intestinal lumen. Furthermore, there is less chance of toxic side
effects to non-targeted organs if the anti-germinant therapeutic drug has a low
oral bioavailability (192). Caco-2 permeability serves as an in vitro surrogate
assay for intestinal permeability (222). Potential drugs are added to the apical
side and the amount of permeation is determined on the basolateral side (Fig.
4.4). The permeation from apical to basolateral suggests the absorption of the
drug across the gut wall and the rate of transport can be calculated. The opposite
is used to determine basolateral to apical permeation. The permeability
coefficient (Papp) is obtained by dividing the rate of permeation by the initial drug
concentration and the area of the monolayer. The permeability ranking for Papp
less than 0.5 is low permeability, moderate permeability is 0.5 to 5 and high
permeability is greater than 5. The basolateral to apical permeability suggests
whether the drug will undergo active efflux. The receiver side buffer is removed
for analysis.
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Figure 4.4. Caco-2 permeability assay

Natural bile salts are regulated in the GI tract by active and passive
transport for reabsorption in enterohepatic circulation (143). Cholic acid,
chenodeoxycholate, taurocholate and other bile salts have high permeability in
simulated gut wall experiments (143, 223, 224). Furthermore, natural bile salts
enhance the permeability of certain molecules across cell monolayers due to
their ability to form micelles at high concentrations (223). The critical micelle
concentration is currently not known for CamSA. In a Caco-2 permeability assay,
CamSA displayed an apical to basolateral permeability coefficient (P app) of 0.00 x
10-6 cm/s. The Papp of CamSA was compared to ranitidine which has a P app of 0.3
x 10-6 cm/s and warfarin which has a P app of 42.9 x 10-6 cm/s. Based on the
permeability scale, CamSA has low to no permeability from Caco-2 cells’ apical
to basolateral side.
Bile salts can enhance permeability of molecules across the intestinal cell
lining by forming micelles (143, 223, 224). The concentration of CamSA used for
these experiments was significantly lower (10 μM) than the critical micelle
concentration (CMC) of other bile salts. The CMCs for taurocholate and
chenodeoxycholate are estimated to be 7 mM and 8 -12 mM, respectively (225,
140

226). These data show that at low concentrations, CamSA does not traverse the
intestinal lining. However, at higher concentrations CamSA may form micelles
like other bile salts. The CMC of CamSA will need to be determined in future
studies.
CamSA displayed a basolateral to apical Papp of 10.9 x 10-6 cm/s. The
basolateral to apical P app was also compared to ranitidine which has a Papp of 1.8
x 10-6 cm/s and warfarin which has a P app of 16.0 x 10-6 cm/s. Based on the
permeability scale described above, CamSA has high permeability from the
basolateral cell side to the apical side. It is likely that CamSA is actively
transported to the apical surface of the Caco-2 monolayers. In the Caco-2
permeability assay, CamSA at 10 μM is not absorbed by the apical surface of the
monolayer and is effluxed from the basolateral.
From both data sets the efflux ratio (RE) can be calculated by dividing the
basolateral Papp by the apical P app. An RE of greater than 2 indicates a significant
efflux activity and indicates a candidate substrate for active transporters such as
P-glycoprotein (227). Ranitidine has a RE of 6, warfarin has a RE of 0.4 and
CamSA has a RE of 11. The sum of this data suggests that CamSA has low
bioavailability and will remain in the lumen of the gut.
An in vitro ADME-Tox test was also conducted to estimate the percent
recovery of CamSA from either the apical to basolateral permeability or
basolateral to apical permeability. In both assays CamSA was recovered at
100% indicating low binding to and low accumulation inside Caco-2 cells. The
recovery of CamSA at 100% also indicates low metabolism by Caco-2 cells (228,
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229). The ADME-Tox test further supports that CamSA will be stable and remain
in the intestinal lumen.
4.3.4. Cytotoxicity of CamSA
Cell culture can be a useful tool to predict toxicity of therapeutic agents to
particular tissues or to immune cells (194-196). There are many ways to
determine cell viability and/or cell death using in vitro assays all with limitations
(230). To minimize variability, we utilized visual observation of rounded cells,
trypan blue exclusion, and ATP production to determine cell viability. Rounding of
mammalian cells in culture upon exposure to C. difficile toxin is used as a visual
determination of sensitivity of cells due to the destruction of the actin
cytoskeleton (87, 92, 231, 232). It is a rapid method to determine the dose of
toxin necessary to induce cell rounding (231). The affect CamSA has on the
morphology of mammalian cells was determined. Trypan blue is a dye exclusion
method that selectively stains dead or dying cells that do not have an intact
(viable) cell membrane (201). ATP concentration assays provide evidence of cell
viability due to its presence in all metabolically active cells. When cell are dying
the amount of ATP decreases allowing for distinction between viable and nonviable cells (202).
Vero and Caco-2 epithelial cell lines were chosen for cytotoxicity studies
because they are the commonly used cell lines used to test for C. difficile toxin
production and toxin damage (92, 197, 198). Vero cells are an immortalized cell
lineage from kidney epithelial cells originating from the African green monkey.
Caco-2 carcinoma cells are human colon epithelial cells. Murine macrophages
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(J774.1) are immune cells that are used extensively in the Abel-Santos
laboratory to study spore phagocytosis (135, 233). Recent studies have analyzed
macrophage responses to C. difficile spores and to C. difficile cellular proteins
(234, 235). Therefore for potential future studies, the cytotoxicity of CamSA was
determined for a murine macrophage cell line.
Cultures of macrophages, vero cells and Caco-2 cells were treated with
DMSO as a negative control or 10% ethanol as a positive control for non-viable
cell experiments. All cell lines treated with DMSO appeared healthy (nonrounded) and very few were stained blue by trypan blue exclusion (Fig. 4.5A). In
contrast, cells treated with ethanol appeared rounded and stained blue by trypan
blue (Fig. 4.5B). CamSA was added to cells at either 50 μM or 200 μM. CamSA
treated cells were undistinguishable from DMSO-treated cells (Fig. 4.5C). In
conclusion, based on the lack of cell rounding and trypan blue staining
experiments, CamSA did not induce cell death at the concentrations tested.

A.

B.

C.

Figure 4.5. Trypan blue
exclusion dye staining.
Macrophages treated with A)
DMSO vehicle (5% v/v), B) 10%
ethanol, or C) CamSA (shown at
200 μM) and stained with trypan
blue exclusion dye.
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Vero and Caco-2 cells were treated as above and assayed for cell viability
due to ATP concentration. Wild type cells and those treated with DMSO resulted
in high basal concentrations of ATP, whereas cells treated with ethanol resulted
in very low amounts of ATP (Fig. 4.6). As described above, CamSA treated cells
were similar to the DMSO treated cells with high levels of ATP (Fig. 4.6). In
conclusion, these combined in vitro experimental results indicate that CamSA at
50 μM and 200 μM is not cytotoxic to vero cells, Caco-2 cells or murine
macrophages.

Figure 4.6. Cytotoxicity cell viability assay. Luminescence due to ATP in vero cells (white
bars) and Caco-2 cells (black bars) after treatment with DMSO, 10% EtOH, or CamSA at
50 μM and 200 μM. Significant differences are observed between 10% ethanol treated
cells and cells treated with DMSO or CamSA (both cell lines) p < 0.005. No significant
difference is observed between DMSO treated and CamSA at either concentration for
both cells lines.

4.3.5. CamSA protection of Caco-2 and Vero Cells
Cell culture is an indirect method to determine protection from C. difficile
induced cell death (78). C. difficile does not tolerate aerobic conditions that are
required for the culturing of tissue cells and tissue cells will not tolerate the
anaerobic conditions necessary for C. difficile growth. Therefore, tissue culture
experiments rely on the production of C. difficile toxin secreted into medium
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during C. difficile vegetative growth (197, 198, 236). Toxin production and
secretion increases when bacteria are in stationary growth phase and is
controlled by an optimum temperature of 37 °C (77, 237, 238). Since toxin is only
secreted by metabolically growing and dividing C. difficile cells, halting
germination should result in less toxin production (78).
C. difficile spores were grown in medium supplemented with taurocholate
and glycine (germinants) to induce spore germination. Because vegetative C.
difficile produces toxins, spores treated with germinants serve as a positive
control for toxin production. Spores were also grown in medium supplemented
with germinants and 50 μM (CamSA 50) or 200 μM (CamSA 200) of CamSA or
chenodeoxycholate. Spores treated with germinants grew normally whereas only
slight growth was observed for CamSA treated spores. Chenodeoxycholate
inhibits spore germination and also prevents C. difficile cell growth and indeed no
growth was observed (140, 141).
Supernatants were recovered from C. difficile supplemented as described
and titrated into vero and Caco-2 cell medium. The supernatant from C. difficile
spores treated with germinants affected vero and Caco-2 cells in a dosedependent manner. As the concentration of germinant supernatant increased,
luminescence due to the presence of ATP decreased (Fig. 4.7A and B). The
decrease in ATP corresponds to fewer viable cells (202). In both cell types,
addition of 5% (v/v) C. difficile germinant supernatant resulted in greater than
95% decrease in viable cells (Fig. 4.7A and B). This data is supported by
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previous reports indicating toxin production during vegetative C. difficile cell
growth and toxin-induced cell death of vero and Caco-2 cells (197, 198, 236).
CamSA inhibits C. difficile spore germination in vitro with an IC 50 of 58 μM.
Therefore, toxin concentration should be less in supernatants from C. difficile
spores treated with CamSA. CamSA 50 supernatants were titrated into
mammalian cell cultures at 0.5%, 1% and 5% (v/v). As the amount of CamSA 50
supernatants increased, a decrease in cell viability was observed in both cell
lines (Fig. 4.7A and B [i.a, and i.b] p < 0.01). A significant difference was
observed between germinant supernatants and CamSA 50 supernatants at 1%
and 5% (Fig. 4.7A and B [1%, *], [5%, **] p < 0.05). The data suggests that a
fraction of C. difficile spores germinated when supplemented with CamSA 50
supernatants and CamSA at 50 μM was able to partially protect mammalian cells
from toxin-induced cell death.
Vero cells treated with CamSA 200 supernatants were better protected
from toxin-induced cell death at 1% than CamSA 50 supernatants (p < 0.05)
(Fig. 4.7A []). Caco cells treated with 1% CamSA 200 or 5% CamSA 200
supernatants were better protected than those treated with CamSA 50 (Fig. 4.7B
[1%, +], [5%, ++] p < 0.05). Interestingly, Caco-2 cells seem to be more sensitive
to toxin than Vero cells. More vero cells (60%) than Caco-2 cells (28%) remained
viable after treatment with 5% CamSA 200 supernatants (Fig. 4.7A and B). Caco2 sensitivity to C. difficile toxin has been previously reported (197). In conclusion,
the sum of these data show that vero and Caco-2 cells treated with CamSA
supernatants are better protected from toxin-induced cell death than when

146

treated with germinant supernatants. Vero and Caco-2 cells treated with
supernatant containing chenodeoxycholate did not differ from untreated cultured
cells. This is likely due to the inability of C. difficile to grow in the presence of
chenodeoxycholate.
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Figure 4.7. Toxin-induced cell viability assay. Luminescence due to ATP in A) vero cells and B) Caco-2
cells. Percent luminescence compared to untreated control cells. Cells were treated with titrated
amounts of supernatant from C. difficile growth
medium with or without CamSA. Statistical analysis of
4.4. Conclusions
ATP reduction per treatment was compared using 1-way ANOVA. Analysis of ATP reduction due to
concentration was compared using the student’s paired t test. For both analyses, the p was set at < 0.05.
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germination compounds could be used in combination therapies to supplement
antibiotic treatments in immunocompromised patients. Once the antibiotic regime
is completed, re-establishment of the normal gut flora will prevent C. difficile
spore germination and anti-germination therapy can also be discontinued.
CamSA is stable to all tested GI tract microenvironments tested except
incubation

with

bile salt

hydrolase-producing

bacteria.

Lactobacilli

and

Bifidobacterium are two main human enteric bacteria that produce bile salt
hydrolases (187, 205, 221). Antibiotics disrupt the normal microflora dynamics of
the gut allowing for outgrowth of C. difficile (74, 142). A recent study in mice
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shows that shifts occur in the bacterial population during antibiotic treatment and
that different antibiotics can individually affect the resulting population shift (142).
The indigenous bacteria in humans and mice differ significantly, for example
Bifidobacterium is commonly found in humans. However, this bacterium was not
found to colonize mice (142, 209). Although there is difference in the natural flora
between mice and humans, the study suggests that the overall dynamics of the
gut can be changed during and after antibiotic treatment. These changes may
play an important role in CDI and CDI recurrence. CamSA is degraded by bile
salt hydrolase-producing bacteria, which populate the normal gut. CamSA is
more sensitive to Bifidobacterium degradation than to Lactobacilli degradation. In
fact, a recent paper reported there are actually four related bile salt hydrolases
produced by enteric bacteria (239). Each hydrolase has activity with all the bile
salts tested however certain enzymes are more effective with specific substrates
(239). This could explain the differences we observed with L. gasseri and B.
longum. Antibiotic treatment disrupts the normal flora thus allowing CamSA to
remain stable in the gut of antibiotic treated mammals. We hypothesize that after
antibiotic treatment is terminated Lactobacilli and Bifidobacterium will be able to
re-colonize the intestines in the presence of CamSA and degrade any remaining
CamSA. This is further supported by the inability of CamSA to affect normal
growth of Lactobacilli and Bifidobacterium in vitro. Future studies will address this
hypothesis.
Orally-administered drugs typically need to penetrate the epithelial
membrane of the GI tract to be systemically circulated. Low bioavailability usually
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leads to increased time in the GI tract (189). Furthermore, oral drugs must be
stable to changing GI tract microenvironments. In contrast to systemic infections,
CDI is a localized intestinal infection. Thus, CDI-targeting drugs require low
permeability and high GI tract stability for maximum efficacy. In vitro assays
indicate that CamSA does not traverse cells in a permeability assay, suggesting
that CamSA will be retained in the intestinal tract of mammals. The poor
bioavailability of CamSA will also reduce toxic effects to other organs since
CamSA is unlikely to circulate outside of the intestinal lumen. The results of the
ADME-tox test indicate that CamSA (recovered at 100%) does not adhere to or
accumulate in Caco-2 cells. Since CamSA does not appear to physically interact
with Caco-2 cells, the concentration of CamSA in the lumen of the gut will not be
affected. Furthermore, Caco-2 cells do not metabolize CamSA. The stability of
CamSA to gut tissue will prevent toxicity due to metabolites and the effective
concentration will not be altered. Collectively, these data show that CamSA will
have low toxicity and high stability in the mammalian GI tract.
CamSA has been shown to inhibit C. difficile spore germination in vitro
and these studies support that mechanism of action. CamSA has no effect on the
growth of vegetative C. difficile cells so the mode of action of CamSA is not as an
antibacterial agent. This is further supported by the cell culture studies involving
C. difficile toxin produced when spores germinate into metabolically active cells.
Increasing concentrations of CamSA resulted in less spore germination therefore
led to less toxin production. Cell cultures treated with CamSA were protected
from C. difficile toxin-induced cell death. CamSA, up to 200 μM, was not
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observed to be cytotoxic. The in vitro data supports further characterization of
CamSA in animal models of CDI.
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CHAPTER 5
A NEW STRATEGY FOR THE PREVENTION OF CLOSTRIDIUM DIFFICILE
INFECTION
5.1. Introduction
Clostridium difficile infection (CDI) is the major identifiable cause of
antibiotic-associated diarrhea in hospitals (13, 14). In the US alone, CDI
develops in over 500,000 patients with up to 20,000 deaths per year (41). The
yearly health care burden has been estimated to be greater than $3 billion in the
United States (43, 44). A recent study reported that CDI is responsible for 25%
more nosocomial infections than methicillin-resistant Staphylococcus aureus
(MRSA) (240). The rate of CDI progression to severe symptoms and death has
been increasing annually since the 1970s (38, 39).
The use of animal models to study the pathophysiology of CDI is a
necessary step in understanding the disease. In vitro data is helpful to predict
certain spore-host interactions such as pharmacokinetic analysis described
previously. Mammalian studies are essential to elucidate specific host-pathogen
relationships in CDI (241-243). Until recently, there has been a lack of
information regarding C. difficile environmental adaptation in vivo.

In fact, a

recent study shows that previously uncharacterized genes and cellular pathways
are only identified in vivo (244). The host-pathogen relationship is very dynamic
and cannot fully be understood by in vitro studies alone. Therefore, several
animal models for CDI have been designed to study the in vivo effects of the
infection and the disease.
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Historically, Syrian hamsters have been the chosen animal model to study
CDI in vivo (242, 245, 246). Hamsters are highly susceptible to infection with C.
difficile after antibiotic exposure and also present signs of recurrence (51, 242,
245, 246). The hamster model is the classical model to study the effects that
antibiotic exposure has on developing CDI signs and also the effects antibiotics
have on treating the established disease (51, 242, 245, 247, 248). Unfortunately,
because hamsters are extremely responsive to CDI, the disease progresses from
severe to lethal very rapidly, usually within 48 hours (51, 204, 249). This intense
presentation is uncharacteristic of human disease since human CDI can range
from asymptomatic to severe (70). Therefore, the hamster model has limitations
for studies that focus on human clinical and pathological conditions. The hamster
model is the current established model to study CDI recurrence in animals (51,
204, 250). Due to their high susceptibility to C. difficile, hamsters that get mild
CDI (or respond to treatment for CDI) and recover typically show signs of
recurrence 10-15 days post infection (51, 250).
A new model for studying CDI has recently been reported utilizing
gnotobiotic piglets(251). The basis for this model is the high frequency of C.
difficile infections that occur on swine farms and affect newborn piglets (23, 24).
The progression of the disease and disease presentation in pigs has been
compared to human disease (24, 251). Severity of disease varies between
piglets infected with C. difficile spores, which is similar to the symptoms
described in humans (251). The authors report a flexible model that can be
tailored according to specific research needs (251).
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Gnotobiotic piglets are

considered germ-free and lack indigenous gut bacteria. This model is adequate
for studying disease characteristics however, due to the lack of natural gut flora
the model is inappropriate when studying colonization resistance. In humans, the
gut becomes susceptible to CDI only after antibiotic exposure and destruction of
the natural gut bacteria (12, 41). The natural bacteria resist colonization by C.
difficile (74). Therefore when studying the dynamics of natural bacteria, C.
difficile, and prevention of CDI and CDI recurrence, the current gnotobiotic piglet
model is inadequate. The authors postulate that conventional pigs could be used
however, there are no current models describing conventional pigs in CDI-gut
dynamics studies.

Other drawbacks to using this model are the expense of

acquiring gnotobiotic pigs (from cesarean section), appropriate housing (space
limitations) and maintenance (rearing) (251, 252).
In recent years, mouse models have been more extensively used for
animal studies of CDI due to the relative ease of handling and low expense
compared to hamsters. Mice are not as sensitive to infection with C. difficile and
although disease signs can become severe and animals reach a clinical
endpoint, lethality is less common (142, 241). Unlike in hamsters, disease
severity in the mouse can be varied with bacterial inoculum size (241). The
flexibility of controlling disease in mice allows researchers to characterize the
host-pathogen interaction, specifically the fate of the C. difficile spore inside the
mammalian GI tract. One drawback to using the murine model in CDI research is
that CDI recurrence has not been established in mice. A recent study reported an
induced CDI relapse model in mice (253). The report more appropriately
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describes a re-infection model since the authors re-challenge mice with C.
difficile after they recover from the initial bout of disease (253). As described
before, human recurrence has been defined as relapse of the same strain due to
persistence in the gut or re-infection by the same or different strain due to
susceptibility (35). To our knowledge there have been no reports of relapse in
mice due to persistence of C. difficile spores in the gut. The lack of a recurrence
model is a slight drawback when choosing the murine model of CDI however; the
potential ability to study the fate of C. difficile spores using anti-germination
therapy outweighs the caveats.
In the current study, CamSA was administered to mice to determine if the
compound has acute toxicity at high doses. Following toxicity studies, animals
were treated with anti-germinants and C. difficile spores and observed for signs
of disease. Disease progression and severity was monitored by visual
observation of signs of disease and the ratio of spores and cells in the GI tract
and feces compared to untreated (healthy) animals.
5.2. Materials and Methods
5.2.1. Animals
The Institutional Animal Care and Use Committee at the University of
Nevada, Las Vegas, reviewed and approved all animal protocols used in this
study. All experiments were performed according to the National Institutes of
Health guidelines in the Guide for Care and Use of Laboratory Animals. Based
on previous CDI murine studies, C57BL/6N mice are susceptible to C. difficile
(241, 253). Weaned Female C57BL/6N mice were purchased from Harlan
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Laboratories (Indianapolis, IN). Animals were housed in groups of five mice per
cage in the UNLV animal care facility. All water, food, bedding and cages were
autoclaved prior to contact with animals. Upon arrival, mice were allowed to
acclimate for one week prior to experimentation. Animal manipulations were
performed in a biosafety level 2 laminar flow hood.
5.2.2. Toxicity of CamSA in Mice
CamSA

and chenodeoxycholate were dissolved in DMSO

to a

concentration of 100 mg/ml. Groups of five mice were treated by oral gavage for
thee consecutive days with 50 mg/kg body weight (b.w.) of CamSA or
chenodeoxycholate. A control group was administered DMSO. Weight changes
were recorded twice daily and mice were observed for adverse reactions such as
vomiting, diarrhea, hair loss, weight loss, difficulty breathing, and lethargy. Other
groups of mice were treated with 300 mg/kg CamSA or chenodeoxycholate and
observed as above.
5.2.3. Preparation of C. difficile for Infection
5.2.3.1. Purified Spores by Abel-Santos Laboratory Method
C. difficile strain 630 and VPI 10463 were obtained from ATCC. Each
strain was plated onto BHI agar supplemented with 1% yeast extract, 0.1% Lcysteine HCl, and 0.05% sodium taurocholate to yield single cell clones.
Individual C. difficile colonies were grown in BHI broth until turbid and re-plated to
obtain bacterial lawns. Plates were incubated for seven days at 37 °C in an
anaerobic environment (5% CO 2, 10% H2 and 85% N2). Spores were harvested
by washing and gentle scraping of the bacterial lawns from plates with ice-cold
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nanopure water. The cells and spores were centrifuged at 8,800 x g for five
minutes at 4 °C. Pellets were washed three times with nanopure water. To
separate spores from bacterial cells, bacterial pellets were centrifuged through a
20% to 50% HistoDenz gradient at 18,200 x g for 30 minutes at 4 °C with no
brake. The resulting purified spores were washed five times with nanopure water.
To determine spore purity, selected samples were stained using the
Shaeffer-Fulton staining method (122, 164). Spore preparations were generally
>95% pure after HistoDenz gradient. Before infection, purified spores were heat
activated at 68 °C for 30 minutes and washed another five times with water.
Purified C. difficile spores were resuspended in water to obtain an OD580 of 1.0. A
spore aliquot was serially diluted onto BHI agar supplemented with cysteine and
taurocholate to determine colony-forming units (CFU).
5.2.3.2. C. difficile Preparation based on Chen et al 2008 (241)
A sample of C. difficile 630 and VPI 10463 were purified by published
procedure (241). Difco cooked meat medium was inoculated with frozen culture
of 630 or VPI 10463 and incubated anaerobically at 37 °C for 36 hours. Mixtures
of spores and cells were harvested by centrifugation at 8,800 x g for 5 min at 4
°C and washed three times with nanopure water. No further purification or heat
activation was performed. CFUs were enumerated as described above. This
preparation of C. difficile is hereto referred to as Chen et al.
To determine if 36 hours is an impractical time for VPI 10463 to sporulate,
a separate culture was grown as above and allowed to incubate for 13 days.
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After this extended period of time, a very low percentage (<10%) of spores were
present by endospore staining.
5.2.3.3. Spore Preparation based on Douce et al 2010 (254)
C. difficile spores were prepared based on previous procedures designed
for the hamster model of CDI (254). Strain VPI 10463 was plated onto BHI agar
supplemented with 1% yeast extract, 0.1% L-cysteine HCl, and 0.05% sodium
taurocholate to yield single cell clones. Individual C. difficile colonies were grown
in BHI broth until turbid and re-plated to obtain bacterial lawns. Plates were
incubated for seven days at 37 °C in an anaerobic environment (5% CO 2, 10%
H2 and 85% N2). Prior to spore harvest, plates with bacterial lawns were
incubated at room temperature in a BSL-2 laminar flow hood overnight in air to
maximize sporulation. Spores were harvested by the addition of 100% ethanol
and gentle scraping the bacterial lawns from plates. Plates were washed once
more with 1 X PBS and spores and cells were harvested by centrifugation at
8,800 x g for 5 min at 4 °C. The resulting pellet was washed three times with
nanopure water. This preparation yielded approximately 25% of VPI 10463
spores. No further purification or heat activation was performed. CFUs were
enumerated as above. This preparation is hereto referred to as Douce et al.
5.2.4. Optimization of C. difficile Inoculum in Mice
C. difficile 630 and VPI 10463 strains prepared above were used to infect
mice as published (241). The murine CDI induction model was based on
published procedures (241). An antibiotic cocktail containing kanamycin (0.4
mg/ml), gentamycin (0.035 mg/ml), colistin (850 U/ml), metronidazole (0.215
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mg/ml), and vancomycin (0.045 mg/ml) was prepared in autoclaved water and
sterile filtered (241). For three consecutive days, mice were allowed to drink the
antibiotic cocktail ad libitum (Scheme 5.1). The antibiotic water was refreshed
daily. After three days of antibiotic water, all mice received autoclaved water for
the remainder of the experiment. A single dose of clindamycin (10 mg/kg) was
administered by intraperitoneal (IP) injection on the fourth day (24 hours before
C. difficile infection). Mice, in groups of five, were challenged by oral gavage with
either 105 or 108 CFUs of water suspensions of C. difficile strain 630 spores or
VPI 10463 spores, preparation by Chen et al. 2008 (241) or preparation by
Douce et al. 2010 (254). A control group of five mice received water by oral
gavage.

Scheme 5.1. Representation of induction of CDI in mice

All animals were observed daily for signs of CDI: decreased weight,
hunched posture, wet tail, lethargy, anal redness, and increased soiling of cages.
Disease signs were scored using a scoring rubric (Table 5.1). Animals scoring 2
or less were considered non-diseased animals scoring 3-4 were considered to
have mild CDI. Animals scoring 5-6 were considered to have moderate CDI.
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Animals scoring >6 were considered to have severe CDI and were immediately
sacrificed.
Table 5.1. Scoring rubric for CDI in mice

5.2.5. Preliminary Testing of Anti-Germinants for CDI Prevention
Antibiotic-treated mice (five per group) were administered CamSA at 300
mg/kg, taurocholate 300 mg/kg, chenodeoxycholate at 50 mg/kg or compound
T88 at 300 mg/kg in DMSO as vehicle one day prior to spore challenge, the day
of spore challenge, and one day following spore challenge for a total of three
consecutive doses (Scheme 5.2). Control animals received neat DMSO. Bile
salts and DMSO were administered to mice by oral gavage. C. difficile strain 630
and VPI 10463 was administered at 108 CFUs by oral gavage. Animals were
observed twice daily for signs of infection and scored appropriately. Animals that
reached clinical endpoint were sacrificed. Cages and water sources were
changed daily.
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Scheme 5.2. Representation of induction of CDI in mice and preliminary test with bile salts

5.2.6. Minimum Effective Dose (MED) of CamSA
Twenty-four hours prior to spore challenge, groups of five antibiotictreated mice received 0 mg/kg (neat DMSO), 5 mg/kg, 25 mg/kg, or 50 mg/kg
CamSA by oral gavage. The day of infection, animals received 108 CFUs of C.
difficile strain 630 spores by oral gavage. One hour post infection, animals
received a second dose of the corresponding bile salt or DMSO (Scheme 5.3). A
third dose of bile salt or DMSO was administered 24 hours post-infection.
Animals were observed twice daily for signs of infection and scored
appropriately. Cages were changed and feces were collected once daily
throughout the experiment. The contents were stored at 4 °C. Aliquots of feces
were heated to 68 °C for 30 minutes. Heated and unheated feces were diluted
as necessary in water and plated on Clostridium difficile selective agar (CDSA).
Plates were incubated anaerobically for 48 hours and colonies were counted to
enumerate CFUs. CFUs obtained from unheated samples represent the sum of
C. difficile vegetative cells and spores. CFUs obtained from heated samples
represent the number of C. difficile spores only. The presence of C. difficile
colonies was verified by PRO disk. Surviving animals were allowed to recover for
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14 days followed by a second course of antibiotics. Surviving mice were injected
with three consecutive doses of clindamycin. Animals were monitored for another
14 days to observe for signs of CDI relapse.

Scheme 5.3. Representation of induction of CDI in mice and MED of CamSA

5.2.7. CamSA Dosage Regime
Antibiotic regimen was repeated with two groups of mice (5 per group). A
single 50 mg/kg dose of CamSA was administered by oral gavage to one group
of mice 24 hours (T-24) before challenge with 108 CFUs of C. difficile 630 spores.
The second group received a single 50 mg/kg dose of CamSA at 10 minutes (T0)
following spore challenge (Scheme 5.4). Animals were observed for CDI signs as
before. Animals that reached clinical endpoint were sacrificed. Cages and water
sources were changed daily to minimize re-ingestion of excreted C. difficile.
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Scheme 5.4. Representation of the induction of CDI in mice and CamSA administered as a
single dose

5.2.8. Onset of CDI Signs in Mice
Antibiotic treated mice were challenged by oral gavage with 108 CFUs of
C. difficile strain 630 spores. Individual groups of five mice were treated with a
300 mg/kg dose of CamSA at the time of infection (T+0) or post-infection.
Animals administered CamSA post-challenge were dosed at 6 hours (T+6), 9
hours (T+9), and 12 hours (T+12) (Scheme 5.5). A second 300 mg/kg dose of
CamSA was administered 24 hours after the first dose. Mice were observed for
signs of CDI twice daily and scored accordingly. Animals that reached clinical
endpoint were sacrificed. Cages and water sources were changed daily to
prevent re-ingestion of excreted C. difficile.

Scheme 5.5. Representation of the induction of CDI in mice and CamSA administered
at different time points
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5.2.9. Fate of C. difficile in the Murine GI Tract
Seven groups of mice with four mice per group, one group with three mice
and one group of one mouse were treated with antibiotics as described before.
All animals except group 1 were challenged by oral gavage with 108 CFUs of C.
difficile strain 630 spores (Table 5.2). Group 1 was sacrificed on Day 0. Groups 2
- 5 were sacrificed 2, 4, 24, or 48 hours post-challenge with C. difficile spores.
Groups 6 – 9 were treated with a 50 mg/kg dose of CamSA for one day prior to
infection and at the time infection for at total of two doses. Animals administered
CamSA were sacrificed 24, 48, 72 or 96 hours post-challenge with C. difficile
spores. Cages were changed every two hours and feces were collected. The
contents were stored at 4 °C. GI tracts of sacrificed animals were observed for
signs of disease. Gastrointestinal tracts were removed in blocks and GI tract
contents were flushed with autoclaved water and stored at 4 °C. Heated and
unheated feces and GI tract contents were diluted as necessary in water and
plated on Clostridium difficile selective agar (CDSA). Plates were incubated
anaerobically for 48 hours and colonies were counted to enumerate CFUs (Fig.
5.1). CFUs obtained from unheated samples represent the sum of C. difficile
vegetative cells and spores. CFUs obtained from heated samples represent the
number of C. difficile spores only. The presence of C. difficile was verified by
PRO disk (Fig. 5.1).
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Figure 5.1. CDSA and PRO disk. Photograph of C. difficile growth on a CDSA plate (left) and
verification of the presence of C. difficile by PRO disk (right upper). Right lower PRO disk is a
sample negative for C. difficile.

Table 5.2. Groups of animals used to determine the fate of spores in the GI tract
of mice treated with CamSA.

5.2.10. Effect of CamSA on Mice Challenged with Vegetative C. difficile
BHI broth was inoculated with a freezer stock of C. difficile 630 and
allowed to grow overnight in an anaerobic chamber at 37 °C. The overnight
culture was diluted 10-fold into fresh BHI broth and incubated for four hours at
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37°C to reach exponential growth phase (75, 255). The presence of vegetative
bacterial cells and absence of spores was verified by microscopic observation of
Shaeffer-Fulton stained samples (122, 164). The bacterial culture was harvested
by centrifugation at 13,700 x g for 1 min. The resulting pellet was resuspended in
1 ml sterile water and serially diluted onto BHI agar containing cysteine and
taurocholate to determine CFUs. To prevent oxygen induced cellular death, the
remaining bacterial culture was capped inside the anaerobic chamber prior to
overnight storage at 4 °C. Antibiotic treated mice received three consecutive 50
mg/kg doses of CamSA and were challenged with 108 CFU C. difficile 630
vegetative cells, as above (Scheme 5.6). Animals were observed for CDI signs
as previously described. Animals that reached clinical endpoint were sacrificed.
Cages and water sources were changed daily to minimize re-ingestion of
excreted C. difficile.

Scheme 5.6. Representation of induction of CDI in mice using vegetative cells or spores and
administration of CamSA

5.2.11. Statistical Analysis
Mice survival (n=5) was analyzed by Kaplan-Meier survival analysis.
Statistical comparison to untreated infected controls was calculated using log-
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rank test. Signs of severity were analyzed as box-whisker plots. Data was
expressed as mean ± standard deviation in box-whisker plots. Analysis of
severity data by 1-Way ANOVA for nonparametric analysis had a statistical
significance set at a p value of <0.01. Standard deviations represent at least
three independent measures, unless otherwise stated. Recovered CFU and
recovered spores represent mean values from a pool of five animals. Student’s
unpaired t-test was used to determine the significance of difference of means.
5.3. Results and Discussion
5.3.1. CamSA Toxicity in Mice
To determine acute toxicity of CamSA, we used the fixed dose procedure
in mice (256). The fixed dose procedure allows researchers to define acute
toxicity of a potential drug at pre-set doses and uses a minimal number of
animals (256). Instead of dosing animals with a gradual increased concentration
of compound, researchers determine a high limit and that concentration is
administered to assess acute toxicity (256). If the compound results in acute
toxicity at the high limit, a lower dose (usually a log lower) is assessed for toxicity
and so forth. CamSA was administered to mice at the high limit of 300 mg/kg
body weight (b.w.) for three consecutive days with no physical adverse effects. A
higher dose of CamSA was not administered. A 300 mg/kg dose of
chenodeoxycholate caused immediate death, probably due to observed
precipitation of chenodeoxycholate upon interaction with mouse saliva and
gastric juice. Chenodeoxycholate at 50 mg/kg did not cause any observable side
effects.
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5.3.2. Optimization of C. difficile Inoculum for Infection
C. difficile strain 630 is a highly virulent and transmissible epidemic strain
clinically isolated from a patient with pseudomembraneous colitis in Zurich,
Switzerland in early 1982 (122). Reference strain VPI 10463 is a toxigenic strain
isolated from an abdominal wound and first described in 1982 (257, 258). These
strains were chosen for the animal studies in this project. Various C. difficile
growth, sporulation, and harvesting procedures exist for preparation of C. difficile
for infection of animals (142, 241, 254). To determine the optimal preparatory
procedure for infection of mice, three different procedures were followed to obtain
C. difficile for infecting animals. The first procedure is the defined Abel-Santos
preparation of purified C. difficile spores (127, 134). Both 630 and VPI 10463
strains produced spores and purified spores (>95% pure) were recovered using
this procedure. When mice were challenged with 105 CFU of C. difficile strain
630 or VPI 10463 purified spores, mild CDI signs developed (score of 3-4) within
48 hours (Fig. 5.2). At 108 CFU, both C. difficile 630 and VPI 10463 purified
spores caused severe CDI signs in the mouse (score > 6) and animals reached
clinical endpoint within 48 hours (Fig 5.2). These data support previous reports
showing increased severity of disease in mice with increased inoculation of C.
difficile (241, 259). Both strains produced spores with this method however the
yield of spores obtained from harvesting strain 630 was substantially higher than
VPI 10463 (>75%). This finding is supported by previous sporulation studies that
have found C. difficile strain VPI 10463 to produce fewer spores than 630 and
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other C. difficile strains (117, 118, 260). In this study, both C. difficile strains
caused disease in mice with a similar dose-dependent response.
C. difficile strain VPI 10463 was also grown as described in Chen et al.
(241). This published procedure is the guideline for inducing CDI in mice. In our
hands, this preparation yielded non-viable vegetative bacteria and did not cause
CDI signs at either 105 or 108 CFU inoculums (Fig 5.2). The procedure describes
that cultures were grown for only 36 hours (241). After 36 hours, medium
inoculated with strain 630 contained mostly spores however, VPI 10463
inoculated broth contained almost entirely vegetative cells. Others and we have
found that C. difficile typically requires nearly seven days for maximum
sporulation (127, 134, 253, 259). To determine if the amount of time was
insufficient, VPI 10463 was grown for 13 days in conditions described by Chen et
al (241) however no spores were observed. Interestingly, C. difficile strain 630
was able to efficiently sporulate under the same conditions and within 36 hours.
This data further supports that C. difficile strain 630 yields more spores than VPI
10463. Due to limited number of animals available, strain 630 spores prepared
from this procedure were not used to infect mice.
The third method described in Douce et al. (254) was used to prepare C.
difficile strain VPI 10463 for infection of animals. This procedure differs from the
Abel-Santos procedure only slightly. C. difficile is grown the same but the harvest
procedure is slightly different using ethanol for the removal of bacterial lawns as
opposed to water. Also, this procedure does not define a purification step for
separating spores from cells after harvest. C. difficile VPI 10463 produced spores
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although not in high yield. It is interesting to note that VPI 10463 did not produce
spores when grown in liquid media based on Chen et al. (241) however, the
same strain produced spores when grown on solid media based on Douce et al.
(254) and the Abel-Santos method (127, 134). Animals treated with either 105 or
108 CFU inoculums of C. difficile VPI 10463 prepared from this protocol induced
similar dose response severity seen with purified spores described before (Fig
5.2). At the lower dose of C. difficile, animals developed mild CDI signs and
recovered. At the higher dose animals developed severe symptoms and reached
clinical endpoint within 48 hours (Fig 5.2). C. difficile strain VPI 10463 prepared
from this method yielded viable and lethal cells and/or spores.

Figure 5.2. Comparison of CDI severity in mice after 48 hours by C. difficile
preparations. White bars represent the severity in mice inoculated with C. difficile at
5
10 CFUs and black bars represent the severity in mice inoculated with C. difficile at
8
10 CFUs. VPI 10463 and 630 are C. difficile strains. Five mice per group. (127, 134,
241, 254)

C. difficile strain 630 consistently yielded larger amounts of infectious
spores than C. difficile strain VPI 10463. Hence, C. difficile strain 630 was used
in nearly all subsequent experiments. The preparation described by Douce et al.
(254) does not provide a method for separating spores from cells. No histodenz
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gradient was used to separate spores from cells therefore the final pellet was a
mixture of spores and cells. Although it is expected that harvesting C. difficile
with ethanol will kill vegetative cells (261) it is not a guarantee. Also ethanol may
not affect toxins remaining in the spore/cell pellet. Furthermore without heat
activation prior to infection, it is possible that persistent vegetative cells or toxins
will induce disease in mice (142, 249). This variability is unacceptable when
studying anti-germinants and their ability to prevent disease by preventing spore
germination in vivo. Therefore, the Abel-Santos method of spore purification was
used for further experiments. The large (108 CFUs) inoculum of spores ensures
homogeneous CDI onset, fast CDI sign progression and allows testing the limits
of anti-germination therapy.
5.3.3. Preliminary Testing of Bile Salts for CDI Prevention
As a preliminary test of bile salt effects on CDI progression and severity,
groups of mice were administered antibiotics and three consecutive days of bile
salts. All but one group of animals (control) were infected with purified C. difficile
spores and observed for signs of disease. A second control group was
challenged with spores but received only DMSO (untreated). Mice that were not
challenged with C. difficile spores did not develop signs of CDI. All infected mice
that were not treated with bile salts developed severe signs of CDI by 48 hours
post challenge and were sacrificed (Fig. 5.3).
Taurocholate has been shown activate C. difficile spore germination in
vitro (127, 140). To determine effects of taurocholate in vivo, a group of mice
were administered taurocholate at 300 mg/kg. Mice that received taurocholate
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developed CDI similar to control infected animals. All but one mouse reached
clinical endpoint by 48 hours. That mouse developed slightly delayed signs and
reached clinical endpoint at 72 hours post challenge (Fig. 5.3). Despite this one
mouse in the taurocholate group, the mice were comparable to untreated mice.
Disease severity was equally severe and onset of disease was similar. Therefore
the data suggests that an excess of germinant in the gut of animals challenged
with C. difficile spores does not affect disease severity or progression. Another
possible explanation is that the inoculum (108 CFU) used in this study to induce
CDI in mice was excessive. This overloading of C. difficile could hide any subtle
differences the addition of germinants may have on disease progression and
severity.
Chenodeoxycholate is a natural bile salt and a known inhibitor of C.
difficile spore germination in vitro (127, 141). In toxicity experiments discussed
previously, chenodeoxycholate was lethal at 300 mg/kg b.w but not at 50 mg/kg.
Infected animals treated with chenodeoxycholate at 50 mg/kg showed a delay in
onset of disease by 24 hours. By 72 hours post challenge, 80% of
chenodeoxycholate-treated animals had reached clinical endpoint (Fig. 5.3). One
animal developed moderate signs of disease and eventually recovered. Due to
the insoluble nature of chenodeoxycholate described previously, it is possible
that concentrated bile salt did not reach the GI tract consistently and remain
soluble to interact with C. difficile spores. Furthermore, chenodeoxycholate has
been shown to be absorbed at a high rate from the colon and recycled to the liver
for enterohepatic circulation (149). It is possible that soluble chenodeoxycholate
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was absorbed before interaction with C. difficile spores. CamSA and compound
T88 are bile salt analogs that are potent inhibitors of C. difficile spore germination
in vitro (134). To determine if CamSA and compound T88 can prevent CDI in the
murine model, each was administered at 300 mg/kg to mice challenged with
purified C. difficile spores. All mice treated with CamSA remained healthy and did
not present signs of CDI (Fig. 5.3). Mice treated with CamSA closely compared
to non-challenged mice. Since there was a 24 hour delay in CDI for mice treated
with chenodeoxycholate, CamSA treated mice were observed for 10 days
following spore challenge. Even after 10 days CamSA treated mice remained
healthy and showed no signs of CDI. Interestingly, even though compound T88 is
a strong inhibitor of C. difficile spore germination in vitro, T88 treated mice
developed severe signs of CDI similar to untreated and taurocholate treated
mice. Unlike chenodeoxycholate, compound T88 treated mice did not display a
delayed onset of CDI but reached clinical endpoint by 48 hours post-infection
(Fig. 5.3). These preliminary results show that CamSA, but not compound T88, is
able to prevent CDI signs in mice challenged with spores from C. difficile strain
630. This experiment was repeated with C. difficile strain VPI 10463 and yielded
similar results.
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Figure 5.3. Preliminary study for the prevention of CDI in mice. Comparison of CDI severity after
48 hours (white bars) and 72 hours (black bars) of animals administered C. difficile and treated
as indicated. Animals in the challenged and T88 groups reached clinical endpoint after 48 hours.
TC = taurocholate, CDCA = chenodeoxycholate. Five mice per group. No significant difference
was observed between not challenged and CamSA-treated animals. Other groups were
statistically significant compared to not challenged or CamSA-treated animals, p < 0.001.

5.3.4. Minimum Effective Dose of CamSA
To determine the minimum effective dose (MED) of CamSA required to
prevent CDI in the murine model, groups of animals were administered
increasing doses of CamSA. Within 48 hours following spore challenge, all
untreated mice (0 mg/kg CamSA) developed severe CDI signs and reached the
clinical endpoint (Fig. 5.4). Mice treated with 5 mg/kg CamSA developed
moderate to severe CDI, although signs onset was delayed by approximately 24
hours (Fig. 5.4). Animals presenting moderate CDI signs eventually recovered.
Mice treated with 25 mg/kg CamSA developed mild CDI signs with delayed signs
onset (Fig. 5.4). All animals recovered before reaching the clinical endpoint. In
contrast, all animals treated with 50 mg/kg CamSA showed no sign of CDI and
were undistinguishable from non-infected controls (Fig. 5.4). All surviving
CamSA-treated animals were treated with a second course of antibiotics, but no
relapse signs were observed even after 14 days.
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Mice treated with 50 mg/kg chenodeoxycholate, a naturally occurring C.
difficile spore germination inhibitor, developed moderate to severe CDI signs. In
fact, animals treated with 50 mg/kg chenodeoxycholate show the same pattern of
CDI signs as animals treated with 5 mg/kg CamSA. The data shows that mice
treated with 50 mg/kg are completely prevented from developing CDI. In fact
there is a dose dependent correlation between CamSA and disease severity.

Figure 5.4. Kaplan-Meier survival plot for C. difficile infected mice treated with increasing
doses of CamSA. Groups of five mice were treated with three doses of 0 (Ο), 5 (☐), 25 (◊) or
50 (Δ) mg/kg CamSA. A separate group was treated with 50 mg/kg chenodeoxycholate (● ).
Log-rank test p=0.0027

Feces were collected from the cages of untreated and CamSA-treated
animals every two hours up to 10 hours and then 24 hours post-challenge with C.
difficile spores. Untreated animals (0 mg/kg CamSA) presenting signs of CDI
started to excrete large amounts of vegetative cells at two hours post-challenge
reaching a maximum between 8 and 10 hours (Fig. 5.5A). Diseased animals
continued to excrete lower amounts of vegetative cells up to the clinical endpoint.
Although some C. difficile spores were excreted in diseased animals, the
amounts were negligible compared to excreted vegetative cells.
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Mice treated with 5 mg/kg CamSA excreted mostly vegetative cells and
developed CDI similar to untreated animals. Interestingly, the maximum amount
of shed bacteria was delayed compared to untreated animals (Fig. 5.5B). This
delay correlated with the delay in signs onset (Fig. 5.4). With a dose of 25 mg/kg
CamSA, the proportion of excreted C. difficile spores increased and disease
signs were milder (Fig. 5.4 and 5.5B). These mice displayed maximum shedding
72 hours following infection. The feces of animals treated with 50 mg/kg CamSA
contained almost exclusively spores (Fig. 5.5A and B) and these mice did not
develop CDI (Fig. 5.4). In these animals, C. difficile spore excretion started 2
hours following infection and continued for 96 hours, peaking 72 hours following
challenge (Fig. 5.5A). In fact, 120 hours post-infection, the sum of excreted C.
difficile spores was quantitatively identical to the number of spores given.

Figure 5.5. Spore excretion from mice. Feces were collected from cages housing five mice
challenged with C. difficile spores and treated with 0 and 50 mg/kg CamSA. A) White bars
represent C. difficile vegetative cells excreted by untreated animals. The amount of C. difficile
spores present in untreated animals was negligible. Black bars represent C. difficile spores
released from CamSA treated animals. The amount of C. difficile vegetative cells in CamSA
treated animals was negligible. B) Feces were collected from cages containing groups of five
mice infected with C. difficile spores and treated with 0, 5, 25, and 50 mg/kg doses of CamSA.
White bars represent C. difficile vegetative cells and black bars represent C. difficile spores.
Both graphs represent CFU per mg feces. Feces were collected per cage housing five animals.
Therefore, no standard deviations could be obtained.
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5.3.5. Refining CamSA Dosage Regime
Since CamSA prevented CDI in mice at 50 mg/kg when given in three
consecutive doses, the next practical step was to determine if CamSA is able to
prevent CDI with one dose. The fecal data from diseased mice, described above,
suggests that at approximately 8 – 10 hours post infection there is an explosion
of C. difficile growth. We hypothesize that this correlates with spore germination.
Therefore, if a single dose of CamSA is to be effective it must be administered
before 8 hours. Animals were administered 50 mg/kg CamSA 24 hours before C.
difficile spore challenge (T-24) and 10 minutes after spore challenge (T=0).
CamSA completely protected animals from CDI with a single 50 mg/kg dose
when administered at time of infection (Fig. 5.6). These mice remained free of
signs even after repeated antibiotic treatments (Fig. 5.7B). Hence, this single
dose of CamSA was sufficient to prevent CDI signs without any signs of relapse.
However, when the single 50 mg/kg CamSA dose was administered 24
hours prior to challenge with C. difficile spores, animals developed moderate to
severe CDI with delayed illness onset. Three animals reached clinical endpoint
48 to 72 hours days post-challenge (Fig. 5.6). Disease severity was more
variable in mice treated with a single dose of CamSA 24 hours before infection
(Fig. 5.7A). All animals remained healthy 24 hours post infection. Two animals
displayed severe signs 48 hours following spore challenge whereas three
presented only mild signs (Fig. 5.7A). Of these, two mice began to recover 72
hours following infection and one mouse worsened to reach the clinical endpoint
(Fig. 5.7A). Animals that did not reach clinical endpoint eventually recovered.
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Since CamSA was administered in only one dose 24 hours before infection, it is
likely that CamSA had been degraded or excreted at the time of C. difficile spore
challenge. Permeability data (discussed in chapter 4) suggests that CamSA will
remain in the intestinal lumen and will not be absorbed. This supports the
likelihood of excretion or degradation. A potential explanation for the variability in
severity is that not all CamSA was excreted by 24 hours, resulting in a varied
concentration in the mouse gut. This is further supported by the dose dependent
response in mice. CamSA is able to prevent CDI in mice with three consecutive
doses or with one single dose as long as it is administered at the time of C.
difficile challenge.

Figure 5.6. Kaplan-Meier survival plot for C. difficile infected mice treated with single doses
of CamSA. Groups of five mice were treated with DMSO (Ο), a single 50 mg/kg dose of
CamSA 24 hours prior to C. difficile spore challenge (Δ), or a single dose of CamSA at the
time of infection (☐). Log-rank test p=0.0495.
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Figure 5.7. CDI severity graphs. Animals challenged with C. difficile spores and treated with
a single 50 mg/kg dose of CamSA A) 24 hours prior to C. difficile spore challenge (Δ), or B)
at the time of infection (☐). Severity of CDI signs was scored using the Rubicon scale
discussed above. Analysis of data by 1-way ANOVA analysis p<0.01 compared to untreated
mice.

5.3.6. Timing of CDI Onset Using CamSA
To determine the onset of CDI in mice, animals were challenged with C.
difficile spores and treated with CamSA at the time of infection (T=0), at 6 hours
(T+6), 9 hours (T+9), or 12 hours (T+12) post-infection. All animals treated with
CamSA at T=0 and T+6 were fully protected from CDI and presented no signs of
disease (Fig. 5.8). In contrast, all animals treated with CamSA at T+9 and T+12
developed severe CDI undistinguishable from untreated mice and reached the
clinical endpoint 48 hours post infection (Fig. 5.8). This data correlates with the
fecal data discussed previously. In untreated mice there is a spike in C. difficile
excreted at the 8 and 10 hour time points (Fig. 5.8). Since mice were completely
protected up to six hours post challenge, it is likely that C. difficile spore
germination or the commitment to germinate is between 6 and 9 hours in the
mouse gut. Mice treated with CamSA after this time had no effect on disease
progression and based on in vitro data CamSA does not affect vegetative growth.
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These data suggest that the mechanism by which CamSA protects mice from
CDI is by inhibition of C. difficile spore germination in vivo.

Figure 5.8. Graph showing the number of surviving animals 48 hours post challenge with C.
difficile spores. Groups of five mice were treated with CamSA at the time of challenge (T=0) or 6
hours (T+6), 9 hours (T+9), or 12 hours (T+12) following spore challenge. Five mice per group.
All animals either survived or all animals reached clinical endpoint at the times indicated
therefore no error bars are shown.

5.3.7. Fate of C. difficile in GI Tract of Mice Treated with CamSA
The GI tracts of diseased and CamSA treated animals were removed in
blocks and observed for signs of disease. The contents of the GI tracts were
analyzed for the presence of C. difficile spores and cells. As previously reported,
GI contents from animals with CDI signs contained almost exclusively (>98%) C.
difficile vegetative cells unevenly distributed throughout the intestinal tract (262).
Furthermore, the cecum and colon of these animals looked inflamed and swollen
(Fig. 5.9). Intestinal content was watery and purulent. The small number of C.
difficile spores recovered from diseased animals was localized to the cecum and
colon (97%) of diseased animals. Approximately 3% of C. difficile spores were
recovered from other gastrointestinal organs (stomach, duodenum, ileum, and
jejunum).
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Similar to the hamster CDI model (262), ingested C. difficile spores
accumulated in the lumen of the cecum and the colon of CamSA-treated mice.
The combined upper GI blocks contained less than 0.5% of total spores
recovered in CamSA-treated mice (Fig. 5.10). Indeed, in animals treated with 50
mg/kg CamSA, the GI contents contained almost exclusively C. difficile spores
(Fig. 5.11). These spores narrowly localized to the cecum and colon at every
time point tested. The cecum and colon of these animals looked healthy and
were undistinguishable from non-infected animals (Fig. 5.9 lower). C. difficile
spores remained in the cecum and colon for 72 hours after spore challenge. By
96 hours, the amount of spores recovered from the cecum and colon of CamSA
treated animals decreased considerably (Fig. 5.11).
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Figure 5.9. Necropsy photos. Disease mouse during necropsy (top) showing the swollen and
gas filled cecum. Cecum from diseased mouse (bottom left) and from CamSA treated mouse
(bottom right).

Figure 5.10. Distribution of C. difficile spores in the GI tract of CamSA-treated animals.
Significant amount of spores were found in the cecum (Ce) and colon (Co). The stomach (St),
duodenum (Du), jejunum (Je), and ileum (Il) showed negligible amounts of spores. No
vegetative C. difficile cells were found in any of the GI tract structures.
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Figure 5.11. Amount of C. difficile spores recovered at different time points following spore
challenge. White bars represent the cecum and black bars represent the colon of mice treated
with 50 mg/kg CamSA.

5.3.8. CDI from Vegetative C. difficile Cells
Murine models can develop CDI signs when infected with vegetative C.
difficile cells (142). Vegetative cells were prepared and used to challenge groups
of five mice treated with three consecutive doses of 50 mg/kg CamSA. While
CamSA prevents CDI in spore-challenged mice, the same dose was unable to
prevent CDI in vegetative cell-challenged mice. Three animals became moribund
between 48 and 72 hours after challenge (Fig. 5.12). Two other animals
developed moderate CDI signs and eventually recovered. This data further
supports the hypothesis that CamSA is able to prevent CDI in mice due to antigermination activity.
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Figure 5.12. Mice treated with C. difficile spores or vegetative cells. Kaplan-Meier survival plot
for animals treated with 50 mg/kg CamSA and challenged with (Ο) C. difficile spores or (●) or
C. difficile vegetative cells.

5.4. Conclusions
CamSA was able to “prophylactically” prevent murine CDI caused by two
different C. difficile strains and ameliorate CDI signs in a dose dependent
manner. Furthermore, a single dose of CamSA was sufficient to prevent CDI
signs without any signs of relapse. No signs of inflammation or damage to the GI
tract were seen in CamSA-treated mice. It is noteworthy that CamSA gave
complete protection from CDI against unnaturally massive C. difficile spore
inoculums. A 75 kg human will have to ingest hundreds of grams of infected
feces to reach the same level of inoculum. And yet, even in these extreme
conditions CamSA was able to completely prevent CDI.
CamSA prevented CDI in mice at concentrations that were more than six
times lower than the dose administered that showed no toxicity. Under the same
conditions, chenodeoxycholate was not able to prevent CDI. In fact, animals
treated with 50 mg/kg chenodeoxycholate show the same symptom patterns as
animals

treated

with

5

mg/kg

CamSA.
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At

higher

concentrations,

chenodeoxycholate showed acute toxicity, likely due to low solubility in biological
fluids. Another compound, compound T88, that showed potent inhibitory activity
in vitro was unable to prevent CDI in mice. In fact, compound T88-treated
animals resembled untreated animals in regards to disease onset and severity.
Taurocholate is the natural bile salt germinant for C. difficile spores (138, 140).
Animals treated with C. difficile spores and taurocholate did not present signs of
disease more severe than untreated animals. Furthermore, the onset of disease
in taurocholate treated animals was no different than untreated mice. It is
possible that disease caused by the high inoculum of C. difficile spores hid any
minor affect taurocholate had on germination and disease progression. Future
studies will need to be performed to determine if taurocholate has an effect on
murine CDI with lower concentrations of C. difficile spores.
When CamSA was given at sub-optimal concentrations, CDI onset was
delayed and signs were less severe than in untreated mice. Similar results were
obtained when an optimal CamSA dose was administered 24 hours prior to
infection. In both cases, late CDI onset and reduced symptom severity could be
attributed to the partial inhibition of C. difficile spore germination by lowered
intestinal CamSA concentrations. These data suggest that CDI severity is linked
to the number of C. difficile spores able to germinate in the GI tract of mice. This
argument is supported by the ratio of C. difficile vegetative cell to spores in
intestine and feces, which correlated with CDI symptom severity. Thus, CamSA
treatment can prevent CDI and ameliorate signs in a concentration dependent
manner. Vegetative C. difficile cells are not believed to be involved in human CDI
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transmission but can infect mice (67, 263-265). CamSA was able to prevent
infections from dormant C. difficile spores, but not from actively dividing C.
difficile cells. Although not clinically relevant, infection of mice with vegetative C.
difficile cells bypasses spore germination requirements and suggests that
CamSA prevents CDI by inhibiting C. difficile spore germination and not by
targeting metabolic processes in the vegetative bacterium.
In our hands, C. difficile preparations from published procedures for
mouse model of CDI (241) produced no detectable spores and did not result in
infection. It is possible that in this case, most C. difficile cells died due to air
exposure or that post stationary phase vegetative cells will not cause disease. In
contrast, when we prepare C. difficile vegetative cells for infection, the cells are
manipulated only in an anaerobic environment and were administered to animals
immediately to minimize oxygen exposure.
Since CamSA blocks C. difficile spore germination in vivo, the fate of
ingested C. difficile spores can be followed without interference from germination
and/or re-sporulation. CamSA-treated mice excreted C. difficile vegetative cells
and/or spores in a dose dependent manner. Ingested C. difficile spores were
quantitatively recovered from feces, cecum, and colon contents of mice treated
with 50 mg/kg CamSA, further supporting the role of CamSA anti-germination
activity in CDI prevention. Thus, CamSA treated mice are able to shed almost all
of the ingested spores before they can be activated for germination. Interestingly,
ingested C. difficile spores rapidly transit through the stomach and small
intestine, but remain in the colon and cecum for up to four days. The mechanism
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of dormant C. difficile spore accumulation in the lower intestine is not understood,
but suggests that ingested C. difficile spores can form a transitory reservoir that
is slowly released from the lower intestine. Although the amount of unattached
spores in the intestines is small, it is tempting to speculate that these spore
reservoirs serve as a focal point for CDI relapse.
CamSA dosage was effective in preventing CDI when administered up to
six hours following spore challenge, but ineffective when administered nine hours
post-challenge. The observation of this narrow three-hour window correlates C.
difficile spore germination with maximum C. difficile shedding in symptomatic
mice. These data suggest that some germinated C. difficile cells are excreted
soon after germination, while the remaining C. difficile vegetative cells lead to
CDI onset.
CamSA has strong prophylactic properties against CDI, but can also be
used as a probe to address mechanistic details on CDI initiation. The sum of this
data suggests that ingested spores rapidly transit through the GI tract and
accumulate in the lower intestine. Six to nine hours after ingestion C. difficile
spores germinate and the newly germinated cells establish infection. C. difficile
vegetative cells start shedding almost immediately after germination and
continue throughout the infection. In contrast, non-germinated C. difficile spores
are slowly shed over a four day period. The timing of C. difficile spore
germination and persistence of ungerminated spores in the lower intestine will
have profound implication in the prophylactic treatment of CDI.
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It is clear that if C. difficile spores germinate in the gut of a patient, CamSA
will be ineffective against CDI. In these experiments, CamSA only failed when we
purposely pushed the limits of effectiveness to test the mechanism of C. difficile
spore germination in vivo. In these cases, CamSA was not optimized as a CDI
prophylactic. Instead, by giving single CamSA doses at different time points after
spore challenge, we were able to determine when and where C. difficile spores
germinated in the mouse gut. Subtly changing the experimental setup allows
CamSA to play two separate roles: as a prophylactic agent against CDI and as a
chemical probe for C. difficile spore germination.
Because CDI onset roughly coincides with antibiotic dosage, one can
determine a priori when a patient will be at risk for CDI. In a clinical setting, one
would not rely on a single CamSA dose. CamSA treatment will be started before
the first antibiotic dose. Our data suggests that one CamSA dose every six hours
will be sufficient to provide continuous protection from CDI. A six-hour interval
between overlapping CamSA doses could indefinitely prevent C. difficile spore
germination and thus compensate for the narrow efficacy window of CamSA.
Since CamSA does not affect bacterial growth, anti-germination treatment can be
continued until the intestinal microbiota has recovered. A multi-dose CamSA
regime is further supported by the low toxicity exhibited by CamSA. Four
therapeutic doses a day is not uncommon in hospitals and can certainly be
improved with better CamSA formulations (e.g. controlled and/or delayed release
capsules).
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In conclusion, there are multiple lines of evidence to support that CamSA
prevents CDI by inhibiting C. difficile spore germination in vivo, thus allowing
ingested spores to be shed before they can establish infection. To our
knowledge, CamSA is the first reported C. difficile spore anti-germinant that also
protects mice from CDI. Furthermore, this is also the first study defining the
temporal and spatial distribution of ingested C. difficile spores using a chemical
probe. This approach represents a new paradigm that could be further developed
and used in CDI management. Instead of further compromising the microbiota of
CDI patients with strong antibiotics, anti-germination therapy could serve as a
microbiota surrogate to curtail C. difficile colonization of antibiotic-treated
patients.

188

CHAPTER 6
Conclusions and Future Directions
Spore germination mechanisms have been studied and described for
Bacillus (131, 266, 267). The activation of spore germination typically requires
the detection of small molecules called germinants (126, 131). These germinants
are recognized and bind to a very sensitive proteinaceous biosensor located on
the inner membrane of the spore (167, 268). These germination (Ger) binding
site(s) are highly conserved in Bacillus and Clostridium and all sequenced
sporulating bacteria have analogs of these Ger binding site(s) (by Basic Local
Alignment Search Tool – BLAST) (95). The exception is Clostridium difficile. C.
difficile encodes for all spore-specific proteins except Ger binding site(s) and
spore coat proteins (95). It is possible that the germination binding site(s) in C.
difficile have diverged from other sporulating bacteria or a different set of proteins
is used as germination binding site(s). In any case, the identity of the germination
binding site(s) for Clostridium difficile is currently unknown (95).
C. difficile spores must germinate to cause disease and a recent article
identifies glycine (amino acid) and taurocholate (bile salt) as germinants (140).
Furthermore, the bile salt, chenodeoxycholate, has been shown to inhibit C.
difficile germination in vitro (141). Neither glycine nor taurocholate has been
reported to activate germination in Bacillus and Clostridium, suggesting a novel
mode of germination recognition in C. difficile spores. Kinetic analysis using
taurocholate and glycine reveals that C. difficile spores bind germinants by a
complex cooperative mechanism. The affinity of the spore for one germinant is
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affected

by

the

binding

of

the

other

germinant

(127).

Furthermore,

chenodeoxycholate is a competitive inhibitor of taurocholate-mediated spore
germination (127). Similar cooperativity of germinants is described for Bacillus
cereus and Clostridium sordellii spores (133, 136). Thus, C. difficile likely
encodes unknown germination binding site(s) proteins to bind to these
germinants (127).
Due to the scarcity of genetic tools to understand C. difficile spore
germination, an alternative approach is to use chemical probes to study the
mechanism of spore germination (127, 133, 136, 151). The current dissertation
project has described chemical probes to elucidate necessary epitopes of amino
acids and bile salts capable of being recognized by the putative C. difficile
germination binding site(s). To characterize the amino acid germination binding
site(s), 30 amino acids and amino acid analogs were analyzed for germinant or
inhibitor behavior with C. difficile spores. The results suggest that the binding
region for amino acids has very little flexibility for the size of the molecule and
functional groups allowed. There is also evidence for multiple binding site(s) that
recognize specific amino acids. Besides glycine, L-phenylalanine, L-argnine and
L-cysteine are able to activate C. difficile spore germination, probably by binding
to separate binding sites (134). The limited number of functional groups on
glycine, the optimal amino acid for germination, restricts the number of practical
analogs that can be tested. Furthermore, none of the amino acids tested were
able to inhibit C. difficile spore germination. As potential anti-germination therapy,
amino acids are unlikely candidates.
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Taurocholate is the natural bile salt that activates C. difficile spore
germination (140). Taurocholate has multiple functional groups available for
characterization. In this study, more than 100 bile salt analogs were analyzed for
germinant and inhibitor behavior with C. difficile spores. The bile salt binding
site(s) is quite complicated and is able to bind to multiple epitopes. The functional
groups recognized for activation of spore germination are more specific than the
functional groups that are simply able to bind (inhibition). Many functional groups
and combinations are able to bind but not activate the C. difficile germination
binding site(s). During this study, correlations were found between molecules that
can activate and inhibit spore germination. Full characterization of the binding
region for bile salts is far from completion. Based on this study, specific functional
groups and interactions warrant further analysis.
Activity-based

protein

profiling

using

compounds

to crosslink

to

germination binding site(s) can be used to determine the amino acid sequence of
the binding region (270). This is an important technique that could be used to
determine the bile salt binding region in C. difficile spores since the germination
binding site(s) are currently unknown (95). The plant cholesterol derivative,
Ouabain, contains an α-methylene-γ-lactone group which is an electrophilic
functional group capable of participating in Michael additions with biological
nucleophiles such as the sulfhydryl groups of cysteine residues forming an
irreversible adduct (181-184). Ouabain was able to bind to C. difficile spores and
inhibit germination. Ouabain could potentially be used as a probe to determine
the binding site(s) binding residues in C. difficile.
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In general, a number of inhibitors of C. difficile spore germination were
discovered during this project. In the big picture, compounds able to inhibit C.
difficile spore germination could potentially be used as anti-germinant therapy in
high risk patients. The lack of prophylactic treatment for CDI is an important
problem and current medications only combat the established disease (35, 269).
Therefore, the best inhibitors were assessed to determine the most practical
approach for further characterization. CamSA was chosen for pharmacokinetic
characterization and in vivo studies due its potency as an inhibitor of C. difficile
spore germination and inexpensive synthesis.
A patient becomes susceptible to C. difficile infection when taking
antibiotic therapy and certain groups of people are at high risk for disease, such
as the elderly and immunocompromised patients (41). This susceptibility is due
to the disruption of indigenous bacteria that aid in the resistance to pathogen
colonization (74, 142). An optimal anti-germination therapeutic should not further
damage the natural flora in GI tract. CamSA does not have antibacterial effects
on the enteric Gram-negative and Gram-positive bacteria tested in this study.
Specifically, CamSA does not affect the vegetative growth of C. difficile. The
proposed mechanism of CamSA is anti-germination activity with C. difficile
spores. The results support this hypothesis since CamSA is unable to prevent
proliferation of vegetative C. difficile cells. Future studies should include the
effects CamSA has on other bacteria known to be important in colonization
resistance (203, 271). For example, Lactobacillus delbrueckii ssp. bulgaricus has
been shown to reduce cytotoxicity of C. difficile toxin in vitro (272). A more
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detailed screen of CamSA with enteric bacteria in vitro will provide a better
understanding of the effect CamSA will have on the indigenous gut populations.
CamSA is stable to the microenvironments of the gut that it will likely
encounter during transit. Simulated gastric and intestinal fluids can be used to
determine the stability of compounds to the changing pH of the GI tract (193).
CamSA is stable to these simulated GI tract fluids. The experiments performed in
this project did not determine the effect of common GI tract proteases (besides
hydrolases describe below) on CamSA degradation. In the future, the effect
proteases have on the stability of CamSA should be assessed. Bacteria in the GI
tract secrete bile salt hydrolases that degrade bile salts (186, 187). CamSA is
especially sensitive to degradation to the bile salt hydrolases produced by B.
longum. Antibiotic therapy compromises and/or destroys the natural flora of the
GI tract (142, 273). CamSA administered as a prophylactic alongside antibiotics
will likely remain stable in the gut. After the cessation of antibiotics and CamSA,
the natural bacterial flora can repopulate the gut and degrade any remaining
CamSA. The direct effects of antibiotic agents on the stability of CamSA were not
tested during this project. However, subsequent animal studies suggest that
antibiotic medications have no affect on the activity of CamSA.
CamSA was analyzed in an in vitro gut permeability assay. This assay
predicted that CamSA is impermeable from the gut lumen into cells. Also, the
assay predicted that CamSA is actively transported into the lumen. These studies
were performed with a very low concentration of CamSA. Bile salts can form
micelles at high concentrations and readily traverse cellular membranes (223-
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225). This critical micelle concentration (CMC) has been used to enhance the
permeability of some molecules (225, 226). The critical micelle concentration of
CamSA will need to be determined to be able to directly compare CamSA with
previously studied bile salts. At the concentrations tested CamSA has low
bioavailability, which is beneficial for treating a disease that is localized to the
intestinal tract. CamSA was recovered at 100% in these permeability assays.
This suggests that the human intestinal cells used in the study do not degrade
CamSA and that CamSA does not adhere to these cells. As predicted earlier, this
data further supports that CamSA will remain stable in the lumen of the gut.
Mammalian cell cultures were used to determine the cytotoxicity of
CamSA in vitro. CamSA did not adversely affect the viability of two types of
epithelial cells or an immune cell line. The epithelial cell lines were also used to
determine toxicity due to vegetative growth of C. difficile. This is an indirect
method to study toxin effect on cell morphology and viability. Based on previous
studies, we hypothesized that C. difficile releases toxins after spore germination
and that CamSA could reduce the toxins produced by preventing spore
germination. Although assays were not performed to detect toxins secretion,
epithelial cells treated with C. difficile germination medium caused morphology
changes and cell death comparable to published results (87, 92, 198). CamSA
reduced C. difficile toxin-induced cell death in a dose dependent manner. In
future experiments, the concentration of toxin A and toxin B can be determined
by enzyme-linked immunosorbent assay (ELISA) or Western blot. The direct
effect CamSA has on toxin production can then be assessed. We predict that the
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total concentration of toxins secreted will decrease with increasing CamSA
concentration.
Taurocholate is the natural bile salt germinant of C. difficile spores (138,
140). We predicted that inoculating mice with C. difficile spores and administering
taurocholate would result in increased disease severity or a faster onset of
disease signs. Unfortunately, we did not see a difference between taurocholatetreated mice and untreated mice. Both presented signs of CDI within 24 hours
and were moribund within 48 hours. The most probable explanation for these
observations is that the C. difficile inoculum was too high to identify affects
taurocholate had on spore germination in vivo. To test this hypothesis, future
studies will have to be performed varying the inoculum of C. difficile spores
administered to animals and the concentration of taurocholate administered. This
will provide evidence that either exogenous taurocholate has effect or no effect
on C. difficile spore germination in vivo. To our knowledge this type of in vivo
study of taurocholate and C. difficile spores has not been reported.
CamSA has low bioavailability based on in vitro permeability assays,
which reduces the risk of toxic effects on non-target organs (192). When CamSA
was administered to mice in high concentrations, there were no observable toxic
effects such as respiratory distress, tremors, salivation, coma, or death (256).
Toxicity of CamSA to internal organs is a necessary next step to determining
CamSA’s safety. The major organs need to be assessed for size, morphology
changes, and signs of toxicity (256). If metabolized, CamSA will likely be
degraded to the cholate backbone and the meta-aminobenzenesulfonic acid
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substituent. Cholate is a natural bile salt and the effects of increased
concentration of cholate in the system will have to be determined. The
substituent is not a natural substance and currently the oral, inhalational, and
dermal toxicity and lethal dose has not been determined. The internal toxicity to
major organs and blood vessels will need to be determined. Although CamSA is
expected to remain in the intestine, the metabolites may not. The concentration
of CamSA breakdown products in the blood, liver, and heart will provide a clearer
picture of the fate of CamSA in the mammalian body (192).
A recent study shows that the biodiversity of the murine gut changes with
the administration of different antibiotics and after infection with C. difficile (142).
The natural flora of the gut resists colonization of C. difficile and certain bacterial
populations are more resistant to infection (74, 142, 271). It is possible that this
change in population dynamics of the natural flora after CDI provides a
susceptible environment for CDI recurrence. Therefore for optimal protection,
CamSA should not alter the natural flora either during or after treatment. In future
murine studies, the population dynamics of the gut flora in mice treated with
CamSA alone and CamSA during infection with C. difficile should be compared
to untreated animals. We do not expect that CamSA alone will affect the
indigenous bacterial populations. We do predict that the natural gut flora of
untreated animals repopulates animals that have been treated with CamSA and
infected with C. difficile. In other words, we expect to see the bacterial
populations in the gut revert to the natural microbial community. The proposed
study will provide a clearer understanding of the interactions between CamSA
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and the microbiota of the gut. If the hypothesis is supported, it is likely that
CamSA will also be able to prevent CDI recurrence.
To determine if CamSA is active in vivo, CamSA was administered to mice
challenged with C. difficile spores. CamSA prevents CDI in these mice in a dose
dependent manner. Furthermore, CamSA can prevent CDI in mice with a single
dose when administered at the time of infection. C. difficile spores used to
challenge mice did not germinate in the gut of mice treated with CamSA. This
provides evidence of the anti-germinant ability of CamSA. Using CamSA as a
chemical probe, the onset of CDI was determined to be between 6 and 9 hours
post-challenge in the murine model. There are currently no prophylactic
treatments for CDI making the discovery of CamSA as an in vivo anti-germinant
an important step toward preventing the disease. Furthermore, to our knowledge
no other studies have reported the timing of C. difficile spore germination in the
murine gut before this study.
The risk of CDI recurrence increases with each episode and is greater
than 60% in patients with more than two CDI episodes (48-50). Currently no
prophylactic protocols exist for CDI and CDI recurrence (35). Recurrence has
been defined as a relapse of CDI with the same strain as the initial episode or reinfection with a new strain (35). Recurrence of CDI is possibly due to the
persistence of C. difficile spores in the gut following treatment and/or re-infection
due to susceptible patients coming into contact with spores in the environment
(101, 274-276). The mechanism of recurrence is poorly understood and
represents a gap in C. difficile research. Mouse and Syrian hamsters have both
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been successful animal models for CDI research (37, 241, 277). Relapse models
in animals are more difficult to induce and to study. One study of relapse in the
mouse has been reported; however, upon close inspection of the article, a model
for reinfection is described (253). The authors induced CDI in mice and after they
recovered, the mice were re-challenged with either the initial strain of C. difficile
spores or a different strain (253). Admittedly, re-infection is one possible cause
for recurrent CDI, due to suppressed patient immune systems and accessibility to
contaminated surfaces (35). However, it is also likely that spores persist in the
gut following CDI episodes and the spores begin outgrowth when therapy has
ceased, causing relapse. CDI relapse has traditionally been studied in hamsters
because the relapse induced in the hamster model mimics human disease more
closely than the mouse (51, 250, 269, 278). A future direction from his current
study will be to determine if CamSA can prevent CDI in the hamster model of
disease and whether CamSA can prevent recurrence in hamsters. CamSA is
able to prevent CDI in mice in a dose dependent manner and I hypothesize that
CamSA will prevent CDI in hamster in a similar way. Furthermore based on the
finding that CamSA-treated mice excrete C. difficile spores quantitatively, I
hypothesize that CamSA will prevent recurrence in the hamster model. Any
persistent spores remaining in the gut following antibiotic treatment will be
prevented from germination and will be excreted. This project has provided
evidence that anti-germination therapeutic compounds can prevent CDI in mice.
The continuation of this project will lead the way for the re-defined management
and prevention of C. difficile infection.
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